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CSF-1  Colony stimulating factor 1 
CSF-1R  Colony stimulating factor 1 receptor  
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SUMMARY 
Chronic lymphocytic leukemia (CLL) is characterized by an accumulation of mature malignant 
CD5+CD19+ B cells. Survival and proliferation of these B cells are highly dependent on the tumor 
microenvironment, which comprises monocyte-derived nurse-like cells (NLCs) as key players that 
possess tumor-supportive properties and resemble tumor-associated macrophages (TAMs). One of 
the main goals of this thesis was to understand and target the tumor supportive properties of 
myeloid cells in CLL.  
 
Colony Stimulating Factor 1 Receptor (CSF-1R) is expressed on cells of the myeloid lineage and 
known to be important for TAM differentiation in solid tumors. Targeting CSF-1R using the 
monoclonal antibody TG3003, reduced NLC numbers in CLL cocultures, a well-accepted in vitro 
model mimicking the lymph node microenvironment in CLL, slightly reduced the expression of 
factors with functional relevance in the CLL tumor microenvironment (e.g. CCL2, sCD14), and 
significantly reduced NLC-mediated survival support for primary CLL cells in vitro. Further, a 
potential therapeutic effect of TG3003 was investigated in a preclinical model of CLL by adoptively 
transferring splenocytes from leukemic Eµ-TCL-1 mice into C57BL/6 mice (TCL-1 AT) with a 
humanized CSF-1R gene. TG3003 treatment resulted in reduced monocyte numbers with a stronger 
effect on Ly6Clow monocytes, a subset that is highly enriched in CLL patients. The observed reduction 
did, however, not lead to a complete normalization of monocytic cell subsets. In conventional 
dendritic cells (cDCs), the expression levels of surface molecules required for adhesion, co-
stimulation of T cells, and antigen presentation remained at low levels in leukemic mice after 
treatment with TG3003. In line with this, adaptive immunity with respect to T cells was also not 
altered. Finally, TG3003 treatment did not lead to an improvement of disease outcome in the TCL-
1 AT model, possibly due to insufficient changes in the immune status of treated mice.  
 
The second focus of this thesis was a comprehensive investigation of the myeloid tumor 
microenvironment in the TCL-1 AT model and under the influence of Ibrutinib, a Bruton’s tyrosine 
kinase (BTK) inhibitor that blocks B-cell receptor (BCR) signaling, and thereby efficiently controls 
and inhibits CLL development in patients. As BTK is also expressed in myeloid cells, an indirect 
activity of Ibrutinib on the CLL tumor microenvironment was hypothesized. Among other findings, 
this study revealed that Ibrutinib is capable of inhibiting the enrichment of the CLL-associated 
Ly6Clow monocyte subset and normalizing several CLL-induced molecules associated with activation 
of cellular growth and proliferation, inflammation and immune suppression (e.g. PECAM-1, TREM-
1, PD-L1). Ibrutinib further enhanced the CLL-associated tolerogenic/immature immunophenotype 
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of cDCs (e.g. expression of PD-L1). Thus, Ibrutinib’s effect on the myeloid tumor microenvironment 
in CLL is of opposing nature, thereby inaugurating room for improvement with respect to therapy. 
 
Exploring mechanisms of Ibrutinib resistance in the TCL-1 AT model was the third aim of the current 
work. Even though Ibrutinib represents a paradigm shift in the treatment of CLL, a growing number 
of resistant patients with highly aggressive disease are identified, whereby the underlying 
mechanism of resistance is so far only partly understood. Despite an initial response to Ibrutinib, 
continuous treatment of TCL-1 AT mice revealed a loss of therapeutic efficacy after several weeks. 
This observation was accompanied by an increase of proliferating leukemic cells in the blood and 
lymphoid organs and phenotypic alterations of Ibrutinib-resistant leukemia cells including 
deregulation of proteins that are involved in the BCR signaling. Re-transplantation of therapy-
resistant tumor cells led to uncontrolled leukemia development under re-applied Ibrutinib 
treatment, demonstrating acquired tumor microenvironment-independent and cell-intrinsic 
resistance of these tumors. Whole exome and RNA sequencing of tumor cells revealed the absence 
of genetic mutations in Btk and its target molecule Plc2. Analysis of transcriptional changes 
identified several gene sets and biological complexes (e.g. Bcl-2 family and NF-B complex) that are 
significantly different in Ibrutinib-resistant and –sensitive cells and which will be the focus of future 
investigations.  
 
In summary, the current thesis illuminates several tumor-promoting as well as dysfunctional 
features of myeloid cells in CLL and under Ibrutinib treatment. These findings may serve as a basis 
for the design of specific therapeutic strategies targeting myeloid cells, and their rational 
combination, for example with existing tumor-targeting drugs, which such as Ibrutinib might harbor 
also non-beneficial effects on the tumor microenvironment. The identification of target molecules 
in leukemic cells that have become resistant to Ibrutinib and are highly independent of their tumor 
microenvironment launches novel therapeutic modalities for patients that relapse under Ibrutinib 
treatment. 
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ZUSAMMENFASSUNG 
Chronische lymphatische Leukämie (CLL) ist durch eine Akkumulation von reifen malignen CD5+ 
CD19+ B-Zellen gekennzeichnet. Das Überleben und die Proliferation dieser B-Zellen sind in hohem 
Maße von der Tumor-Mikroumgebung abhängig, welches von Monozyten abgeleitete nurse-like 
cells (NLCs) als Schlüsselspieler umfasst, die tumorunterstützende Eigenschaften besitzen und 
tumor-associated macrophages (TAMs) ähneln. Eines der Hauptziele dieser Doktorarbeit war es, 
die tumorunterstützenden Eigenschaften von myeloischen Zellen in der CLL zu verstehen und zu 
untersuchen. 
 
Colony Stimulating Factor 1 Receptor (CSF-1R) wird auf Zellen der myeloiden Linie exprimiert und 
ist bekanntlich für die TAM-Differenzierung in soliden Tumoren wichtig. Die Verwendung des 
monoklonalen Antikörpers TG3003 gegen CSF-1R, reduzierte NLC-Zahlen in CLL-Kokulturen, einem 
gängigen in vitro Modell, welches die Lymphknoten-Mikroumgebung in CLL nachahmt. Hierbei 
führte TG3003 zu einer geringfügig verringerten Expression von Faktoren mit funktioneller Relevanz 
in der CLL-Tumor-Mikroumgebung (z.B. CCL2, sCD14) und reduzierte die NLC-vermittelte 
Überlebensunterstützung für primäre CLL-Zellen in vitro signifikant. Darüber hinaus wurde ein 
potentieller therapeutischer Effekt von TG3003 in einem präklinischen Modell von CLL untersucht, 
indem Splenozyten aus leukämischen Eμ-TCL-1 Mäusen adaptiv in C57BL/6 Mäuse (TCL-1 AT) mit 
einem humanisierten CSF-1R Gen transferiert wurden. Die Behandlung mit TG3003 führte zu 
verringerten Monozytenzahlen mit einer stärkeren Wirkung auf Ly6Clow-Monozyten, einer 
Subpopulation, die bei CLL-Patienten stark angereichert ist. Die beobachtete Reduktion führte 
jedoch nicht zu einer vollständigen Normalisierung von monozytischen Subpopulation. In 
conventional dendritic cells (cDCs) blieben die Expressionslevel von Oberflächenmolekülen, die für 
Adhäsion, Kostimulation von T-Zellen und Antigenpräsentation benötigt werden, bei leukämischen 
Mäusen nach Behandlung mit TG3003 auf einem niedrigen Niveau. In Übereinstimmung damit 
wurde auch die adaptive Immunität in Bezug auf T-Zellen nicht verändert. Schließlich führte die 
Behandlung mit TG3003 nicht zu einer Verbesserung des Krankheitsergebnisses im TCL-1-AT 
Modell, welches möglicherweise auf die unzureichenden Veränderungen des Immunstatus in den 
behandelten Mäusen zurückgeführt werden kann. 
 
Der zweite Schwerpunkt dieser Arbeit lag auf einer umfassenden Untersuchung der myeloischen 
Tumor-Mikroumgebung im TCL-1 AT Modell und unter dem Einfluss von Ibrutinib, einem Bruton’s 
tyrosine kinase (BTK)-Inhibitor, der die B-Zell-Rezeptor (BCR)-Signalgebung blockiert und dadurch 
die CLL Entwicklung bei Patienten effizient kontrolliert und inhibiert. Da BTK auch in myeloischen 
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Zellen exprimiert wird, wurde eine indirekte Aktivität von Ibrutinib auf die CLL-Tumor-
Mikroumgebung vermutet. Unter anderem zeigt diese Studie, dass Ibrutinib in der Lage ist, die 
Anreicherung der CLL-assoziierten Ly6Clow-Monozyten-Subpopulation zu inhibieren und mehrere 
CLL-induzierte Moleküle, die in Verbindung mit der Aktivierung von Zellwachstum und Proliferation, 
Entzündung und Immunsuppression stehen (z. B. PECAM-1, TREM-1, PD-L1), zu normalisieren. 
Ibrutinib erhöhte weiterhin den CLL-assoziierten tolerogenen/unreifen Immunphänotyp von cDCs 
(z. B. die Expression von PD-L1). Demzufolge ist die Wirkung von Ibrutinib auf die Mikroumgebung 
des myeloiden Tumors bei CLL von gegensätzlicher Natur und eröffnet somit Raum für 
Verbesserungen in Bezug auf die Therapie. 
 
Die Erforschung der Entwicklung einer Resistenz gegen Ibrutinib im TCL-1 AT-Modell war das dritte 
Ziel der vorliegenden Arbeit. Obwohl Ibrutinib einen Paradigmenwechsel bei der Behandlung von 
CLL darstellt, wird eine wachsende Anzahl resistenter Patienten mit hochgradig aggressiven 
Erkrankungen identifiziert, wobei der zugrunde liegende Resistenzmechanismus bisher nur 
teilweise verstanden wird. Trotz eines anfänglichen Ansprechens auf Ibrutinib, zeigte die 
fortlaufende Behandlung in TCL-1 AT Mäusen nach einigen Wochen einen Verlust an 
therapeutischer Wirksamkeit. Diese Beobachtung wurde begleitet von einem Anstieg an 
proliferierenden leukämischen Zellen im Blut und den lymphoiden Organen und phänotypischen 
Veränderungen von Ibrutinib-resistenten Leukämiezellen, welche die Deregulierung von Proteinen, 
die an der BCR-Signalgebung beteiligt sind einschließt. Die Retransplantation von 
therapieresistenten Tumorzellen und erneute Behandlung mit Ibrutinib, führte zu einer 
unkontrollierten Leukämieentwicklung, welches die erworbene, von der Tumormikroumgebung 
unabhängige und zelleigene Resistenz dieser Tumoren verdeutlich. Vollständige Exom- und RNA-
Sequenzierung von Tumorzellen zeigte das Fehlen von genetischen Mutationen in Btk und dessen 
Zielmolekül Plc2. Die Analyse von Veränderungen im Transkriptom identifizierte mehrere Gen-
Sätze und biologische Komplexe (z. B. Bcl-2-Familie und NF-B-Komplex), die sich in Ibrutinib-
resistenten und -sensitiven Zellen signifikant unterscheiden und die im Fokus nachfolgender 
Untersuchgen stehen werden. 
 
Zusammengefasst beleuchtet die vorliegende Arbeit mehrere tumorfördernde sowie 
dysfunktionale Merkmale von myeloischen Zellen in der CLL und unter Ibrutinib-Behandlung. Diese 
Ergebnisse werden als Grundlage für die Entwicklung spezifischer therapeutischer Strategien für 
myeloide Zellen und deren sinnvolle Kombination beispielsweise mit vorhandenen 
Tumortherapien, die wie im Falle von Ibrutinib möglicherweise auch partiell unvorteilhafte 
Auswirkungen auf die Tumor-Mikroumgebung haben können, dienen. Die Identifizierung von 
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Zielmolekülen in Leukämiezellen, die resistent gegenüber Ibrutinib und unabhängiger von ihrer 
Tumor-Mikroumgebung geworden sind, eröffnet neue therapeutische Möglichkeiten für Patienten, 
die unter Behandlung mit Ibrutinib einen Rückfall erleiden. 
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1 INTRODUCTION 
1.1 Cancer and the role of chronic inflammation 
The term “cancer” describes a group of diseases that shows abnormal cell growth in conjunction 
with the potential of uncontrolled, tissue-independent spreading of cells throughout the body, 
which usually is fatal to the affected individual without adequate treatment1. Cancer is thought to 
be the result of the acquisition of multiple hallmarks (such as sustained proliferation and replicative 
immortality, evasion of growth suppressors, activation of invasion and metastasis, induced 
angiogenesis, and resistance to cell death) and is further supported by enabling characteristics 
including tumor-promoting inflammation1. 
 
Inflammation can be sub-classified in acute and chronic inflammation. Acute inflammation 
mediated by immune cells is a response to an alteration induced by a pathogen or a physical or 
chemical insult that is usually followed by the elimination of the damage, tissue repair, wound 
healing and restoration of homeostatic state2, 3. Acute inflammation plays a central role in 
controlling tumor growth and is concurrently characterized to be of short-term and self-limiting2, 3. 
Chronic inflammation on the other hand, is a deregulated process that can instead promote 
malignant transformation of cells and carcinogenesis by supplying various molecules to the tumor 
microenvironment, including growth factors, survival factors, proangiogenic factors, and 
extracellular matrix-modifying enzymes2, 4. Eventually, these signals result in the activation of 
cancer-enhancing processes, such as epithelial-mesenchymal transition, invasion, metastasis, and 
angiogenesis which are especially relevant in the context of solid tumors1, 2, 4.  
It is well-known, that exogenous inflammation due to infections, exposure to irritants or 
autoimmune diseases can foster tumor formation and about 20% of human cancers are linked to 
infections5. Helicobacter pylori is a well-characterized example where gastritis caused by bacterial 
infection has been shown to markedly increase the risk for outgrowth of stomach cancer and also 
associated with gastrointestinal lymphoma6, 7.  
Beside the impact of extrinsically-induced inflammation processes for the induction of cancer, 
tumor cells also tend to modulate immune cells to establish a beneficial niche for their survival.  For 
example, genetic mutations in cancer cells can trigger aberrant production of inflammatory 
mediators, which create an inflammatory microenvironment that further exacerbates tumor 
formation. For example, aberrant Ras-Raf signaling, a pathway that is frequently mutated and 
aberrantly activated in many cancers, can drive tumor-promoting inflammation to a certain extent8. 
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Hence, chronic inflammation shares various signaling pathways and molecular targets with the 
carcinogenic process2. 
 
The concept of ‘cancer immunoediting’ describes the many facets of an interaction between the 
immune system and the tumor and is composed of three phases - elimination, equilibrium, and 
escape9. In the elimination phase of cancer immunoediting, the innate and adaptive arms of the 
immune system become alerted to danger signals deriving from stromal remodeling processes as a 
result of tissue disruption or from oncogene-induced transformed cancer cells themselves10. This 
phase represents the phase of an intact immunosurveillance, as immune cells detect and eradicate 
malignant cells before they become clinically established tumors 2, 9, 10. During elimination phase, 
the balance favors an anti-tumor immune response due to an increase in expression of tumor 
antigens, MHC class I, Fas and TRAIL receptors on tumor cells and perforin, granzymes, IFN-γ, IL-12, 
and TNF-α in cells of the tumor microenvironment2. 
Equilibrium is the second phase of cancer immunoediting where the immune system is able to 
sustain the tumor in a state of functional dormancy2, 9, 10. However, some cancer cells evolve under 
the immune pressure and manage to resist immune recognition, for example through defects in 
antigen presentation and induce immunosuppression through upregulation of immune checkpoint 
molecules, such as PD-L12, 9. In this phase, a balance exists between anti-tumor and tumor-
promoting cytokines (IL-10, IL-23)9, 10. During the escape phase of cancer immunoediting, the 
immune system is no longer able to restrict tumor outgrowth and tumor cells manage to evade 
immune recognition2, 9, 10. The ability of the malignant cells to escape from the immune system’s 
surveillance is assigned to acquired traits, such as the loss of tumor antigens, MHC I or co-
stimulatory molecules, an increased expression of molecules, associated with survival (anti-
apoptotic molecule Bcl-2), immunosuppression (IDO, PD-L1), resistance (STAT-3), and secretion of 
cytokines that can enhance angiogenesis (VEGF, TGF-β, IL-6, M-CSF)2, 9, 10. In addition, the immune 
cells within the microenvironment can promote the shifted balance towards tumor progression 
through the production of immunosuppressive cytokines and molecules such as IL-10, TGF-β, VEGF, 
IDO, PD-L12, 9, 10. 
 
One disease that merits considerable attention in connection with chronic inflammation is chronic 
lymphocytic leukemia11. Initiation and progression of chronic lymphocytic leukemia are believed to 
result from the paradox situation of excessive inflammatory response on the one side and a poor 
response to infectious stimuli on the other side, suggesting that chronic inflammation is of prime 
importance for the pathophysiological role in this disease11. 
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1.2 Chronic Lymphocytic Leukemia 
Chronic lymphocytic leukemia (CLL) is the highest-incidence leukemia in Northern America and 
Europe, with an age-adjusted incidence rate of 4.7 newly diagnosed cases per 100,000 people and 
1.3 number of deaths per 100,000 in the US12. CLL is a B cell malignancy affecting mostly elderly 
patients with a median age at diagnosis of 70 years and higher prevalence in males compared to 
females (1.7:1)12, 13. The increased risk of the disease with age and the general increasing life 
expectancy suggests that the CLL burden will continue to rise in the upcoming years14. 
 
1.2.1 CLL diagnosis and clinical staging 
1.2.1.1 CLL diagnosis 
Diagnosis of CLL is performed according to the latest recommendations of the International 
Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines based on blood counts, blood 
smears, and immunophenotyping of circulating B cells15. The following criteria are included in the 
iwCLL guidelines from 2008 and were confirmed to be up-to-date recently14: 
One criterion for CLL diagnosis is the presence of lymphocytosis (the abnormal increase in absolute 
number of blood lymphocytes) with at least 5,000 B cells per µL in the peripheral blood for a 
duration of at least three months14, 15. Furthermore, these highly enriched B cells should display the 
typical immunophenotype characteristic for CLL which comprehends the co-expression of the B cell 
surface antigens CD19, CD20, CD23 (whereby surface levels of immunoglobulin, CD20 and CD79b 
are typically low compared with the levels on normal healthy B cells), and the T cell antigen CD514, 
15.  
Typically, CLL is composed of one single B cell clone14, 15. Two types of light chains are found in 
immunoglobulin molecules, either the lambda chain or the kappa chain16. Since all progeny of a 
particular B cell will carry an identical light chain, testing for the expression of either kappa or 
lambda light chains is used in diagnosis to confirm the clonality of the CLL cells14, 15, 16. 
Morphologically, CLL cells appear as small mature B cells, with a compact nucleus filling the cell, 
surrounded by a narrow cytoplasm14, 17. Nucleoli are not or only rarely found and the chromatin 
appears to some extent aggregated14, 17. Besides the typical CLL cells, a larger fraction of smudge 
cells is found in blood smears of patients as a result of crushed cells during slide preparation14, 17. 
Moreover, prolymphocytes characterized by a single clear nucleolus and larger size as compared to 
CLL cells can also be identified in patients’ blood smears14, 17.  
Other tests that are performed at diagnosis of CLL are molecular cytogenetics to determine 
aberrations in karyotype or frequently mutated genes like TP53, mutational status of 
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immunoglobulin genes (IGVH, VH3.21 usage) expression of ZAP-70 or CD38, quantification of serum 
markers (CD23, thymidine kinase, and β2-microglobulin), and bone marrow examination14. 
However, these tests are not required to establish the diagnosis but may help to predict prognosis 
in CLL14.  
Notably, CLL shares commonalities with other malignancies and thus needs to be distinguished 
from these: Small lymphocytic lymphoma (SLL) represents a malignancy of the hematopoietic and 
lymphoid tissue being mainly characterized by lymphadenopathy and distinguished from CLL by less 
lymphocytosis and absence of cytopenia14. Monoclonal B-lymphocytosis (MBL) is characterized by 
the presence of less than 5,000 B cells/µL in peripheral blood and concurrent absence of 
lymphadenopathy or organomegaly, cytopenia, or disease-related symptoms14, 18. MBL may 
progress to CLL at an annual rate of 1% to 2% and is considered as an asymptomatic CLL precursor 
state14, 18.  
The majority of patients are asymptomatic at the time of diagnosis and treatment is not considered 
for this group14. Patients entering a more advanced disease stage display increased involvement of 
bone marrow, lymphadenopathy, splenomegaly and hepatomegaly as compared to an early and/or 
asymptomatic disease stage14, 15. Once identified with a symptomatic stage, patients are enrolled 
into appropriate treatment regiments14, 17. Despite initial treatment response some patients 
eventually display MRD (Minimal residual disease), which might lead to resistance to treatment and 
relapsed/refractory CLL14. Disease progression includes progressive CLL and Richter’s 
Transformation14. Richter’s Transformation is the emergence of an aggressive transformation of CLL 
into high-grade lymphoma that is either DLBCL (Diffuse large B-cell lymphoma) or HL (Hodgkin 
lymphoma) and associated with dismal clinical outcome19.  
 
1.2.1.2 Clinical staging 
Once CLL is clearly diagnosed, one of the two co-existing clinical staging systems, the Rai and Binet 
staging, named after the first authors of the original publications, are applied 20, 21. The Rai staging 
system is practiced more in the U.S. while the Binet staging system is more common in Europe14, 15. 
The Rai staging system defines three risk groups and is based on clinical symptoms of lymphocytosis 
in the blood and/or marrow, presence or absence of lymphadenopathy, organomegaly 
(splenomegaly and/or hepatomegaly), anemia and thrombocytopenia20, 21. The very similar Binet 
staging system considers the actual number of the involved areas affected by lymphadenopathy 
and/or organomegaly. Both systems are widely accepted and serve as a prediction of clinical 
outcome. However, it was reported that the Rai staging system may have an advantage in the 
prediction of clinical outcome by a better definition of a subgroup with good prognosis22.  
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1.2.2 B cell development and proposed cellular origin of CLL 
1.2.2.1 Normal B cell development 
B cells undergo several developmental stages during lymphopoiesis, initiated by the differentiation 
of hematopoietic stem cells (HSCs) that first give rise to multipotent progenitor cells and 
subsequently either to common lymphoid progenitors or common myeloid progenitor cells16. 
Common lymphoid progenitors subsequently commit themselves either to the B cell lineage or the 
T cell lineage16. In the early stages of B cell development, precursor B cells are generated in the 
bone marrow where they receive signals from the specialized microenvironment, in particular from 
stromal cells providing ligands, cytokines, and chemokine16. These signals stimulate the 
rearrangement of the B cells’ immunoglobulin genes in order to generate the B cell receptor (BCR) 
in form of cell surface immunoglobulin M (IgM)16. These immature B cells then undergo a process 
of ‘negative selection’, eliminating B cells that bind to self- antigens, thereby reducing the BCR 
repertoire16. At this point, immature B cells are ready to migrate out of the bone marrow through 
the circulatory system to the spleen to proceed through the final transitional stages in B-cell follicles 
to become fully mature16. There, B cells bind to foreign antigens leading to their activation and 
affinity maturation of the BCR, followed by production of long-lived memory cells and antibody-
secreting plasma cells which reside in the bone marrow and lymphoid tissues16. The majority of B 
cells in the secondary lymphoid organs consists of follicular B cells (or B2 B cells) and a minor 
population of marginal zone B cells, named after their location in the marginal zone of the spleen. 
Both, follicular B cells and marginal zone B cells, derive from a common lineage and diverge at the 
transitional stages and are components of the adaptive immune system16. In addition, there is a 
third subset of B cells that are considered as part of the innate immune system, which are B1 B 
cells16. B1 B cells display a high spontaneous production of immunoglobulins and do not depend on 
T cell help or stromal cell-derived stimuli for their activity16. Their BCR shows no signs of affinity 
maturation and they are not able to develop substantial memory 16. Different than follicular B cells 
and marginal zone B cells, B1 B cells are generated from a separate lineage of progenitor cells in 
the fetal liver during fetal and neonatal stages and are mainly found in the body cavities and only 
in low numbers in lymphoid organs16. In addition, these cells possess self-renewing capacity16. 
However, the knowledge on B1 B cells is mainly gained through mouse experiments and their role 
in humans is not fully understood16.  
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1.2.2.2 Cellular origin of CLL 
During the recent years, the concept of CLL as a disease arising from mature B cells was challenged 
by indications of the involvement of hematopoietic stem cells HSCs as cell of origin of CLL. HSCs 
from CLL patients transplanted into immunocompromised mice were capable of self-renewal 
followed by clonal selection of their B cell progeny leading to a CLL-like disease23. This indicated the 
presence of early genetic and/or epigenetic changes in HSCs as a primary event followed by further 
oncogenic events in the B cell lineage promoting the disease. Some early mutational events 
identified in multipotent progenitor cells are located in well-known CLL oncogenes (such as 
NOTCH1, TP53, and SF3B1) and may therefore, serve as driver mutations24.  
 
Apart from a suggested HSC or early progenitor cell as origin of CLL, B1 B cells had been proposed 
as the direct precursor cell for the CLL clone25, 26. In contrast to B cells from the conventional B2 
lineage, B1 B cells (in particular B1a B cells) express CD5 on their surface27. The self-renewal capacity 
of B1 cells prompted the question whether CD5+ B1 B cells might be the cellular origin of CLL with 
increasing age.  
The discovery of the two main CLL subsets, cases with mutated (M-CLL) or unmutated (UM-CLL) 
immunoglobulin genes led to the assumption that M-CLL must derive from a cell that has 
undergone somatic hypermutation of the BCR genes in the germinal center28. 
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Figure 1: Cellular origins of CLL. 
This figure is derived from Kipps, T. J. et al. Nature Reviews Disease Primers, 201717. 
 
Therefore, the proposal of B1 B cells as the cell of origin for all CLL subtypes became incompatible 
leaving still the possibility that UM-CLL could be derived from naïve B cells that have not gone 
through germinal center maturation. A detailed gene expression profiling study from 2012 included 
different healthy B cell subsets isolated from human blood and the two main CLL subsets, M-CLL 
and UM-CLL, and showed high similarities of both CLL subtypes in their gene signature, suggesting 
that both subsets most likely derive from an antigen-experienced cell29. Indeed, in the same study, 
the existence of a small CD5+CD27+ post-germinal center B cell population (with CD27 marking 
somatically mutated cells) was reported and shown to have the highest similarity to CLL cells29. 
Hence, it was postulated that UM-CLL derives from CD5+CD27- B cells, while M-CLL derives from 
CD5+IgM+CD27+ B cells. Notably, CD5+ B cells possess similar traits as CLL cells since they were 
described to possess a tendency for ‘stereotyped’ BCRs, a hallmark of CLL that will be explained in 
chapter 1.2.4.2 in more detail30, 31, 32. A recent publication further pointed out that early generated 
B1 B cells can be the origin of a CLL-like disease in aged mice33. These B1 B cells were equipped with 
restricted BCRs and displayed continuous expression of moderately up-regulated c-Myc and down-
regulated Bmf33. The transcription factor c-Myc regulates cell cycle, as well as apoptosis by targeting 
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Bcl-2, while reduction of Bmf expression promotes B cell survival with disease development 
independent of T cells and BCR mutations33, 34, 35. A more recent publication with focus on DNA 
methylation data, not only classified CLL into three subtypes but also demonstrated that CLL tumors 
originate largely from a continuum of different maturation states, which reflect normal B cell 
developmental stages36. Even though the authors did not include CD5+ and CD5- B cells into their 
analyses, they could demonstrate that CLL cells resemble memory B cells with respect to their 
global methylation landscape, as they exhibit ~70-100% of the pattern for high-maturity memory B 
cells36. However, despite several proposed hypotheses, the precise cell of origin of CLL is still under 
debate and active investigation. 
 
1.2.3 Genetic alterations in CLL 
There exists a high degree of genetic variability in CLL, involving several cellular pathways and 
functions, such as cell cycle, apoptosis, NOTCH signaling, WNT signaling, inflammatory pathways, 
RNA processing, DNA damage, chromatin remodeling and transcription regulation, and B cell 
receptor-related pathway17, 37. 
Despite the highly diverse mutational landscape in CLL patients, there is a small number of 
consistently recurrent genetic alterations including chromosomal alterations, somatic mutations, 
and epigenetic alterations17, 37.  The mechanisms of pathogenesis of CLL remain elusive because no 
genetic alteration has been ultimately proven to initiate CLL development. 
 
1.2.3.1 Recurrent chromosomal alterations and somatic mutations 
By using fluorescence in situ hybridization (FISH) to detect chromosomal aberrations in 325 CLL 
cases, over 80% of patients were shown to carry chromosomal abnormalities at diagnosis38. The 
five most common chromosomal abnormalities are deletion in 13q (55%), deletion in 11q (18%), 
trisomy of 12q (16%), deletion in 17p (7%), and deletion in 6q (6%)38. These aberrations helped to 
define several risk groups and serve as useful predictors for survival38. Deletion of 17p or 11q 
predicts poor survival, whereby 17p deletion forecasts the worst prognosis38. They are followed by 
12q trisomy and normal karyotype cases38. Interestingly, patients with 13q deletion as a single 
aberration had the longest estimated survival time38. The prognostic value of these chromosomal 
alterations helped in improving treatment decisions.  
For some of these aberrations, disease-associated genes have been identified. The most common 
chromosomal alteration, del13q contains the DLEU2/miR-15a/16-1 cluster within the deleted 
region39. This cluster was suggested to exhibit a tumor suppressor role in CLL through 
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downregulation of genes controlling cell cycle entry and by this controlling the expansion of the 
mature B cell pool39. MiR-15a and miR-16-1 expression were also shown to be inversely correlated 
with Bcl-2 expression in CLL40. Both microRNAs were able to negatively regulate Bcl-2 at a 
posttranscriptional level and their absence was shown to trigger apoptosis resistance in cell lines40. 
The 17p deletion leads to the loss of the tumor suppressor gene TP5341. And deletion of the 11q 
region is mainly linked to alterations in the ATM gene coding for a protein that is important for DNA 
repair42, 43, 44. The impact of trisomy 12q and chromosome 6q deletions on disease relevant genes 
and pathways remain yet unclear and are under current investigation.  
The most recent insights into the genomic landscape of CLL are attributed to next generation 
sequencing techniques that tremendously helped to identify biologically relevant mutations in CLL 
and their frequencies. The spectrum of somatic mutations found in CLL comprises a long list of 
affected genes involving several cellular pathways. Some of the most recurrent somatic mutations 
found in patients involve NOTCH1, TP53, SF3B1, ATM, POT1, PAX5, MYD88, and CHD237, 45. The most 
recurrent genetic alterations including chromosomal aberrations and somatic mutations and their 
contribution to biological pathways are illustrated in Figure 1. 
 
 
Figure 2: The genetic landscape of CLL. 
The percentage of patients with CLL who harbor recurrent CLL-associated genetic lesions grouped according 
to biological pathways in which they are involved. The frequency of genetic alterations in unselected cases 
(ALL) (grey) and in the IGHV-M (red) and IGHV-UM CLL (purple) subgroups. This figure is derived from Fabbri 
and Dalla-Favera, Nature Reviews Cancer, 201637. IGHV-M and IGHV-UM further referred to as M-CLL and 
UM-CLL in this work. 
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Recent attempts were aiming at studying clonal evolution in CLL and the identification of 
tumorigenic driver mutations on one side and passive, passenger mutations on the other side46. For 
this purpose, the frequency of mutations in a few pre-treatment, post-treatment, and relapsed 
patients was monitored and indeed was reported to change over time, reflecting a dynamic 
composition of subclones46. Moreover, the patterns of clonal evolution appear rather 
heterogeneous between patients, whereby a relatively stable molecular phenotype is correlated 
with milder disease progression and better drug response, whereas an increased subclone 
development rather correlates with resistance to treatments and bad disease outcome46. Larger 
cohort studies confirmed indications for clonal evolution when comparing matched pre-treatment 
samples with samples from relapsed patients46, 47. Notably, subclone development was already 
identified in the pre-treatment samples46, 47. Moreover, the dynamic intra-tumoral genetic 
heterogeneity may provide insight into the order of mutation acquisition in CLL and therefore may 
be indicative of events present in the founder subclone in contrast to later occurring events47.  
Hence, the overall goal of such large-scale longitudinal studies will be the implementation of the 
gained information into the improvement of response prediction for individual patients for instance 
through earlier targeted and sequential treatment directed against CLL subclones.  
 
1.2.3.2 Epigenetic changes  
Comparing CLL methylomes to several normal mature B cell subsets using whole-genome bisulfate 
sequencing and microarrays disclosed a widespread hypomethylation of DNA, affecting mostly 
enhancer loci, combined with local hypermethylation48. Interestingly, the two CLL subtypes, UM-
CLL and M-CLL, display differential DNA methylation profiles and further seem to reflect the 
methylation imprint of naïve and memory B cells, that have been proposed as their putative cells 
of origin48, 49. Intra-tumoral DNA methylation studies revealed that the CLL methylome is 
remarkably stable over time when comparing samples at diagnosis with follow-up samples49. 
Similarly, also resting CLL cells derived from peripheral blood (G0 or early G1 phase of the cell cycle) 
and CLL cells from lymph nodes of the same patients showed a relatively similar methylation 
profile49. In contrast to the overall maintenance of DNA methylation profiles within individuals, a 
high degree of methylation heterogeneity between different patients was observed50, 51. Moreover, 
the genetic evolution of CLL mentioned before is similarly reflected in the ‘methylation evolution’: 
High levels of stochastically disordered intra-sample methylation heterogeneity correlate with high-
risk genetic lesions, CLL clonal evolution, and an adverse clinical outcome50, 51. Hence, the 
methylation profile in CLL may be used to further support clinical subgroup classification for optimal 
risk management. 
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1.2.4 B cell receptor signaling  
Two forms of B cell receptor signaling are distinguished, which are termed ‘active’ and ‘tonic’ BCR 
signaling52. Active BCR signaling is initiated in an antigen-dependent fashion and leads to the 
initiation of germinal center reactions, while tonic BCR signaling most likely appears in an antigen-
independent fashion leading being required for B cell survival52.  
 
1.2.4.1 BCR signaling in normal B cells 
The BCR is composed of membrane-bound immunoglobulin molecules that are able to bind antigen, 
which results in receptor aggregation and thus initiation of active BCR signaling52. Two heavy and 
two light chains form the mIg, which is non-covalently bound at the cytoplasmic part of the receptor 
to a heterodimer consisting of the subunits CD79a and CD79b. These proteins pass on signals 
through their immune-receptor tyrosine-based activation motifs (ITAMs) to the cell interior as 
illustrated in Figure 352, 53. The aggregation of the BCR leads to phosphorylation of ITAM tyrosines 
by SRC-family kinases, including LYN, BLK5, and FYN54. Next, the tyrosine kinase SYK is recruited to 
the phosphorylated ITAMs leading to its phosphorylation and activation by SRC-family kinases and 
by autophosphorylation55. The SRC-family kinases together with SYK form a ‘signalosome’ 
assembling various other kinases and adaptor proteins52. SYK recruits a complex of CIN85 and BLNK, 
which in turn coordinates the phosphorylation and activation of BTK followed by PLCγ2 activation56. 
The signaling enzyme PLCγ2 then catalyzes the hydrolysis of PIP2 into DAG and IP3 triggering 
calcium release52. DAG and the increased intracellular calcium level are required for activation of 
PKCβ, which in turn phosphorylates different molecules, among others CARD11, a signaling adaptor 
that orchestrates a signaling complex for the activation of the nuclear factor-κB (NF-κB) pathway57. 
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Figure 3: B cell receptor signaling. 
This figure is derived from Hendriks, Yuvaraj & Laurens; Nature Reviews Cancer, 201458. 
 
In parallel, the transmembrane receptor CD19 is phosphorylated by the SRC family kinase LYN, 
recruiting PI3K to the BCR. PI3K phosphorylates PIP2 resulting in generation of PIP3, which is 
responsible for recruitment of BTK and AKT to the plasma membrane59. The result of proximal BCR 
signaling is the activation of NF-κB, PI3K, MAPK, NFAT and RAS pathways, which promote 
proliferation and survival of normal as well as malignant B cells60. 
 
1.2.4.2 BCR signaling in CLL and the central role of BTK 
BCR expression is a hallmark of CLL, but it has been unclear whether the leukemia is actually driven 
by BCR signaling and specific antigens. One-third of CLL patients, including both M-CLL and UM-CLL 
cases, carry highly similar BCR immunoglobulins, referred to as ‘stereotyped’ BCRs32. Out of the 
repertoire of 65 existing functional human IGHV gene segments, only a few are found to be 
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expressed in CLL32, 61. This limited use of variable regions of Ig genes and the selection of 
stereotyped BCRs indeed highly suggest a role for involvement of specific antigens. Candidate 
antigens proposed include proteins associated with apoptotic cells and known self-antigens31, 62, 63, 
64.  
Indeed, for a subset of CLL cases, it has been demonstrated, that BCR signaling does not dependent 
on exogenous antigens64. Instead, BCR activation involves the binding of one region of the BCR (the 
heavy-chain complementarity-determining region) to self-epitopes on variable regions of the 
receptor itself64.  
The two main outcomes of BCR signaling in CLL are either enhanced B cell activation or B cell anergy, 
a state defined by unresponsiveness to antigen stimulation65. While the latter outcome is less well 
understood in the context of CLL, it seems to involve activation of inhibitory molecules 
accompanied with only restricted activation of pathways typically associated with B cell 
activation65. One important molecule suggested to be involved in the limitation of B cell activation 
is SHIP1 which is counteracting the activity of PI3K66, 67. Interestingly, B cell anergy predominates in 
M-CLL cases while elevated B cell activation is more commonly observed in UM-CLL cases68. As 
anergic B cells are less expected to proliferate, this is in line with the observation of a rather indolent 
disease course for M-CLL69.  
In support of that, ZAP70, a paralogue of SYK, is expressed in UM-CLL but not the M-CLL subtype 
and capable of enhancing BCR signaling70, 71.  Another molecule that has a central role in BCR 
signaling is Bruton’s tyrosine kinase (BTK)68. In some patients, BTK is overexpressed and 
constitutively phosphorylated72. Activation of BTK is initiated by its association with the cell 
membrane and its phosphorylation by a SRC kinase or SYK, at position Y551 in the kinase domain73, 
74. This results in the autophosphorylation of BTK at position Y223 promoting its catalytic activity73, 
74. BTK is mostly responsible for the phosphorylation of PLCγ2 which induces its lipase activity 75. 
Moreover, BTK is important for BCR-mediated NF-κB signaling, exemplified by the lack of NF-κB 
activation upon BCR stimulation in BTK-deficient B cells76, 77. However, T cell-dependent NF-κB 
activation that is mediated by CD40 ligand (CD40L)–CD40 interaction between T cells and B cells, 
respectively, remains unchanged76, 77. 
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1.2.5 Tumor microenvironment in CLL 
During the recent years, researchers have solidified the pivotal role of the tumor microenvironment 
(TME) in cancer development1. The TME comprises a diverse composition of cells that in addition 
to cancer cell-intrinsic traits, contribute to tumorigenesis1. The dependency of CLL cells on the 
crosstalk with non-malignant accessory cells in the tissue TME is exemplified by their characteristic 
to rapidly undergo apoptosis in vitro, when cultured in monocultures78. This illustrates that 
apoptosis resistance, one of the hallmarks of cancer, is not a cell-intrinsic feature of CLL cells1. In 
contrast, survival of CLL cells depends on the presence of non-malignant bystander cells or on 
soluble factors released by them 79, 80, 81, 82. While CLL cells in peripheral blood attain a gene 
expression profile similar to that of resting, non-proliferative cells, active division of CLL cells (0.1-
1% proliferation of the entire CLL clone per day) is locally restricted to proliferation centers or so-
called pseudofollicles in the lymph nodes, the bone marrow, and the spleen where the cells are in 
close proximity to bystander cells62, 70, 83, 84, 85. The importance of microenvironmental signals is 
further underscored by the observation that the expression of genes involved in CLL cell migration 
and motility are associated with poor prognosis in patients 86, 87. Hence, gene expression of CLL cells 
is induced by intrinsic oncogenic hits as well as by extrinsic microenvironmental cues. Indeed, CLL 
cells also shape their microenvironment by contributing to the recruitment of supportive cell 
populations86, 88. Key players of bi-directional crosstalk between leukemia cells and their niche are 
stromal cells, endothelial cells, T cells, NK cells, follicular dendritic cells, as well as different myeloid 
cells (monocytes and macrophages) and communicate via cell-cell contact, soluble factors and, as 
more recently demonstrated, through extracellular vesicles89, 90, 91. 
 
Similar to the steady state, stromal cells provide CLL cells with different factors and by this mediate 
tissue homing16, 92, 93. Stromal cells secrete the chemokine CXCL12 (also known as SDF-1) that binds 
to its receptor CXCR4 on CLL cells, leading to their attraction to the lymphoid organs, e.g. into the 
bone marrow92, 93. They mediate cell-cell adhesion through the interaction of VCAM-1 or fibronectin 
with VLA-4 integrins on CLL cells94. Moreover, CLL cells (but not normal B cells) can be rescued from 
apoptosis and conferred with drug resistance by stromal cells as lately exemplified in a study 
showing that uptake of cysteine (converted from cystine) released from stromal cells compensates 
for the limited ability of CLL cells to transport cystine for glutathione synthesis95. But also stromal 
cells themselves are a target of different CLL-derived stimuli, for example by CLL cell-derived 
vesicles that can enhance stromal cells to differentiate into αSMA+ cancer-associated fibroblasts96. 
  INTRODUCTION 
15 
 
 
Figure 4: Cellular and molecular components of the CLL microenvironment. 
This figure is derived from Hacken and Burger, Biochim Biophys Acta., 201689. 
 
Endothelial cells are an additional cellular component of the CLL TME, which induce an increased 
expression of the survival factor ET-1 in CLL cells in a contact-dependent manner97. Endothelial cells 
(as well as CLL cells) express the ETA receptor on their surface suggesting that CLL-released ET-1 
may contribute to establishing a nursing and protective niche by setting up an autocrine loop and/or 
by acting on the microenvironment98. In addition, endothelial cells protect leukemic cells from 
apoptosis mainly mediated through β1- and β2- integrins97.  
Also, follicular dendritic cells attract CLL cells via the CXCL13/CXCR5 axis into the growth-promoting 
TME of secondary lymphoid organs where they tightly co-localize resulting in a strong ZAP-70/Syk 
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and BTK activity and enhanced proliferation of the leukemic cells99, 100. The expression of LTαβ 
(lymphotoxin αβ) on leukemic cells activates follicular dendritic cells through LTαβ/LTβR axis 
leading to upregulation of CXCL13 resulting in a regulatory feedback loop99. Follicular dendritic cells 
have been demonstrated to protect CLL B cells from undergoing apoptosis, at least in part through 
a CD44-dependent mechanism involving up-regulation of the anti-apoptotic protein Mcl-1101. 
Furthermore, TNF superfamily members BAFF and APRIL are follicular dendritic cell-derived key 
molecules in normal B cell survival and differentiation and likewise also serve as pro-survival factors 
for CLL B cells16, 102. They can among others be produced by follicular dendritic cells and stromal 
cells and were suggested to mediate survival in CLL through the NF-B pathway103, 104, 105. Of note, 
also the normal B cell homeostasis and response to antigen requires the interaction of B cells with 
the respective cellular counterparts in the healthy microenvironment. Hence, the dependency of 
CLL cells on their TME partly reflects the natural demand of B cells to receive and send signals from 
and to their neighboring compartments89, 90.  
In addition, T cells and Natural killer (NK) cells contribute to CLL pathogenesis. Both provide pro-
survival signals to CLL cells and their functional impairment is of pathological relevance. T cells and 
CLL cells co-localize in the pseudofollicles where T cells facilitate the engagement of CD40 on the 
leukemic cells promoting survival and proliferation106, 107, 108, 109. The T cell compartment in CLL is 
altered in different ways: Absolute numbers of T cells are elevated while T cell subsets are shifted 
towards a relative increase in cytotoxic CD8+ T cells110, 111. These elevated T cell counts are 
associated with poor patients’ outcome suggesting a tumor-supportive T cell phenotype112. 
Interestingly, T cells from CLL patients are characterized by their inability to form intact immune 
synapses pointing to a failure of adequate immune response110, 112, 113, 114, 115. T cells from CLL 
patients also highly upregulate the immune checkpoint molecule PD-1, an immune inhibitory T cell 
exhaustion marker, and its ligand PD-L1 is upregulated on CLL cells, together favoring immune 
evasion of CLL cells from T-cell cytotoxicity112, 113.  
NK cells in CLL are expanded too and exhibit a reduced cytotoxic capacity linked with low expression 
of NK cell activating receptors NKp30 and NKGD2116, 117, 118. Also CLL and NK cells cross-talk, as for 
example through soluble BAG6, released by CLL cells, was identified to contribute to the inhibition 
of NKp30 on NK cells119.  
Another group of immune cells, which play a major role in the CLL microenvironment, are 
monocytes and macrophages. As they are of special relevance for the current thesis, they will be 
introduced in more detail in a separate chapter.  
In brief, over the last decades many studies have demonstrated that CLL pathobiology is not solely 
tumor cell-autonomous but rather involves systemic defects in the immune system, chronic 
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inflammation, and dependency on the TME. Hence, CLL has become a model for research on TME 
in cancers. 
 
1.3 The myeloid cell lineage  
1.3.1 Development of the myeloid cell lineage  
Cells of the myeloid cell lineage originate in the bone marrow, initiated by the differentiation of 
HSCs that first give rise to multipotent progenitor cells and subsequently develop via various 
myeloid progenitor stages into the different myeloid cell types16. Several models for the 
differentiation of the myeloid cell lineage have been proposed, which predominantly suggest a 
common myeloid progenitor cell (CMP) expressing the surface glycoprotein CD34, but not the stem 
cell antigen-1 (SCA-1) as earliest precursor cell 120, 121, 122. CMPs give rise to granulocyte and 
macrophage progenitor cells (GMPs), characterized by expression of the Fcγ receptors CD16 and 
CD32120. Subsequently, GMPs diverge into (1) granulocyte progenitor cells (GP), serving as a source 
for basophils, eosinophils, and neutrophils, or (2) myeloid-dendritic progenitor cells (MDP)123. The 
latter cell population is characterized by the expression of the CSF-1 receptor (CSF-1R), CX3CR1 and 
Flt-3 (CD135)124, 125. MDPs serve as progenitors for osteoclast (bone marrow macrophages) 
precursors and common monocyte precursors (cMoP) 126, 127, 128. cMoPs subsequently differentiate 
into monocytes in response to CSF-1 and are then released into the circulation128. Monocytes then 
further differentiate into dendritic cell (DC) subsets125, 129, 130. In addition, conventional and 
plasmacytoid DCs can also arise directly from MDPs125, 129, 130. There are reports on a common DC 
precursor cell (CDP), proposed to be DC-restricted, but this is still under debate125, 131, 132. 
 
1.3.1.1 The central role of the CSF-1/CSF-1R axis 
The CSF-1/CSF1-R axis plays a crucial role in pushing the different progenitor cells towards their fate 
and is also of special interest regarding the current work. CSF-1 is a glycoprotein that was initially 
shown to stimulate the formation of macrophage colonies133. Subsequently, the CSF-1 receptor 
(CSF-1R or cFms) was identified and described to possess intrinsic tyrosine kinase activity134, 135. The 
receptor is expressed at low levels on HSCs and at higher levels on monocytes and tissue 
macrophages, osteoclasts, myeloid dendritic cells, and microglia and is responsible for the 
development of these cell types134, 136, 137, 138, 139, 140. CSF-1R downstream signaling promotes a 
number of pathways leading to (1) myeloid differentiation, (2) monocytic commitment, and the (3) 
survival, proliferation as well as chemotaxis of macrophages141.  
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For example, during differentiation of GMPs (1) that is initiated by the CSF-1R, Erk1/2 plays a central 
role142, 143. Moreover, further commitment to the monocytic cell fate (2) is instructed through the 
CSF-1R-mediated up-regulation of the myeloid transcription factor PU.1137. Additionally, CSF-1/CSF-
1R-mediated macrophage survival and proliferation (3) involves several pathways including PI3K, 
Akt, and Mek144, 145, 146, 147, 148, 149. Despite the important role of the CSF-1R signaling, additional 
factors, such as CSF-2, IL-3, and IL-4 are involved in driving the different progenitor cells towards 
their fate, which is also dependent on the context150, 151. For example, CSF-1 receptor downstream 
signaling together with IL-4 is required for Langerhans cell development and leads to inhibition of 
dendritic cell differentiation – illustrating the complexity of myeloid cell development152.  
 
1.3.2 Monocytes, macrophages and dendritic cells in steady state 
1.3.2.1 Monocytes 
After being generated in the bone marrow from cMoP cells, monocytes enter the bloodstream, 
from where they can again be recruited into different tissues of the body153. Monocytes have been 
regarded for a long time to mainly serve as precursors for macrophages in tissues. This is a well-
accepted concept as for example blood-derived and bone marrow-derived monocytes can be 
differentiated into macrophages with serum or adequate growth factors such as CSF-1 in vitro. 
However, this view is currently being revised based on reports about the existence of tissue-
resident macrophages154. 
Two subsets of circulating monocytes exist: The first is thought to remain in the vasculature and 
‘patrol’ the blood vessels with endothelial cell-supporting function while the second type acquires 
the ability to migrate through the endothelium into tissues and lymphoid organs once receiving 
respective signals. Accordingly, the first subset is usually referred to as ‘patrolling monocytes’ and 
the latter as ‘migratory monocytes’ or even more commonly as ‘inflammatory monocytes’ since 
they can be recruited to the site of inflammation. 
However, this terminology might be misleading as migratory/inflammatory monocytes also 
perform constitutive extravasation independent of incoming inflammatory signals155. In this 
context, expression of the chemokine receptor CCR2 on migratory monocytes has been reported 
to facilitate egress from the bone marrow156. Moreover, these cells gain many properties in 
response to inflammation and substantially help to dissolve inflammation and restore normal tissue 
structure and function157. An alternative terminology for the two distinct subsets of monocytes 
(used throughout this thesis from here on) is based on their typical surface expression of marker 
proteins. Marker proteins that distinguish the two monocyte subsets in humans are CD14 and CD16, 
whereby inflammatory monocytes show high expression of CD14, whereas patrolling monocytes 
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are recognized by high CD16 expression158, 159. In mice, high Ly6C expression (Ly6Chigh) is typical for 
inflammatory monocytes and low Ly6C expression (Ly6Clow) for patrolling monocytes. 
 
Figure 5: The mouse monocyte compartment. 
This figure is derived from Ginhoux and Jung Nature Reviews Disease Primers, 2014128. 
 
Notably, a direct lineage dependency between the two subsets is widely accepted by now, with 
Ly6Clow monocytes arising from their Ly6Chigh counterparts160. However, not much is known about 
the details which mediate monocyte cell fate. The transition from Ly6Chigh to Ly6Clow monocytes is 
believed to occur in a NR4A1-dependent manner161, 162. Also, CX3CR1 has been reported to be highly 
expressed on Ly6Clow monocytes and is important for their survival163. More recently, a study 
revealed that DLL1 expression on endothelial cells mediates the transition of Ly6Chigh to Ly6Clow 
monocytes via NOTCH signaling164. In steady state, Ly6Chigh monocytes have a short half-life in the 
circulation of approximately 1 day and rapidly convert into Ly6Clow or migrate from the circulation 
into the tissue as exemplified in experiments with parabiotic mice, showing that donor Ly6Chigh 
monocytes do not reach equilibrium with host Ly6Chigh monocytes155, 160, 165. 
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Besides their role to serve as a source for macrophages and dendritic cells, monocytes play a crucial 
role in host defense as players of the innate immune system166, 167. Notably, work by several groups 
has now demonstrated a role for Ly6Chigh monocytes in adaptive immunity mediated by their ability 
to present antigens to cognate T cells, supporting their differentiation in T helper cell subsets, 
follicular T cells, and cytotoxic CD8+ T cells 157. Yet, it is unclear whether monocytes are poor antigen 
presenting cells (APCs) or perform antigen presentation in a similar fashion as dendritic cells, the 
so-called ‘professional’ APCs of the immune system157. Last but not least, monocytes are also 
involved in the suppression of T cell immunity by three different mechanisms: (1) direct killing of 
effector T cells or antigen-bearing DCs via nitrogen or oxygen, (2) indirect killing of T cells as a result 
of amino acid deprivation, and (3) suppressive effect on T cell function through enhanced Treg 
production, induced by recruitment of IL-10 producing monocytes168, 169, 170. 
 
1.3.2.2 Macrophages 
During inflammation and injury, monocytes are attracted by a number of pro-inflammatory 
mediators and terminally mature in the tissues into long-lived macrophages157. In addition, most 
tissues contain also tissue-resident macrophages that develop from embryonic monocyte precursor 
cells in the yolk sac and fetal liver and possess self-renewing capacity128, 154. Historically, these tissue 
macrophages were given specific names, such as red pulp macrophages (in the spleen), microglia 
(in the brain), alveolar macrophages (in the lung), Langerhans cells (in the skin), Kupffer cells (in the 
liver), and osteoclasts (in the bones)152, 157. Depending on the tissue site, macrophages fulfill a 
number of trophic functions and are involved in bone morphogenesis, ductal branching, and neural 
networking152. Besides granulocytes and dendritic cells, macrophages together with monocytes are 
the main phagocyting cells of the immune system16, 157. Macrophages constitutively express pattern 
recognition receptors (PRRs) such as toll-like receptors (TLRs) that enable them to recognize 
extracellular and intracellular PAMPs (pathogen-associated molecular patterns) and DAMPs 
(damage-associated molecular patterns)16.  
In addition to first-line pathogen defense, macrophages orchestrate immune functions, help induce 
inflammation, and produce a number of cytokines and chemokines that recruit and activate other 
cells of the immune system, which results in the release of ROS, high expression of inflammatory 
cytokines (e.g. IL-12), and upregulation of MHC class II (MHC-II) molecules171, 172.  Much effort was 
spent to classify macrophage subsets that are simplified referred to as pro-inflammatory versus 
pro-resolving, or M1-type versus M2-type macrophages, respectively, mirroring T helper type 1 
(Th1) and T helper type 2 (Th2) polarization172, 173. However, these terms have become mostly 
obsolete and many more subsets have been discriminated reflecting the ‘macrophage plasticity’ 
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that depends on the signals in their local microenvironment172. The main two phenotypes of 
macrophages can be recapitulated in vitro by their stimulation with lipopolysaccharides and IFN-y 
(M1-like) or IL-4 (M2-like), respectively174, 175. However, cross-differentiation of macrophages in yet 
undefined numbers of phenotypes during the course of an immune response is very likely152. 
 
1.3.2.3 Dendritic cells 
Similar to monocytes and macrophages, also dendritic cells develop from progressively restricted 
bone marrow progenitors165. There are two major types of dendritic cells: conventional (or classic) 
dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs)16. pDCs are thought to be involved in 
early defense against viral infection, exemplified by their expression of TLRs and high IFN- 
production176, 177. They are not considered to perform efficient antigen-specific activation of naïve 
T cells, exemplified by their low surface expression of MHC-II, co-stimulatory molecules, and also a 
rapid recycle of their MHC-II molecules. This suggests that they are not capable to present antigen 
to T cells for longer periods compared to cDCs178, 179. However, pDCs have been reported to act as 
helper cells for cDCs to sustain their secretion of the pro-inflammatory molecule IL-12180.   
In contrast, cDCs make up the majority of dendritic cells and their main role is the uptake of 
extracellular antigens or viruses and their processing in an increasingly harsh environment181, 182. As 
phagocytes, they alert the immune system that an invader is present via pathways initiated by PRRs, 
such as TLRs and optimize cytokine secretion to stimulate and direct T cell responses183. Eventually, 
cDCs perform antigen presentation to CD4+ or CD8+ T cells via MHC-I or MHC-II molecules, 
respectively184, 185.  
In mice, splenic cDCs can be categorized into CD8+CD11b- and CD8-CD11b+ dendritic cells186. Gene 
expression (meta) analysis of the transcriptome of several murine and human DC subsets has 
revealed that mouse CD8+ DCs are related to human CD141+ DCs, whereas mouse CD11b+ DCs are 
related to human CD1c+ DCs187. These two cDC subpopulations possess distinct functions. CD8+ DCs 
have the potential to induce Th1 responses, cross-prime CD8+ T cells and produce large amounts of 
IL-12188, 189. CD8- DCs in contrast, do not have the ability to cross-prime CD8+ T cells, but 
preferentially induce Th2 responses188, 189. The CD8+ cDC subset can be further subdivided into CD4+ 
and CD4- subsets, whereby the functional differences of these are yet unclear190. Moreover, they 
are also considered as products of separate lineages191. 
 
INTRODUCTION   
22 
 
1.3.3 Monocytes and macrophages in CLL 
In cancer, including CLL, myeloid cells show tumor-induced alterations, even though many of their 
principal biological pathways are maintained. In addition to stromal cells, follicular dendritic cells, 
T cells and NK cells, the tumor-supportive microenvironment consists also of monocytes, 
macrophages and possibly dendritic cells and plays a major role in CLL pathogenesis89. Burger et al. 
provided the first evidence for the existence of so-called nurse-like cells (NLCs), which are located 
in the lymph nodes of CLL patients and were demonstrated to be monocyte-derived78, 192. NLCs 
spontaneously differentiate in high-cell-density co-cultures of CLL cells and monocytes and are able 
to promote CLL cell survival and drug resistance78, 192. A gene expression profiling analysis revealed 
that NLCs resemble tumor-associated macrophages (TAMs) that were initially described for solid 
tumors and have features similar to tumor-supportive M2-type macrophages, such as for example 
expression of CD163193, 194, 195. Soluble factors, such as the chemokines CXCL12 and CXCL13 are 
secreted by NLCs and attract CLL cells through binding to their cognate receptors CXCR4 and 
CXCR5196, 197. Cell-cell contact of NLCs and CLL cells induces pro-survival pathways via the 
CD38/CD31 axis, and the TNF family members BAFF and APRIL, which interact with their receptors 
BCMA, TACI, and BAFF-R86, 104, 198. Interestingly, the gene expression pattern of CLL cells co-cultured 
with NLCs is similar to that of CLL cells that were freshly isolated from lymph nodes62. Moreover, 
BCR signaling is activated in CLL cells after co-culture with NLCs196. This pointed to the possibility 
that CLL cells might recognize BCR ligands that are expressed by NLC199. The impact of CLL cells on 
the differentiation of NLCs is based on the observation that CD14+ monocytes from healthy donors 
differentiated to NLCs in co-culture with CLL cells. In fact, the release of extracellular NAMPT, an 
enzyme with cytokine-like properties, by CLL cells, with an associated release of tumor promoting 
and immunosuppressive cytokines such as IL-6, IL-8, and IL-10, respectively, promoted M2-skewing 
of macrophages200. Further, NLC differentiation was shown to be induced by HMGB1/RAGE 
interaction in which CLL-secreted HMGB1, a chromatin protein secreted by injured or dying cells, 
leads to stimulation of TLR9-signaling in macrophages201.  
 
Analysis of monocytes in human CLL blood samples showed an abnormal distribution of the two 
main subsets of CD14+ and CD16+ monocytes favoring a shift towards the CD16hi (patrolling) 
subset202. This shift was recently confirmed in blood, spleen and bone marrow of leukemic Eµ-TCL1 
mice, the most commonly used mouse model for CLL203. Moreover, monocytes showed an 
increased expression and secretion of chemoattractive cytokines, such as CCL2, CCL3, CCL4, CXCL9, 
and CXCL10, as well as of immunosuppressive IL-10, which are elevated in plasma of diseased 
mice203. These data confirmed previous findings that many of these cytokines are upregulated in 
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blood serum of CLL patients79. CCL2 is one of the factors extensively studied as it was shown to be 
upregulated in monocytes upon coculture with CLL cells and, similar as in other cancer entities, 
might be responsible for monocyte recruitment to secondary lymphoid tissues79. Additional co-
culture approaches also revealed that CLL cells stimulate monocytes to release soluble CD14, which 
mediates CLL cell survival via induction of NF-κB signaling80. More recently, the pivotal role of 
monocytes and macrophages as main drivers of CLL progression was shown in a mouse study using 
Clodronate liposomes to deplete all phagocytic cells. This resulted in reduction of immune 
dysfunction and reduced systemic inflammation and impaired disease development203. 
 
Lately, several studies have proposed the existence of myeloid-derived suppressor cells (MDSC) in 
CLL204. MDSCs are defined as cells of myeloid origin that, due to an imbalance in myelopoiesis, 
expand in the context of cancer and possess immune-suppressive properties205. Accordingly, 
CD14+HLA-DRlow-expressing MDSCs in CLL were described to be increased and to significantly 
contribute to immune dysfunction in CLL patients204. These MDSCs expressed a number of markers 
associated with an anti-inflammatory, tolerogenic monocyte phenotype as well as with inhibition 
of T cell response, including PD-L1, CD124, CD163, and HLA-G204. Their functional ability to 
significantly decrease T-cell proliferation and promote T cell differentiation towards 
immunosuppressive regulatory T cells confirmed their identity as MDSCs204.  Moreover, this study 
confirmed that CLL cells actively shape the phenotype of monocytes, as CLL cells, but not healthy B 
cells, induced the expression of IDO1 on monocytes, which is an important mediator of T cell 
suppression204. 
A recent study by Haderk et al. illustrated that CLL-derived exosomes can be taken up by 
monocytes, leading to cytokine release and PD-L1 expression in monocytes91. The mechanism was 
proposed to act via binding of hY4 (a noncoding Y RNA enriched in CLL exosomes) to TLR7, initiating 
the observed downstream effects91.  
  
The role of dendritic cells in CLL is not as clear as in solid tumors, where a functional impairment of 
DCs appears as one of the mechanisms of tumor escape from the control of the immune system206. 
However, there are a number of indications that suggest a similar mechanism in CLL, as for example 
MHC-II was recently reported to be downregulated on dendritic cells of TCL-1 mice203. 
In summary, by a bi-directional crosstalk CLL cells induce major changes in the myeloid 
microenvironment, in particular mediating an immunosuppressive and tolerogenic phenotype in 
monocytes and macrophages that might in part explain T cell dysfunction and impaired anti-tumor 
response in CLL. Consequently, the interaction between CLL cells and their microenvironment is 
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often accused to be involved in therapy failure and therefore itself is becoming an attractive target 
for therapy207. 
 
1.3.4 Targeting myeloid cells in cancer 
A number of different monocyte/myeloid cell-targeting strategies have been applied to various 
cancer models over the recent years that will be briefly introduced in the following section. 
(1) Preventing macrophage mobilization and recruitment to the tumor site via blockade of 
chemokine gradients: 
Two examples of well-investigated chemokine axes for monocyte recruitment are CXCL12/CXCR4 
and CCL2/CCR2. In a study with a mammary tumor mouse model, which is linked to enhanced 
CXCL12 production and increased metastasis, the inhibition of CXCR4 reduced invasion, 
intravasation, and metastasis208. Inhibition of CCL2 in a mammary tumor model with pulmonary 
metastasis blocked the recruitment of inflammatory monocytes that promote metastatic seeding 
of tumor cells and by this favored the inhibition of metastasis and extended the survival of tumor-
bearing mice209.  
(2) Reprogramming/Re-education of M2-like macrophages to receive an anti-tumor M1-like 
phenotype or improved antigen-presenting capacity: 
For example, NF-B targeting reeducated TAMs as demonstrated by changes towards an M1-like 
phenotype with higher IL-12 and MHC-II expression levels, but low IL-10 and arginase-1 levels210. 
Tumor regression was promoted and proposed to be a consequence of regained antitumor 
cytotoxicity and IL-12-dependent recruitment of NK cells210. In another study, a small molecule 
antagonist against the macrophage migration inhibitory factor MIF attenuated its contribution to 
TAM alternative activation, immunosuppression, neoangiogenesis, and tumor outgrowth in a 
melanoma mouse model211.  
(3) Enhancing immune responses of antitumor T cells through reprogramming of the 
immunosuppressive tumor microenvironment via macrophage targeting: 
For example, the use of a CD40 agonist showed efficacy in a model of pancreatic ductal 
adenocarcinoma212. CD40 is expressed on APCs and known for its ability to regulate antitumor 
immune responses, in part by improved immune activation213. The application of the CD40 agonist 
caused macrophages to infiltrate tumors, increase their antigen presentation, upregulate MHC-II 
and CD86 expression, and disrupted the dense tumor stroma, all together leading to an improved 
antitumor outcome212. 
(4) Addressing myeloid cell subpopulations in cancer by specific pro-tumorigenic traits, such as 
angiogenesis:  
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TIE-2-expressing macrophages have been suggested to limit the success of therapeutic agents that 
aim at disrupting the vasculature in tumors214. Hence, TIE-2-expressing monocytes/macrophages 
could be targeted using neutralizing TIE-2 antibodies or angiopoietins215. 
(5) Macrophage-depleting strategies involving inhibitors and antibodies against the CSF-1R: 
In a mouse model of orthotopically transplanted cancer cell lines, derived from the mammary 
MMTV-PyMT mouse model, CSF-1R inhibition depleted macrophages within the tumor, 
accompanied with high numbers of infiltrating cytotoxic T cells and delayed tumor growth216. 
In reality, these different monocyte/myeloid cell-targeting strategies are likely to act through 
different mechanisms simultaneously such as for example reprogramming (2) and enhancing an 
immune response of antitumor T cells (3).  
In fact, in some studies the applied ‘strategy’ was not clearly defined in the beginning and such 
classification rather took place afterwards. The gained results and herein raised questions have 
been motivating for researchers to unravel the different mechanisms accounting for the various 
outcomes – particularly understanding the different myeloid subpopulations, such as tissue-
resident macrophages, and repopulating macrophages that are derived from blood monocytes and 
their interplay with cytotoxic T cells in different cancers. 
 
1.4 Genetically engineered mouse models of CLL 
Genetically engineered mouse models together with xenograft models represent a valuable tool 
for studying disease pathogenesis and its underlying asymptomatic disease states. Several 
genetically engineered mouse models have been generated that mirror human CLL disease. This is 
exemplified by their common feature of long latency, which mimics human CLL as a disease of the 
elderly217. These mouse models can be divided into two categories: (1) Mouse models mimicking 
the spectrum of deletions of chromosomal region 13q14, and (2) mouse models mimicking the 
deregulated expression of genes in human CLL.  
The 13q14 deletion models, carrying deletions of varying lengths in the murine chromosome 14qC3 
provided the first in vivo evidence for a tumor-suppressor function of the most frequent genetic 
deletion in human CLL patients38, 39, 218. Albeit a considerable number of these mice develop CLL-like 
symptoms, these models possess a relatively low penetrance (20-50%) which makes them rather 
unsuitable for testing of new therapies or to study the CLL microenvironment39, 218.  
In addition, several mouse models have been generated based on the deregulated expression of 
genes in human CLL, such as double transgenic mice with overexpression of the anti-apoptotic 
protein BCL-2 and the tumor necrosis factor receptor-associated factor TRAF, or the Eµ-TCL1 mouse 
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line 219, 220. While all the above-mentioned models offer valuable insights into the pathogenic 
mechanisms of CLL, the Eµ-TCL1 mouse line represents the most comprehensively studied mouse 
model of CLL, at the same time being a convenient preclinical model. 
 
1.4.1 Eµ-TCL-1 mouse model of CLL 
The principle of the Eµ-TCL1 transgenic mouse model is an aberrantly high expression of the T-cell 
leukemia-1 (TCL-1) gene, a protooncogene originally associated with T cell leukemia and expressed 
in malignant cells of almost all CLL patients220, 221, 222. Although the TCL-1 gene shows variable 
expression in CLL patients, its expression positively correlates with the aggressive UM-CLL 
phenotype, 11q deletion and a shorter lymphocyte doubling time221, 223, 224. As its name indicates, 
TCL-1 was identified in T cell lymphomas and leukemias222. By introducing the human TCL-1 gene 
into the murine genome under the control of the IGHV promoter and IGH enhancer (Eµ), the 
expression of TCL-1 is confined to mature and immature B-cells220. These Eµ-TCL-1 transgenic mice 
develop a CLL-like disease characterized by an expanded CD5+IgM+ B cell population that is arrested 
in the G0/G1 phase of the cell cycle220. Based on the occurrence of IGHV unmutated BCRs with 
stereotyped HCDR3 regions, the Eµ-TCL-1 mouse model corresponds to the aggressive, treatment-
resistant UM-CLL subtype in humans221, 225. Moreover, similarly as in patients, it was reported that 
autoantigens might play a key role in driving leukemia development in this model226, 227. 
Starting from 4 months of age, CLL-like cells appear first in the peritoneum, then in the peripheral 
blood and spleen. Finally, at 10 - 15 months of age, the mice develop CLL-like disease affecting 
almost 100% of the animals220. The mode of action through which TCL-1 promotes oncogenic 
progression was proposed to be through binding and regulation of molecular factors implicated in 
proliferation, survival, inhibition of apoptosis and epigenetic regulation. In particular, TCL-1 was 
identified as a co-activator of AKT, a key member of the BCR pathway leading to enhanced AKT 
kinase activity and its translocation to the nucelus228, 229. TCL-1 also interacts with the p300 
transcription factor resulting in NF-B activation in human B cells230. Hence, TCL-1 leads to an 
enhanced BCR responsiveness upon stimulation224. However, the long disease latency of CLL in this 
model may suggest that the ectopic TCL-1 overexpression acts as an initial hit or a predisposing 
factor for a further oncogenic transformation of B cells. Hence, it is assumed that various other 
genetic or microenvironmental aberrations may be required for full CLL development231. At the 
same time, this points to the possibility that CLL-associated inflammation may contribute and to 
some extent drive disease development in these mice. Various genetic players of CLL disease have 
been extensively investigated in the Eµ-TCL-1 mouse model or after it was crossed with mice of 
different genetic backgrounds as illustrated in Figure 6232, 233. 
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Figure 6: Study of pathogenic mechanisms of CLL in the TCL-1-driven leukemia model. 
Various mouse models have been crossed with Eμ-TCL-1 mice to generate overexpression (transgenic [tg]) or 
deficiency of different molecules in the Eμ-TCL-1 transgenic mouse model resulting in variable effects on the 
disease phenotype (BM, bone marrow; TAM, tumor-associated macrophages). This figure is derived from 
Simonetti et al., Blood, 2014231. 
 
Microenvironmental interactions have been the focus of several of these studies and play also a 
major role in this thesis. Ectopic expression of BAFF and APRIL, which mediates the interaction 
between CLL cells and CLL-associated macrophages in TCL-1 mice led to an accelerated and more 
aggressive disease development234, 235. In a study were Eµ-TCL-1 mice were crossed with 
(macrophage migration inhibitory factor) MIF-/- mice, animals showed delayed leukemia onset 
highlighting the role of MIF  for disease development236. 
 
Other players of the TME, such as T cells, have been demonstrated to exhibit dysfunctions in this 
model, and skewing of subpopulations, similarly as in CLL patients, could be addressed with 
immunotherapy approaches, again confirming the suitability of this model for studying the CLL 
microenvironment 237, 238. 
However, one downside of the transgenic CLL models including the Eµ-TCL-1 model for their use as 
preclinical models is the long latency and heterogeneous disease development. This issue can be 
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solved by adoptively transferring splenic leukocytes or B cells from diseased donor Eµ-TCL-1 mice 
into syngeneic wildtype or immunodeficient recipient mice, which results in leukemia development 
within 2 to 3 months237, 239, 240. This transplantation method benefits from an accelerated and more 
homogeneous disease course and a genetically homogeneous population of leukemic mice, thereby 
allowing for a more systematic study of novel therapies.  
 
1.5 Current and emerging therapies in CLL 
A large number of agents are available for treatment of CLL patients covering different categories 
of therapeutics including cytostatic agents, monoclonal antibodies, small molecule inhibitors, and 
immunomodulatory agents. For several decades, treatment of CLL included only monotherapy with 
cytostatic agents: alkylating agents such as Chlorambucil or Bendamustine and purine analogs, with 
Fludarabine being the most commonly used14, 241. The development of Rituximab, a monoclonal 
antibody against CD20, enabled the introduction of immunochemotherapy as a standard frontline 
therapy with Rituximab, Fludarabine and Cyclophosphamide (FCR) proven to improve outcome for 
patients in the CLL8 study of the German CLL study group242, 243. A recent, randomized study (CLL10) 
comparing FCR to Bendamustine and Rituximab (BR) confirmed FCR as standard first-line therapy 
for fit patients. However, even though the combination with BR was found to be less active than 
FCR it has been also accepted as an alternative treatment approach for patients with higher 
comorbidities due to less toxic effects and similar overall survival244. Furthermore, the newer FDA 
approved anti-CD20 antibodies Ofatumumab and Obinutuzumab enriched the options for 
immunochemotherapy leading to improvement for Fludarabine-refractory patients245, 246.  
Lenalidomide is an immunomodulatory drug, mostly used for CLL second-line treatment with a 
unique and multifactorial mode of action in CLL, comprising a wide range of immunomodulatory 
actions, the disruption of interactions in CLL microenvironment and direct effects on the leukemic 
cells14, 247. Its main target is the protein cereblon and Lenalidomide was shown to inhibit the 
proliferation of CLL cells via a cereblon/p21 (WAF1/Cip1)-dependent mechanism248, 249. 
Lenalidomide shows promising results in the treatment of high-risk CLL patients including patients 
with 17p deletion, and achieves even better response rates in combination with Rituximab250, 251, 
252.  
Especially, the deeper molecular understanding of the BCR signaling gained in the recent years has 
enhanced the rapid development of novel small molecular inhibitors, including Ibrutinib (a BTK 
inhibitor which is covered in more detail in the following chapter) and Idelalisib (a PI3Kδ inhibitor) 
that were included into the therapeutic repertoire for CLL253, 254.  
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More recently, Venetoclax was approved for treatment of CLL patients255. In CLL, the expression of 
the anti-apoptotic protein BCL-2 is constitutively elevated facilitating resistance to apoptosis256. 
Venetoclax belongs to the class of BH3-mimetic anticancer agents and mimics the activity of the 
physiologic antagonists of BCL-2 and related proteins and by this initiates apoptosis of CLL cells257, 
258, 259. 
These novel agents more and more shift treatment of CLL from toxic chemotherapy toward specific, 
low toxic, targeted therapy. The choice for optimal treatment depends on different parameters that 
need to be considered: the clinical stage of disease, the patient’s physical condition and symptoms, 
genetic alterations (presence or absence of 17p deletion and TP53 mutations), and response to 
previous treatment (first or second line treatment)14, 241.  
In addition to approved drugs for CLL, several promising novel agents in phase I-III trials may 
challenge existing therapeutics and add combination possibilities, such as Ublituximab (anti-CD20), 
the next-generation BTK inhibitors, Acalabrutinib and ONO-4059, proposed to possess higher 
specificity for BTK, and additional PI3Kγ and PI3Kδ inhibitors, Duvelisib (PI3Kγ and PI3Kδ inhibitor), 
and TGR-1202 (PI3Kδ inhibitor)260, 261, 262, 263, 264.  
CAR (chimeric antigen receptor) T cell therapy is another promising approach where autologous T 
cells are engineered to express artificial receptors that recognize and eliminate tumor cells. In 2011, 
Porter et al. reported the first successful use of CAR T cells generated with a lentiviral vector in 3 
refractory CLL patients265. The used CAR consisted of an antigen recognition domain for CD19 and 
an intracellular T cell receptor-ζ (TCR-ζ) (a signal-transduction component of the TCR) domain that 
was coupled with CD137 (a costimulatory receptor in T cells) causing augmented T cell response 
and anti-tumor efficacy266, 267. Lately, CD19-specific CAR-T cells were shown to be highly effective in 
relapsed/refractory CLL high-risk patients or patients who have experienced treatment failure with 
Ibrutinib therapy266, 268. However, clinical outcome of CLL patients is inversely correlated with tumor 
burden which lead to the speculation that excessive tumor mass results in non-functional infused 
T cells that suffer from exhaustion269. Thus, the area of CAR-T cell therapy in CLL remains a 
challenging field of research.  
 
1.5.1 Targeting Bruton’s tyrosine kinase in CLL with Ibrutinib  
1.5.1.1 The effect of Ibrutinib on CLL cells  
Ibrutinib (also known as PCI-32765) is a small molecule BTK inhibitor that has shown clinical activity 
in patients with various B cell malignancies, including CLL and mantle cell lymphoma (MCL) 270, 271. 
Ibrutinib irreversibly and selectively binds to the C481 site of BTK and by this inhibits its kinase 
activity with an IC50 value of 0.5 nM272. BTK was initially discovered in XLA (inherited 
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immunodeficiency disease X-linked agammaglobulinaemia) patients273. XLA patients carry a 
mutated version of the gene causing defective B cell development and leading to an almost 
complete absence of B cells and immunoglobulins while other cells remain unaffected274, 275. 
Subsequently, BTK was shown to be involved in BCR pathway as stimulation of B cells induces 
phosphorylation and kinase activity of BTK276, 277. Several findings demonstrated that BTK 
contributes to the pathogenesis of CLL. BTK was shown to be overexpressed and constitutively 
phosphorylated in some CLL patients72. Overexpression of human BTK in a mouse model dampened 
sensitivity to apoptosis whereas in a CLL mouse model, BTK deficiency prevented tumor 
formation278, 279. Besides its well-studied role in BCR signaling, BTK is also involved in signaling 
pathways downstream of other receptors, including G protein-coupled chemokine receptors and 
Toll-like receptors (TLRs)280. Treatment of CLL cells with Ibrutinib inhibits the tonic BCR pathway and 
reduces survival and proliferation of CLL cells in vitro281, 282. Ibrutinib treatment also efficiently 
blocks CXCL12-induced and CXCL13-induced migration of CLL cells in vitro suggesting that BTK might 
be required for migration of leukemic cells to proliferation centres in lymph nodes of patients281, 
282. Ibrutinib’s effect on migration of CLL cells may also explain the induced transient lymphocytosis 
observed in CLL patients as well as in a mouse model following the initiation of therapy270, 282. This 
mobilization out of the lymph nodes detracts CLL cells from their nursing microenvironment as well 
as antigenic BCR stimulation62. 
 
1.5.1.2 The effect of Ibrutinib on the microenvironment 
Despite the obviously B cell-restricted phenotype in XLA patients, BTK is not only expressed in B 
cells but in all hematopoietic cells, except T cells283, 284. Indeed, several pieces of evidence suggest 
that the response to Ibrutinib cannot be solely explained by direct effects on BCR signaling in CLL 
cells. CLL patients show variation in response which is not correlated to BTK protein expression 
suggesting that in addition to intrinsic dependencies also microenvironmental signals might play an 
important role in this context. Hermann et al. have shown that Ibrutinib was able to overcome 
protection of CLL cell apoptosis by stromal cells by reducing different microenvironmental stimuli 
such as CD40L, BAFF, TNF-α, IL-4, and IL-672.  
Of interest, BTK is a key regulator of multiple functions in monocytes and macrophages. In bone 
marrow-derived macrophages, BTK has been described to be required for phagocytosis of apoptotic 
cells as a downstream function of TLR signaling285. Multiple TLRs in myeloid cells are known to signal 
via BTK. As BTK is involved in the response of macrophages to LPS, a ligand of TLR4, Ibrutinib might 
impact on their polarization286.  Because BTK was proposed to be a positive regulator of the TREM-
1 signaling pathway, Ibrutinib might also inhibit the inflammatory potential of monocytes and 
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macrophages287, 288. In addition, BTK inhibition can inhibit downstream signaling of Fc receptors in 
monocytes and macrophages in vitro289 . Moreover, BTK has been identified to be constitutively 
phosphorylated in acute myeloid leukemia (AML) where Ibrutinib was able to inhibit cell 
proliferation of AML cells, NF-B activity, adhesion to bone marrow stromal cells, and 
CXCL12/CXCR4 mediated migration290, 291. These observations highlight the importance of 
investigating effects of BTK inhibition by Ibrutinib in myeloid cells within the CLL microenvironment.  
In addition, it has been shown that Ibrutinib inhibits kinases that are similar to BTK, like BLK (IC50=0.5 
nM), ITK (IC50=10.7 nM), and TEC (IC50=78 nM)272. Blockade of ITK (IL-2 T cell inducible kinase) 
appears to mediate an off-target effect of Ibrutinib with clinical importance since it transmits a 
selective advantage for T helper 1 (Th1)-based immune response292. T cells from patients with CLL 
show only minor proliferation in response to TCR stimulation using anti-CD3/CD28 beads293. 
However, 5–11 cycles of Ibrutinib treatment reversed this proliferation defect in T cells to levels 
comparable to those of healthy donors293. Most recently, Ibrutinib has been shown to decrease the 
number of regulatory T cells in patients and impact on the cytokine network294, 295. In addition, 
Ibrutinib impacts on CLL-associated clonal T cell expansion through an increase of the T cell 
repertoire diversity296. 
 
1.5.1.3 Ibrutinib resistance in CLL patients 
Despite the remarkable success of Ibrutinib during the recent years, there have been reports on the 
occurrence of acquired resistance to Ibrutinib in a subset of patients297. Two types of Ibrutinib 
resistance have been proposed. In the first group of patients, Richter’s transformation occurs rather 
early after treatment initiation within 12 to 15 months298. In the second group of patients, CLL 
progresses at a later time point (15+ months) and the resistance development is associated with 
somatic mutations in genes of the BTK pathway, in particular mutations of the Ibrutinib-binding site 
of BTK and/or different mutations of the direct downstream molecule PLCG2298. Accordingly, high-
sensitivity sequencing approaches have been developed for early detection of mutations in BTK or 
PLCG2 in patients treated with the BTK inhibitor299.  
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Figure 7: Molecular patterns of Ibrutinib-resistant disease. 
This figure is derived from Ahn, I.E. et al. Blood, 2017298. 
 
The identification of a resistant case as part of the response assessment is a challenge for clinicians. 
Since most patients will not achieve a complete response and many will have circulating CLL cells 
in the blood for long periods of time, determining which patients are indeed relapsing and 
discriminating them from patients that are still sensitive for Ibrutinib treatment can be a difficult 
task300. One hallmark of patients under Ibrutinib treatment is clonal evolution of CLL, favoring 
selection and expansion of rare subclones that are already present before start of treatment298, 301.  
 
Targeting of BTK with other promising small molecule inhibitors that do not depend on binding to 
the mutated site of the enzyme, such as GDC-0853 may be a feasible therapy option for Ibrutinib-
resistant patients302. In addition, targeting of the BCR pathway downstream of BTK and PCLG2 such 
as via PKCβ may be an alternative and effective treatment strategy. However, clinical studies need 
to be conducted in this respect. One promising treatment approach lately applied for Ibrutinib-
treated relapsed/refractory CLL patients is by therapy with the BCL-2 inhibitor Venetoclax. In an 
ongoing clinical phase II study, Venetoclax treatment of CLL patients who have relapsed or are 
refractory to Ibrutinib and/or Idelalisib showed an overall response rate of 61% among patients 
that are refractory to Ibrutinib303. This may be related to the finding that BTK inhibition enhances 
mitochondrial BCL-2 dependence, which is accompanied by an increase in the pro-apoptotic protein 
BIM304. 
However, even though CLL relapse on Ibrutinib is primarily mediated through the acquisition of 
mutations, there are rare cases where neither mutations in the targeted or downstream genes were 
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found, nor Richter transformation was observed. Therefore, there will be increasing attempts not 
only to find rational treatment regimens for patients with identified mutations, but also to 
understand the so far elusive events causing progression of disease under Ibrutinib treatment.  
 
1.6 Objectives 
The first aim of this thesis was to test the potential of therapeutically targeting myeloid cells in CLL, 
which were previously suggested to possess tumor-promoting abilities in this disease. As CSF-1R is 
expressed on all cells of the myeloid lineage and known to be important for TAM differentiation in 
solid tumors, it was hypothesized that therapeutic intervention with the CSF-1/CSF-1R axis would 
lead to an improvement of disease outcome. An antibody-mediated strategy was chosen using 
TG3003, a monoclonal antibody that specifically targets human CSF-1R. Initial in vitro tests aimed 
at characterizing the effect of TG3003 on NLC generation and activity, which represent a well-
accepted culture model, mimicking the lymph node microenvironment in CLL. A special focus was 
given here to changes in NLC-mediated survival support of CLL cells and to potential changes in the 
profile of secreted factors with functional relevance for CLL. In addition, the effect of TG3003 was 
addressed in a preclinical model of CLL by adoptively transferring splenocytes from leukemic Eµ-
TCL-1 into C57BL/6 mice (TCL-1 AT) with a humanized CSF-1R locus. The question was whether 
treatment with TG3003 would induce changes in the TME, and specifically in myeloid cells, including 
Ly6Clow monocytes, the subset that is highly enriched in CLL. The final question of this part was, 
whether this treatment would lead to an improved disease outcome and therefore represent a 
promising therapy approach for CLL.  
 
The second goal of this work was an extensive comparison of myeloid cells in mice in steady state 
and in the leukemia model to obtain insights into their pathological role in CLL. In addition to the 
proposed tumor-promoting abilities of myeloid cell in CLL, there have been also reports, that cells 
of the myeloid lineage may exhibit immunosuppressive properties. Multicolor-flow cytometry and 
flow sorting of specific myeloid cell subset (Ly6Clow and Ly6Clow monocytes, and conventional 
dendritic cells) followed by gene expression profiling were used to gain a comprehensive overview 
about specific characteristics and potential functionalities of these cells. One further research 
interest was the influence of the BTK inhibitor Ibrutinib on myeloid cell subsets that also express 
BTK, suggesting an indirect activity of Ibrutinib on the CLL tumor microenvironment. The intention 
was to unravel, if Ibrutinib induces a normalization of the CLL-associated phenotype of myeloid cells 
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and thereby contributes to the clinical success of this drug, or if Ibrutinib negatively impacts on 
these cells, which would require therapeutic intervention.  
 
The third objective of the current work was the investigation of resistance development to Ibrutinib 
treatment in the TCL-1 AT model. This is of importance given the fact that a raising number of 
patients relapse with severe disease progression under Ibrutinib treatment, while the underlying 
mechanism is not fully understood, except for those cases that present with mutations in BTK or 
PLC2. A major focus of this part was to analyze tumor kinetics and tumor phenotypical features 
during resistance development in the TCL-1 AT model. Moreover, whole exome and RNA 
sequencing served as selected methods for identification of resistance-underlying mechanisms. 
Finally, these analyses aimed at identifying and understanding molecular mechanisms of Ibrutinib 
resistance in CLL patients which can be used to design and optimize future therapy options. 
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2 MATERIAL AND METHODS 
2.1 MATERIAL 
2.1.1 Mouse lines 
Lines  Distributor/source 
C57BL/6 (J and N substrain) Charles River Laboratories, Sulzfeld, Germany 
Eµ-TCL1 on C57BL/6 (J and N substrain) Dr. Carlo M. Croce, The Ohio State University, 
College of Medicine, USA 
CSF-1 KI on C57BL/6 background, N substrain Taconic Biosciences, Hudson, New York 
 
2.1.2 Human and murine flow cytometry antibodies 
Antibody Fluorochrome Clone Distributor 
anti-human CD5 FITC L17F12 BD Biosciences  
anti-human CD19  APC HIB19 BD Biosciences 
anti-mouse CD3e FITC 145-2C11 eBioscience  
anti-mouse CD3e V450 500A2 BD Biosciences  
anti-mouse CD4 APC RM4-5 eBioscience  
anti-mouse CD4 APC/Cy7 GK1.5 Biolegend  
anti-mouse CD5 APC 53-7.3 BD Biosciences  
anti-mouse CD8a Alexa Fluor® 700 53-6.7 Biolegend  
anti-mouse CD8a APC/Cy7 53-6.7 Biolegend  
anti-mouse CD11b APC M1/70 eBioscience  
anti-mouse CD11b PE/Cy7 M1/70 eBioscience  
anti-mouse CD11b PerCP M1/70 Biolegend  
anti-mouse CD11c Brilliant Violet 605 N418 Biolegend 
anti-mouse CD11c PerCP N418 Biolegend  
anti-mouse CD11c PerCP/Cy5.5 N418 Biolegend  
anti-mouse CD19 FITC 1D3 eBioscience  
anti-mouse CD19 PE 1D3 eBioscience  
anti-mouse CD19 PE/Dazzle™ 594 6D5 Biolegend 
anti-mouse CD31 PE 390 eBioscience  
anti-mouse CD38 PE 90 eBioscience 
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anti-mouse CD43 PE S7 BD Biosciences  
anti-mouse CD43 PerCP/Cy5.5 S7 BD Biosciences  
anti-mouse CD44 Alexa Fluor® 700   IM7 eBioscience  
anti-mouse CD45 APC/Cy7 30F-11 Biolegend  
anti-mouse CD45 PerCP/Cy5.5 30F-11 Biolegend 
anti-mouse CD54 PE YN1/1.7.4 eBioscience  
anti-mouse CD83 APC Michel-19 Biolegend  
anti-mouse CD86 PerCP/Cy5.5 GL-1 Biolegend  
anti-mouse CD115 PE AFS98 eBioscience  
anti-mouse CD117 Brilliant Violet 605 2B8 BD Biosciences 
anti-mouse CD86 PE GL-1 eBioscience  
anti-mouse F4/80 APC BM8 eBioscience  
anti-mouse F4/80 PE BM8 eBioscience  
anti-mouse Ki67 FITC SolA15 eBioscience  
anti-mouse KLRG1 PE/Cy7 2F1 eBioscience  
anti-mouse LAG3 PE eBioC9B7W eBioscience  
anti-mouse Ly6C APC/Cy7 HK1.4 Biolegend  
anti-mouse Ly6G FITC 1A8 Biolegend  
anti-mouse Ly6G PE 1A8 BD Biosciences  
anti-mouse Ly6G V450 1A8 BD Biosciences  
anti-mouse MHC-II I-
A/I-E 
Alexa Fluor® 700  
 
M5/114.15.2 eBioscience  
 
anti-mouse MHC-II I-
A/I-E 
PE  M5/114.15.2 eBioscience  
 
anti-mouse NK1.1 FITC PK136 Biolegend 
anti-mouse NK1.1 V450 PK136 BD Biosciences  
anti-mouse PD-L1 PE MIH5 eBioscience  
anti-mouse PD-L1 APC B7-H1 Biolegend 
anti-mouse TER-119 FITC TER-119 Biolegend  
anti-mouse TREM-1 PE 174031 R&D  
anti-mouse IL-12/IL-
23  
PE C17.8 eBioscience 
anti-mouse Il-1b  APC NJTEN3 eBioscience 
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anti-mouse TNF-a PerCP/Cy5.5 MP6-XT22 Biolegend 
pBTK (pY223)/Itk 
(pY180) 
PE N35-86 BD Biosciences  
Rat IgG1  Isotype 
Control 
PerCP/Cy5.5 eBRG1 eBioscience 
Rat IgG1  Isotype 
Control 
FITC eBRG1 eBioscience 
 
2.1.3 Other antibodies 
Antibody Fluorochrome Clone Distributor 
F(ab')2-Goat anti-
Mouse IgM (mu) 
Secondary Antibody 
unconjugated polyclonal eBioscience 
TG3003 (/H27K15)  unconjugated monoclonal Transgene SA, Illkirch 
Graffenstaden Cedex, 
France 
human IgG1 kappa 
control antibody 
unconjugated monoclonal GeneTex , Inc., Irvine, 
California 
anti-IL-10R unconjugated clone 1B1.3A BioXcell, West 
Lebanon, NH 
rat IgG1 isotype 
contol 
unconjugated clone: HRPN BioXcell, West 
Lebanon, NH 
anti-IFN unconjugated clone: XMG1.2 BioXcell, West 
Lebanon, NH 
 
2.1.4 Buffers 
Buffer  Composition/Distributor 
ACK buffer 150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, 
pH 7.2-7.4  
Annexin V Binding Buffer (10X) BD Biosciences, Heidelberg, Germany  
FACS (Fluorescence-activated cell sorting) 
buffer  
1x PBS, 2% FCS, 0.02% (v/v) NaN3  
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Freezing medium for human cells Respective complete medium + 10% FCS + 
10% DMSO  
Freezing medium for mouse cells 90% FCS + 10% DMSO  
MACS buffer (autoMACS Running Buffer)  Miltenyi Biotec, Bergisch Gladbach, Germany  
Phosphate Buffered Saline (PBS, pH7.4)  NaCl (137mM), Na2HPO4 (9.2mM), KCL 
(2.7mM), KH2PO4 (1mM)  
eBioscience™ IC Fixation Buffer eBiosciences, Frankfurt am Main, Germany 
eBioscience™ 1-step Fix/Lyse Solution (10X) eBiosciences, Frankfurt am Main, Germany 
RBC Lysis Buffer (10X) Biolegend, San Diego, California, USA  
eBioscience™ Permeabilization Buffer (10X) eBiosciences, Frankfurt am Main, Germany 
Foxp3 / Transcription Factor Staining Buffer 
Set 
eBiosciences, Frankfurt am Main, Germany 
Complete medium for human cells 
(‘complete human medium’) 
DMEM High Glucose + 10% FCS + 1% 
penicillin/streptomycin 
Complete medium for mouse cells 
(‘complete mouse medium’) 
RPMI 1640 (2mM Glu) + 10% FCS + 4 mM L-
glutamine + 1% penicillin/streptomycin + 0.1% 
2-mercaptoethanol 
T cell stimulation medium DMEM High Glucose + 10% FCS + 1% 
penicillin/streptomycin + 10 mM HEPES + 1 
mM sodium pyruvate  
 
2.1.5 Cell culture reagent and material 
Material   Distributor 
Biocoll separating solution   Biochrom, Berlin, Germany  
 
DMEM High Glucose (4.5g/L Glucose, 
4mMGlu) 
Gibco / Life Technologies, Karlsruhe, Germany  
Fetal Calf Serum (FCS) Biochrom / Merck, Darmstadt, Germany  
Normal Rat Serum Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA  
PBS Dulbecco’s Gibco Gibco / Life Technologies, Karlsruhe, Germany 
Penicillin / Streptomycin (10.000 U/ml) Gibco / Life Technologies, Karlsruhe, Germany 
RPMI 1640 (2mM Glu) Gibco / Life Technologies, Karlsruhe, Germany  
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Histopaque®-1083 Sigma-Aldrich, Munich, Germany 
 
2.1.6 Cell isolation 
Material   Distributor 
CD14 MicroBeads, human Miltenyi Biotec, Bergisch Gladbach, Germany 
CD19 MicroBeads, mouse Miltenyi Biotec, Bergisch Gladbach, Germany  
Leucosep™ tubes, 50 mL  Greiner Bio-One International GmbH, 
Kremsmünster, Austria  
Lipopolysaccharide (LPS) Sigma-Aldrich Gmbh, Munich, Germany  
MACS LS separation columns   Miltenyi Biotec, Bergisch Gladbach, Germany  
 
MACS Magnet and stand Miltenyi Biotec, Bergisch Gladbach, Germany  
M-CSF, human recombinant R&D Systems, Minneapolis, MN, USA 
Monocyte Isolation Kit II, human Miltenyi Biotec, Bergisch Gladbach, Germany  
Monocyte Isolation Kit (BM), mouse Miltenyi Biotec, Bergisch Gladbach, Germany  
Multiwell plates, 12-well, 24-well, 48-well TPP Techno Plastic Products AG,  
Trasadingen, Switzerland Pasteur pipettes / 
VWR®  
Disposable Transfer Pipets VWR International, Radnor, PA, United States  
Red Blood Cell Lysis Solution (10X) Miltenyi Biotec, Bergisch Gladbach, Germany  
Easysep™ Mouse Pan-B Cell Isolation Kit Stemcell Technologies, Vancouver, Canada 
C-tubes  Miltenyi Biotec, Bergisch Gladbach, Germany  
 
2.1.7 Chemicals and other reagents 
Material   Distributor 
2-mercaptoethanol Sigma-Aldrich, Munich, Germany  
β-Cyclodextrin Sigma-Aldrich, Munich, Germany  
Bovine serum albumin (BSA) Sigma-Aldrich, Munich, Germany  
Ethanol Merck, Darmstadt, Germany  
Methanol Roth, Karlsruhe, Germany  
7-aminoactinomycin (7-AAD) BD Biosciences, Heidelberg, Germany 
Dimethylsulfoxid (DMSO) Sigma-Aldrich, Munich, Germany  
Fixable Viability Dye eFluor 506™ eBiosciences, Frankfurt am Main, Germany  
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Fixable Viability Dye eFluor 780™ eBiosciences, Frankfurt am Main, Germany  
Fludarabine Enzo Life Sciences, Lörrach, Germany  
Ibrutinib/ PCI-32765 (for in vitro purposes) Selleckchem, Munich, Germany  
Ibrutinib/ PCI-32765 (for in vivo purposes) Provided by collaboration partner Prof. 
Stephan Stilgenbauer  
Idelalisib Selleckchem, Munich, Germany  
Ionomycin Sigma-Aldrich, Munich, Germany  
L-Glutamine Gibco / Life Technologies, Carlsbad, USA  
PE Annexin V BD Biosciences, Heidelberg, Germany  
RNaseZap® Life Technologies, Carlsbad, USA 
123count™ eBeads Counting Beads eBiosciences, Frankfurt am Main, Germany 
DAPI (4′,6Diamidin-2-phenylindol) Life Technologies, Carlsbad, USA 
eBioscience™ Protein Transport Inhibitor 
Cocktail 
eBiosciences, Frankfurt am Main, Germany 
eBioscience™ Cell Stimulation Cocktail (500X) eBiosciences, Frankfurt am Main, Germany 
Thiazolyl blue (MTT) 3-(4,5-Dimethyl-2-
thiazolyl)-2 ,5-diphenyl-2H-tetrazolium 
bromide 
Biomol GmbH, Hamburg 
 
2.1.8 Instruments 
Instrument Distributor 
ABI Prism 7900HT   Life Technologies, Carlsbad, USA 
Agilent 2100 Bioanalyzer Agilent Technologies GmbH, Berlin, Germany  
BD FACSAria™ II BD Biosciences, Heidelberg, Germany 
BD FACSCanto II BD Biosciences, Heidelberg, Germany 
BD LSRFortessa™   BD Biosciences, Heidelberg, Germany 
gentleMACS™ Dissociator Miltenyi Biotec, Bergisch Gladbach, Germany 
Incubator Hera Cell 150i ThermoFischer Scientific, Scoresby Vic, 
Australia 
Mithras LB940 Plate Reader Berthold Technologies, Bad Wildbad, Germany 
NanoDrop® ND-1000 Spectrometer NanoDrop, Wilmington, US 
OctoMACS Separator Miltenyi Biotec, Bergisch Gladbach, Germany 
Pipet-Lite XLS+  Multichannel Mettler Toledo, Giessen, Germany 
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Pipettes (20μl, 100μl, 200μl, 1000μl) Gilson, Middleton, Germany 
QuadroMACS Separator Miltenyi Biotec, Bergisch Gladbach, Germany 
Vi-CELL XR 2.03 Beckman Coulter Inc.,Brea, USA 
Water Bath GFL 1086 GFL Gesellschaft für Labortechnik GmbH, 
Hannover 
Easysep™ Magnet Stemcell Technologies, Vancouver, Canada 
UV-Gel Documentation System BioRad, Hercules, USA 
 
2.1.9 Kits 
Kit Distributor 
DNeasy Blood & Tissue Kit Qiagen, Hilden, Germany  
RNeasy Micro Kit Qiagen, Hilden, Germany  
AllPrep DNA/RNA/Protein Mini Kit Qiagen, Hilden, Germany 
BD Cytometric Bead Array (CBA) Human 
Enhanced Sensitivity Master Buffer Kit 
BD Biosciences, Heidelberg, Germany 
BD Cytometric Bead Array (CBA) Human IL-6 
Flex Set 
BD Biosciences, Heidelberg, Germany 
BD Cytometric Bead Array (CBA) Human 
Soluble CD14 Flex Set 
BD Biosciences, Heidelberg, Germany 
BD Cytometric Bead Array (CBA) Human MCP-
1 (CCL2) Flex Set 
BD Biosciences, Heidelberg, Germany 
MILLIPLEX MAP Mouse Cytokine/Chemokine 
Magnetic Bead Panel 
Merck Millipore, Germany 
Quantikine® ELISA Human M-CSF R&D Systems, Minneapolis, MN, USA 
Quantikine® ELISA Human TNF- R&D Systems, Minneapolis, MN, USA 
 
2.1.10 Database and online tools 
Databases and online tools   Source 
Immgen  https://www.immgen.org/ 
Pubmed www.ncbi.nlm.nih.gov/pubmed/ 
Venny  http://bioinfogp.cnb.csic.es/tools/venny/ 
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2.1.11 Software 
Software   Distributor 
BD FACS Diva BD Biosciences, San Jose, USA  
Bioanalyzer 2100 Expert  Agilent Technologies, Santa Clara, USA 
Chipster v3.11 http://chipster.csc.fi/ (open source) 
EndNote X8 Thomson Reuters, Carlsbad, USA  
FlowJo V10 FlowJo, Ashland, OR, USA  
ImageJ 1.47v Wayne Rasband, National Institutes of Health, 
USA  
Ingenuity® Systems IPA http://www.ingenuity.com/  
Inkscape https://inkscape.org/de/ (open source) 
Microsoft Excel 2013 Microsoft, Redmond, USA 
Microsoft PowerPoint 2013 Microsoft, Redmond, USA 
Microsoft Word 2013 Microsoft, Redmond, USA 
Prism 7 GraphPad GraphPad Software, La Jolla, USA 
R https://www.r-project.org/ (open source) 
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2.2 METHODS 
2.2.1 Cell culture of primary CLL cells and monocytes 
2.2.1.1 Isolation of human PBMC and monocytes 
For experiments with human CLL cells, peripheral blood mononuclear cells (PBMCs) were retrieved 
from CLL blood samples provided by collaboration partners at University Clinic, Ulm and National 
Center for Tumor diseases (NCT), Heidelberg. For experiments with monocytes, PBMCs were 
isolated from peripheral blood buffy coat samples, purchased from the Institute for Clinical 
Transfusion Medicine and Cell Therapy (IKTZ, Heidelberg, Germany). Primary human monocytes 
were subsequently isolated from PBMCs samples. 
In brief, 15mL Biocoll solution, adjusted to RT, was added into Leucosep™ tubes and then 
centrifuged at 1,000 x g for 1 min. Blood samples were diluted (buffy coat samples 1:4, CLL patient’s 
blood 1:2) in room-tempered PBS and transferred to Leucosep™ tubes, adding 35mL per tube to 
obtain a total volume of 50mL. Samples were then centrifuged at 1,000 x g for 20 min, at RT, without 
brake. The PBMC interphase was carefully transferred to a new 50mL Falcon tube using a 5mL pipet 
while avoiding excess transfer of the upper plasma layer and lower Biocoll layer. PBMCs were 
washed twice in cold PBS, centrifuged at 300 x g for 10 min and then resuspended in ice-cold MACS 
buffer, prior to cell counting.  
As approximately 10% of PBMCs are monocytes, respective cell numbers were used for further 
positive selection of CD14+ monocytes to retrieve the needed cell numbers for downstream 
experiments. Isolation of monocytes was conducted by magnetic activated cell sorting (MACS), by 
labeling monocytes directly with magnetic bead-coupled anti-human CD14 antibodies (positive 
selection) according to manufacturer’s instructions. In brief, cells were centrifuged at 300 x g for 10 
min and resuspended in ice-cold MACS buffer (80µL per 1x107 cells) and anti-human CD14 
microbeads (20µL per 1x107 cells). Samples were incubated for 15 min at 4°C followed by washing 
in MACS buffer and centrifugation at 300 x g for 5 min. Cells were resuspended (500µL per 1x108 
cells) in ice-cold MACS buffer and applied onto columns, which were previously equilibrated with 
ice-cold MACS buffer and placed at the magnetic stand. Flow through was discarded and magnetic 
columns were washed three times with 2mL ice-cold MACS buffer. Magnetically labelled monocytes 
were eluted in 5mL ice-cold MACS buffer. Monocytes were centrifuged at 300 x g for 10 min, 
resuspended (500µL per 1x108 cells) in ice-cold MACS buffer and column-based purification was 
repeated one additional time to achieve better purity. CD14+ monocytes were counted and 
resuspended in complete human medium (DMEM High Glucose + 10% FCS + 1% 
penicillin/streptomycin).  
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2.2.1.2 Co-culture of primary CLL cells with monocytes and NLC co-cultures 
For NLC cocultures, PBMCs from CLL patients with high tumor load were seeded in a high cell 
density (1.5x107/mL), in 500µL volume of complete human medium per well of a 48-well plate, as 
described previously and cultured for 12 to 14 days to induce NLC differentiation305.  
For CLL-monocyte cocultures, CLL-PBMCs and CD14+ monocytes were retrieved as described above. 
Cells were co-seeded, whereby CLL cell were added in excess. The detailed conditions are indicated 
in the respective result part.  
 
2.2.2 Animals and tumor models 
All animal experiments were carried out according to governmental and institutional guidelines and 
authorized by the local authorities (Regierungspräsidium Karlsruhe, permit numbers: G42/15, G-
16/15. Mice were monitored for signs of illness and were sacrificed at indicated time points. 
 
2.2.2.1 Transgenic Eµ-TCL-1 mice 
Eµ-TCL-1 transgenic mice were used as a source for primary tumors in the TCL-1 adoptive transfer 
model described in the following section. Eµ-TCL-1 (TCL-1) transgenic mice (C. Croce, OH, USA) were 
bred on a C57BL/6 background in pathogen-free conditions at the central animal facility of the 
German Cancer Research Center (DKFZ). In brief, heterozygous TCL-1 mice were bred with wild-
type (WT) C57BL/6 mice generating progeny of heterozygous TCL-1 mice and WT littermates. 
Leukemia typically developed in TCL-1 transgenic mice at an age of 10-15 months, indicated by 
palpable spleens and followed by confirmed presence of CD5+CD19+ cells in the peripheral blood.  
 
TCL-1 mice were bred separately for the two major C57BL/6 substrain backgrounds: C57BL/6 N and 
C57BL/6 J, which were confirmed by single nucleotide polymorphism analysis of tail DNA using the 
Genome Scanning Service at The Jackson Laboratory (Bar Harbor, Maine, USA). 
Genotyping of TCL-1 mice was performed with DNA isolated from tail tissue using DNeasy Blood & 
Tissue Kit, Qiagen. The PCR reaction was conducted using Phire®Hot Start II PCR Master Mix and 
the following forward and reverse primers: forward_TCL-1-5'GCCGAGTGCCCGACACTC'3 and 
reverse_ TCL-1-5'CATCTGGCAGCAGCTCGA'3. The PCR program comprised the following steps: 
initial denaturation at 98°C for 30 seconds, denaturation at 98°C  for five seconds, annealing at 59°C 
for five seconds, extension: 72°C for one min (30 cycles), and final extension at 72°C for one min. 
The PCR products were separated on 1% agarose gel, stained with ethidium bromide, and visualized 
using UV-Gel Documentation System. 
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2.2.2.2 Eµ-TCL-1 adoptive transfer model 
Two different strategies for Eµ-TCL-1 adoptive transfer (TCL-1 AT) model were applied: For the first 
approach, splenocytes from different leukemic Eµ-TCL-1 donor mice with primary disease were 
pooled and 2x107 cells were transplanted into 6-12 weeks old WT C57BL/6 females via i.v. 
(intravenous) or i.p. (intraperitoneal) route. This strategies circumvented the limited availability of 
primary tumor cells and abated heterogeneity of single donor tumors as all animals within one 
study received an identical pool of tumor cells. For the second approach primary tumors isolated 
from primary TCL-1 mice were first expanded by i.p. injection of 2x107splenocytes into 6-12 weeks 
old WT C57BL/6 females. Tumors arising from these expansions were used for further i.v. or i.p. AT 
of 1-2x107splenocytes into 6-12 weeks old WT C57BL/6 females. In line with previous observations, 
this strategy generated faster engraftment of tumors226. The applied approach was described in 
detail in the respective results sections. 
Adoptive transfer of splenocytes was performed solely within the same C57BL/6 substrain. 
Accordingly, only tumors from TCL-1 mice with C57BL/6 N background were injected into WT 
C57BL/6 N mice and only tumors from TCL-1 mice with C57BL/6 J background were injected into 
WT C57BL/6 J mice. 
 
2.2.2.3 Negative selection of B cells 
Prior transplantation of splenocytes for TCL-1 AT experiments, splenocytes from TCL-1 mice were 
negatively depleted from unwanted cells to enrich for malignant B cells using the Easysep™ Mouse 
Pan-B Cell Isolation Kit. In brief, this kit makes use of an isolation cocktail, containing biotinylated 
antibodies recognizing the surface markers against CD4-, CD8-, CD11c-, CD49b-, CD90.2-, Ly-6C/G 
(Gr-1)-, and TER119-positive cell. Streptavidin-coated magnetic particles are then used to remove 
the labeled cells.  
 
2.2.2.4 Randomization 
For some experiments, treatment was started once a considerable tumor load in peripheral blood 
had been established. Animals were then randomized to the different treatment arms prior 
treatment start, in a fashion, resulting in comparable mean percentages or absolute numbers of 
CD5+CD19+ cells. The tumor load in peripheral blood at time of randomization is depicted in the 
respective results section.  
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2.2.2.5 Antibody treatment  
Animals were injected i.p. every second day with TG3003 (anti-CSF-1R) or the control antibody 
Synagis in a concentration of 3mg/kg, as tested by the founder company before. Frozen aliquots of 
TG3003 (stock concentration: 5.8mg/mL) and Synagis (stock concentration: 7.6mg/mL) were 
thawed and diluted prior each injection in a total volume of 200µL PBS per mouse. Animals were 
weight weekly and amount of antibody was adjusted accordingly. 
Antibody treatment with anti-IL-10RA and anti-IFN was performed as part of a study from Dr. Bola 
Hanna. Animals were i.p. injected with 1mg of anti-IL-10RA (clone 1B1.3A) or anti-IFN (clone: 
XMG1.2), or rat IgG1 isotype antibody (clone: HRPN) and subsequent doses of 0.5mg every three 
days for another two weeks.  
 
2.2.2.6 Ibrutinib treatment 
Ibrutinib was given to mice through the drinking water in a concentration of 0.16 mg/mL resulting 
in optimal doses (25mg/kg/day) as reported previously in the literature282. In brief, control vehicle 
drinking water was produced by dissolving 10g β-Cyclodextrin in 1L autoclaved tab water (1% β-
Cyclodextrin) and pH was adjusted to 7-8. For preparation of Ibrutinib drinking water, control 
vehicle was prepared as described above and adjusted to <pH3. Then, 1.6mg Ibrutinib was dissolved 
in 1L vehicle water. After complete dissolution pH was adjusted to 7-8. Ibrutinib and vehicle drinking 
water were sterile filtered and kept for maximum one week at 4°C. Treatment water was replaced 
every two to three days freshly from the prepared stock. Animals were treated from the time point 
of randomization continuously with the drug until the end of the study.  
 
2.2.2.7 Calculation of tumor growth inhibition (TGI) 
Tumor growth inhibition (%TGI) at week 2 post treatment start was calculated by the formula: %TGI 
= (Ct-Tt)/(Ct-C0)*100 where Ct = median tumor volume of control group at time point t, Tt = median 
tumor volume of treated group at time point t, and C0 = median tumor volume at time 0. Tumor 
volume is absolute number of leukemic cells measured per µL blood, time 0 presented time point 
of randomization, time t is week 2 post treatment start. 
 
2.2.2.8 Lymphocyte doubling time 
Lymphocyte doubling time was calculated by the formula: (duration∗log(2))/(log(Final 
counts)−log(Initial counts)) where duration is the number of days between Initial counts  and Final 
Counts and Counts are the absolute number of CD5+CD19+ tumor cells. 
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2.2.2.9 Collection of tissue samples and preparation of cell suspension 
Withdrawal of peripheral blood from animals during the course of experiment, was drawn weekly 
or every second week via puncture of the submandibular vein in EDTA-coated tubes and further 
used for surface staining.  
For collection of tissue samples at the end of experiments, mice were euthanized by CO2 gradient 
and peripheral blood was drawn via cardiac puncture using a 25G syringe. Blood was collected into 
Eppendorf tubes (for serum preparation) or EDTA-coated tubes (for surface staining).  
Spleens and inguinal lymph nodes were harvested and kept in complete mouse medium (RPMI 1640 
(2mM Glu) + 10% FCS + 4 mM L-glutamine + 1% penicillin/streptomycin + 0.1% 2-mercaptoethanol) 
and PBS + 5% until the moment of single cell preparation. Single cell suspension were prepared by 
mechanical disruption of the tissues through 70µm cell strainers. In some experiments, single cell 
suspensions from spleens were prepared in Milteny C-tubes using a gentleMACS™ Dissociator. 
Erythrocytes in spleen were removed by lysis in ACK lysis buffer for 8 min, followed by two washing 
steps with cold PBS, and a final filter step through a 70µm cell strainers. ACK lysis was conducted 
for lymph nodes, if many erythrocytes were present in the lymph node cell suspension.  In such 
case, cells were pelleted, then then resuspended in 500µl ACK lysis buffer, incubated for 1 min 
followed by washing steps with cold PBS. Femurs and tibia were harvested and bone marrow cells 
and flushed using 27G needle with 5ml PBS + 5% FCS. Traces of blood contamination were removed 
by 1 min treatment with 1ml of ACK lysis buffer. Cells were washed twice with cold PBS and finally 
suspended in FACS buffer. Cell counts were determined using Vi-CELL XR, pelleted and resuspended 
in appropriate concentration in FACS buffer for flow cytometric experiments or complete mouse 
medium for culturing purposes.  
 
2.2.2.10 Mouse PBMC isolation from blood 
For the purpose of intracellular flow cytometry staining in cells from blood, peripheral blood nuclear 
cells were isolated conducting a gradient separation.  Room-tempered blood was mixed with the 
same volume of PBS and carefully layered on top of Histopaque®-1083 (2X volume). After 30 min 
centrifugation at RT PBMC layer was carefully removed and washed with cold PBS. ACK lysis was 
conducted in addition if erythrocytes were visibly remaining.  In such case, PBMC pellet was then 
resuspended in 500µl ACK lysis buffer, incubated for 7 min followed by a washing steps with cold 
PBS. Cell counts were determined using Vi-CELL XR, pelleted and resuspended in appropriate 
concentration for flow cytometric experiments. 
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2.2.3 Flow cytometry  
2.2.3.1 Staining of cell surface proteins  
Staining of cell surface proteins was conducted using either a protocol with or without cell fixation 
and applied to cells retrieved from the spleen, lymph nodes and bone marrow.  
Staining without fixation was performed using a homemade FACS Buffer (PBS containing 2% FCS 
and 0.02% sodium azide) containing the antibodies for 30 min at 4°C using previously titrated 
antibody dilutions. To avoid unspecific binding of antibodies to splenic myeloid cells, splenocytes 
(3x106) were preincubated for 15 min in FACS buffer with 2% rat serum. Cells were then washed 
twice with cold FACS Buffer and resuspended in 200μl of FACS buffer, which in some cases 
contained 0.2μg/ml DAPI (4′,6Diamidin-2-phenylindol) for the purpose of live/deal discrimination. 
This protocol was also used for fluorescence activated cell sorting. 
For surface staining with subsequent fixation, cells were stained in an antibody-PBS mix for 30 min 
at 4°C protected from light, washed twice with cold PBS and then incubated for 30 min at room 
temperature with eBioscience™ IC Fixation Buffer. Samples were washed twice with PBS, 
resuspended in 200μl of PBS and stored at 4°C until measurement. 
 
Staining and fixation of cell surface proteins in whole blood was conducted using 25-50µl of 
peripheral blood collected in EDTA tubes to prevent coagulation. Whole blood cells were stained 
with an antibody-PBS mix for 30 min at 4°C protected from light. Afterwards, 2 ml of 1x 
eBioscience™ 1-step Fix/Lyse Solution was added to the sample and incubated for 10 min at room 
temperature. Samples were centrifuged and supernatants were carefully aspirated. Cells were 
resuspended in 150µl of 1x eBioscience™ 1-step Fix/Lyse Solution. For staining of whole blood cells 
where fixation was not desired 1x Biolegend RBC Lysis Buffer was used instead of 1x BD FACS™ 
lysing solution. 
Before sample acquisition 123count™ eBeads Counting Beads (same volume as blood) were added. 
Absolute cells numbers in blood were calculated according to the formula: absolute count (cells/μL) 
= (cell count x bead volume x bead concentration)/ (bead count x cell volume). 
 
2.2.3.2 Intracellular phospho-protein staining 
For intracellular phospho-protein staining of phosphoBTK, 1.5x107 splenocytes were suspended in 
cold PBS in a 2mL Eppendorf tube. Then cells were fixed by adding equal volume of IC Fixation Buffer 
was added quickly and cells were incubated for 30 min at RT.  After washing twice with PBS+ 1% 
BSA, cells were pulse vortex to loosen the pellet and permeabilized by adding slowly 1mL methanol. 
  MATERIAL AND METHODS 
49 
 
Cells were chilled on ice for 30 min, then washed and resuspended in PBS for further staining 
according to the protocol for lymphoid organs without fixation describes in the previous section. 
 
2.2.3.3 Stimulation of T cells and monocytes and intracellular staining 
Staining of intracellular proteins in myeloid cells and T cells from spleens was performed after 
incubation with respective stimuli. For T cell effector function measured by cytokines 2x106 
splenocytes were seeded per well of a 96-well plate and stimulated for 5 hours with 1X Cell 
Stimulation Cocktail (containing PMA and Ionomycin) and 1X Protein Transport Inhibitor Cocktail.  
For myeloid cell stimulation 3x106 splenocytes were incubated in 200µL complete mouse medium 
with LPS (final concentration of 1 µg/ml) at 37°C for one hour. Then 1X eBioscience™ Protein 
Transport Inhibitor Cocktail was added and cells were incubated for additional 5 hours. 
 
At the end of the stimulation, cells were washed with PBS, incubated for 15 min with PBS + 2% rat 
serum  in the case of myeloid cells, followed by another washing step. Cells were then resuspended 
in PBS containing 0.1% fixable viability dye and antibodies for surface stain and incubated for 30 
min at 4°C protected from light. Cells were washed twice and fixed with 100µL IC Fixation Buffer for 
30 min at RT. After a washing steps, cell were permeabilized and stained with antibodies against 
the intracellular protein or the respective isotype controls in 200µL 1X eBioscience™ 
Permeabilization Buffer for 30 min at RT. After washing twice with 1X eBioscience™ 
Permeabilization Buffer, cells were resuspended in a final volume of 200µl 1X eBioscience™ 
Permeabilization Buffer.  
Intracellular Ki-67 staining was performed similar except that 200µL Foxp3 
Fixation/Permeabilization Buffer instead of 100µL IC Fixation Buffer was used. 
 
Data were acquired on BD LSRII, BD LSRFortessa or BD Canto flow cytometer. Same multicolor 
panels within one experiment were acquired at the same machine. Data analysis was performed 
using FlowJo V10.0.8 software. For all flow cytometric measurement, median fluorescence intensity 
(MFI) was recorded and normalized by subtracting the MFI of the respective fluorescence-minus-
one (FMO) (containing the respective isotype control instead of the antibody, labeling the molecule 
of interest) control. 
 
2.2.3.4 Fluorescence activated cell sorting 
For the purpose of fluorescence activated cell sorting (FACS) isolated splenocytes were stained as 
described in the section before without cell fixation. For sorting of splenic monocyte subsets and 
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cDCs, samples were debulked from B cells prior staining using microbeads specific for mouse CD19. 
The magnetic cell separation procedure was carried out as described above for human CD14 section 
2.2.1.1. The negative fraction (flow-through containing the unlabeled) was used for FACS sorting. 
Operator-free sorting of live cells was performed at the Aria II using a nozzle size of 100µm. Cells 
were sorted into collection buffer (PBS + 5% FCS) and all sorted populations were re-analyzed for 
purity. Cells were further used for extraction of RNA or simulations RNA/DNA/protein extraction 
using the respective Qiagen kit. 
 
2.2.4 RNA and DNA isolation 
2.2.4.1 RNA isolation 
Total ribonucleic acid (RNA) was extracted using the RNeasy® Micro kit (Qiagen, Hilden, Germany) 
according to manufacturer’s protocol. In brief, 1-10x105 flow-sorted cells were centrifuged and 
resuspended in 350µl RLT buffer + 1% β-mercaptoethanol. Complete cell lysis was attained by 
vigorous vortexing. Subsequently, the same volume of 70% ethanol was added to the lysate, mixed 
well by pipetting, transferred to an RNeasy MinElute spin column and centrifuged for 15 sec at 
≥8000 x g. The flow through was discarded and the column was washed with 700μl Buffer RW1, 
then 500μl Buffer RPE and finally with 500μl of 80% ethanol. The column was centrifuged at full 
speed for 5 min with lid open to eliminate residual ethanol. Finally, RNA was eluted in 14μl of RNase-
free water was stored at -80°C. RNA concentrations were determined using the NanoDrop 
spectrophotometer. 
 
2.2.4.2 RNA and DNA isolation 
For simultaneous isolation of total RNA and genomic DNA (and protein) for submission to RNA 
sequencing and whole exome sequencing of CD5+CD19+ FACS-sorted cell the AllPrep 
DNA/RNA/Protein Mini Kit was used according to manufacturer’s protocol. 
 
2.2.5 Array-based gene expression profiling  
RNA was subjected to a quality check using a RNA Nano chip assay on an Agilent 2100 Bioanalyzer. 
Processing of raw data was conducted by the Genomics and Proteomics Core Facility, DKFZ. Gene 
expression data of myeloid cells was further analyzed using first the bioinformatics software 
Chipster, R, and Ingenuity Pathway analysis using the GeneChip® Mouse Gene 2.0 ST Array.  
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2.2.6 RNA sequencing and DNA whole exome sequencing 
Total RNA and genomic DNA were isolated, subjected to RNA and DNA quality check. RNA integrity 
was confirmed as described above using RNA Nano chip assay on an Agilent 2100 Bioanalyzer. DNA 
quality was verified using the Genomic DNA ScreenTape assay at a TapeStation System, which was 
kindly conducted by the Sample Processing Laboratory (SLP) at DKFZ. Samples were submitted to 
the Genomics and Proteomics Core Facility at DKFZ. Library preparation of RNA was performed 
according to the Illumina TruSeq Stranded protocol on a HiSeq 2000 v4 sequencer, paired-end 125 
base pairs with five samples per lane. For DNA whole exome sequencing libraries were prepared 
according to Agilent Low Input Exom-Seq Mouse protocol and sequenced on a HiSeq 4000 
sequencer, paired-end 100 base pairs with three samples per lane. 
 
2.2.7 Mapping and SNV calling of whole exome sequencing data 
Raw sequencing reads from whole exome sequencing were mapped to mm10 reference genome. 
Single nucleotide variants (SNVs) were called using MuTect (SNV caller from Broad Institute) with 
the aligned bam files. The resulting vcf files from each treatment cohort were merged together and 
used to create further intersections. In order to retrieve for example resistance-specific SNVs 
following intersection was created: Merged Ibrutinib_late SNVs – merged Ibrutinib_early SNVs – 
merged Vehicle_late SNVs – merged Vehicle_early SNVs. In addition, all SNVs were subtracted from 
SNVs present in the parental DNA from the TCL-1 donor mouse.  
 
2.2.8 Analysis of V(D)J rearrangement of BCR of whole exome sequencing data 
Bam files were converted into fastq format and used as input for stand alone IgBLAST for identifying 
potential V(D)J rearrangements. The number of unique V(D)J rearrangements was then counted for 
each sample. 
 
2.2.9 Gene expression profiling using differentially expressed transcripts 
Raw sequencing reads from RNA sequencing were aligned to the mm10 reference genome. Read 
counting was performed using featureCounts. Gene expression matrix with raw read counts was 
used as input for DESeq2 for downstream analysis like normalization, unsupervised hierarchical 
clustering with 1000 most variable transcripts and identifying differentially expressed transcripts at 
a cut off of adjusted p-value of less than 0.05.  
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For gene ontology (GO) analysis DEGs with a cutoff of less than 0.05 were used. For gene set 
enrichment (GSE) analysis no cutoff was set. All DEGs were ranked according the adjusted p values 
before submitting to the GSEA platform. 
 
2.2.10 Quantification of cytokines and chemokines 
2.2.10.1 Preparation of mouse serum cell culture supernatant 
Mouse blood was collected via cardiac puncture and allowed to clot by leaving it undisturbed at 
room temperature for at least 30 min. Clot was removed and serum (resulting supernatant) was 
obtained by two times centrifugation for 10 min at 2,000 x g at 4°C.  
To obtain cell culture supernatants, cells were first centrifuged for 10 min at 300 x g at 4°C. 
Supernatants were transferred to a new tube and centrifuged for 15 min at x 1,000 x g at 4°C. 
Pelleted cells were collected for other procedures, e.g. cell viability via Annexin V/7-AAD staining 
and washed twice cold PBS. Serum and cell culture supernatants were immediately aliquoted and 
frozen at -80°C until used. 
 
2.2.10.2 ELISA and bead-based immunoassays 
Multiplexed bead-based arrays facilitating simultaneous measurement of different analytes. 
Human CCL2, sCD14, and IL-6 in co-culture supernatants were quantified using cytometric bead 
arrays according to manufacturers’ protocols (BD).  Murine CSF-1 was quantified within a bead 
panel using MILLIPLEX Mouse Cytokine/Chemokine Magnetic Bead Panel (Merck Millipore, 
Germany) according to manufacturers’ instruction. Human CSF-1 and human TNF- in culture 
supernatants were measured by enzyme-linked immunosorbent assay (ELISA) according to 
manufacturers’ protocols (R&D Systems, Minneapolis, MN, USA).  
 
2.2.11 Quantification of viable cells 
2.2.11.1 Cell viability 
Cell viability was determined by measuring the percentage of early and late apoptotic cells within 
a population that are able to bind the Annexin V protein and are positively stained for 7-AAD (7-
Amino Actinomycin). For this purpose 1x106 cells were incubated in 30µL PE Annexin V/7-AAD mix 
(1X Annexin V Binding Buffer containing 10% PE Annexin V and 10% 7-AAD) for 15 min at 4°C 
protected from light. Afterwards, 150µL 1X Annexin V Binding Buffer was added to the sample and 
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measured by flow cytometry gating on lymphocytes within the following 15 min. Double-negative 
cells were quantified as viable cells. 
 
2.2.11.2 MTT assay for NLC quantification 
NLC numbers were determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) solution as described before201.In brief, CLL fraction (suspension cells) was removed and 
adherent cells were washed three times with pre-warm complete human medium. Adherent cells 
were then incubated with fresh medium containing 0.5mg/mL MTT for 2 hours at 37°C. The water 
soluble yellow MTT is reduced by mitochondrial dehydrogenase into formazan crystals by living 
cells. Morphology of NLCs that contain formazan was then observed by phase-contrast microscopy. 
Two pictures from different areas of a well, each from two technical replicates were, taken for 
further quantification using Image J.  
 
2.2.11.3 Statistics 
Data were analyzed using GraphPad Prism 7.02 software. Comparisons of two non-paired groups 
were performed using the Welch t test. It assumes that the two compared data sets are sampled 
from Gaussian populations, but may have different standard deviation (SD). The statistical test used 
for each data set is indicated in the figure legends. Replicates represent biological replicates, unless 
otherwise indicated in the figure legend. All graphs show means ± SD. ns = ≥ 0.05, *p < 0.01 to 0.05, 
**p < 0.001 to 0.01, ***p < 0.0001 to 0.001, ****p < 0.0001.   
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3 RESULTS 
3.1 Modulating the myeloid tumor microenvironment in CLL by targeting 
the CSF-1 receptor 
In order to target and investigate the potential role of the CSF-1R in CLL, in vitro experiments were 
performed in the initial phase. For this purpose a monoclonal antibody targeting the human CSF-
1R (provided by Transgene SA., France) named TG3003 was applied in coculture setups, using either 
(1) human CLL-monocyte cocultures, or (2) ‘NLC cocultures’. 
As recapitulated in the introduction, similar to stromal cells also healthy monocytes can serve as 
feeder cells to promote CLL cell survival306, 307. This is a suitable model for investigations of 
monocytes in coculture with CLL cells, and at the same time for comparing the effects of the 
antibody with monocyte monocultures. It is also convenient in view of the challenge to isolate 
sufficient numbers of monocytes from CLL blood samples, since these are by definition highly 
enriched with leukemic cells. 
In addition, the NLC coculture model represents a well-accepted autologous in vitro model for the 
CLL microenvironment308. In this case, unsorted CLL-PBMCs are cultured in high cell density for 8 – 
14 days, and it was shown that monocytes differentiate in these cultures into supportive nurse-like 
cells (NLCs) which is induced by cell-cell contact with CLL cells78. Especially with regard to the need 
of an in vitro platform mimicking the CLL lymph node microenvironment, NLC cocultures seem a 
perfect solution, as lymph node biopsies from CLL patients are highly limited. 
However, such in vitro cultures can only partially represent the in vivo situation and are not capable 
of reflecting the complex interactions between the various cells of the immune system. Therefore, 
the aim was to subsequently investigate effects of targeting the CSF-1/CSF-1R axis on tumor 
development and its TME in the Eµ-TCL-1 adoptive transfer mouse model of CLL (referred to as TCL-
1 AT from here), using TG3003 antibody. 
 
3.1.1 Targeting CSF-1R in the tumor microenvironment of CLL in vitro  
In order to answer if the CSF-1/CSF-1R axis might be as suitable microenvironmental target for CLL 
treatment, first cocultures of primary human CLL cells and healthy monocytes were set up. CLL cells 
and monocytes were derived from PBMCs isolated from CLL patients and healthy donors by Ficoll 
density gradient, followed by magnetic cell sorting with anti-CD14 coated beads for monocyte 
enrichment. Supernatants from these cocultures were harvested at day 3, 6 and 14 and the level of 
CSF-1 was measured using enzyme-linked immunosorbent assay (ELISA). CSF-1 did not reach a 
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detectable level at day 3 (data not shown) and only in 1 out of 3 cocultures at day 6, while it was 
detectable in all three cocultures at day 14 (Figure 8a). 
As CSF-1 was present in CLL-monocyte cocultures, the next step was to test if TG3003 treatment 
would impact on CSF-1R-expressing monocytes/macrophages. For this purpose, monocultures of 
monocytes were set up. As monocytes in vitro require supporting factors to survive, the 
monoculture was supplemented with recombinant human CSF-1 as well as another important 
growth factor, CSF-2, which are known to induce differentiation of monocytes to macrophages. 
TG3001 was added, based on pre-testing of the founder company Transgene SA, in a concentration 
of 1µg/mL to cocultures every second day. Cells that were treated with the control isotype antibody 
developed star-like shaped elongations, a typical morphology of in vitro differentiated 
macrophages, whereby the degree of elongations has been proposed to positively correlate with 
M2-macrophage polarization (Figure 8b)309. In contrast, the addition of the CSF-1R-specific antibody 
TG3003 to the culture prevented the formation of these elongations and favored a round cell shape, 
indicating a modulating effect on monocyte differentiation (Figure 8b). 
Next, NLC cocultures were used to address the question if modulation of CSF-1R-expressing cells 
might affect the survival of CLL cells. Unsorted PBMCs from CLL patients with a high tumor load 
were seeded in high cell density as previously described and cultured for 14 days to induce nurse-
like cell differentiation305. As described before, nurse-like cells differentiation started after 
approximately 3 to 5 days (depending on the patient donor), and as expected CLL cell survival was 
maintained. Application of the antibody TG3003 to the culture lead to a significant decline in the 
survival of CLL cells from different patients as measured by the percentage of CD5+CD19+ cells that 
were negative for Annexin V/7-AAD staining (Figure 8c). Higher doses of TG3003 up to 10µg/mL 
also did not further reduce CLL survival indicating that this dose was already sufficient to achieve 
the maximum effect (data not shown). 
Of note, the number of NLCs in these cocultures varied between the CLL patients. In this context, it 
is interesting to note that indeed cocultures that displayed fewer NLC numbers in the control wells 
showed also a weaker anti-CSF-1R-induced disruption of CLL survival support in response to 
TG3003. This observation supported the hypothesis that the effect of TG3003 was mediated 
through CSF-1R-expressing NLCs in these cocultures. In addition, also survival of purified CLL cells 
(using magnetic cell sorting with anti-CD19 coated beads) in monocultures was not affected by 
TG3003 up to a concentration of 10µg/mL (data not shown). 
 
To further elucidate TG3003-induced disruption of NLC-mediated survival support, different 
treatment regimens were conducted: TG3003 was applied (1) during the complete duration of the 
NLC coculture (day 1 to 14), (2) only during the first half of the NLC coculture (day 1 to 7), or (3) only 
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during the second half of the NLC coculture (day 8 to 14). NLC-mediated CLL cell survival was most 
effectively disrupted if TG3003 was present in the culture from day 1 to 14. Treatment restricted to 
the first week was similarly efficient in reducing survival support, whereas later treatment onset 
did not impact on survival support (Figure 8d). 
 
Morphologically, NLCs appear as large and round cells and no change in their shape was observed 
upon TG3003 treatment. NLC cocultures treated with TG3003 displayed a decreased number of 
NLCs as compared to control antibody-treated cocultures (Figure 8e,f). In line with the latter 
observation, NLC cocultures that were treated with TG3003 during day 1 to 7 and day 1 to 14 
displayed less NLC differentiation compared to control wells (data not shown). In NLC cocultures 
with late TG3003 treatment onset, the distribution of NLCs looked similar to the control wells. These 
results suggest that targeting CSF-1R signaling in monocytes with TG3003 prevented differentiation 
of NLCs. 
 
Supernatants of NLC cocultures were collected and used for quantification of various secreted 
factors by cytometric bead array or ELISA. The cytokine CCL2, which was previously shown to be 
induced in monocytes by the presence of CLL cells and elevated in CLL sera, was significantly lower 
in TG3003-treated cultures (Figure 8g, left)79. Soluble CD14 (sCD14), reported to be secreted by 
monocytes and improving CLL survival, and IL-6 that is known to be secreted by monocytes and 
elevated in patient sera, were slightly decreased in the supernatants upon TG3003 treatment (not 
significant) (Figure 8g, middle and right)306, 310, 311.  
In contrast, CSF-1 concentrations in NLC cocultures remained stable upon TG3003 treatment 
(Figure 8h). This is in line with data from Transgene SA which suggested that TG3003 does not block 
binding and internalization of CSF-1 to the receptor. This was important for future (pre-) clinical 
applications, as elevated plasma CSF-1 levels, may lead to rebound effects in treated patients312. 
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Figure 8: Anti-CSF-1R treatment impacts on NLC differentiation and thereby on CLL cell survival in vitro. 
Peripheral blood mononuclear cells (PBMCs) were isolated from CLL patient whole blood by Ficoll density 
gradient. To retrieve monocytes, CD14+ cells were enriched using magnetic cell sorting. PBMCs from CLL 
patient’s whole blood were used directly. (a) CSF-1 concentrations in the culture supernatant of CLL-
monocyte cocultures (5x106 CLL cells : 2.5x106 monocytes in 500µL medium/well in a 24-well plate) were 
assessed at day 6 and day 14 by enzyme-linked immunosorbent assay (ELISA). Each bar represents mean of 
three technical replicates. (b) Light microscopy images of monocyte monocultures (5x106 monocytes/mL) 
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differentiated for 5 days with recombinant human CSF-1 (20ng/mL) and CSF-2 (100ng/mL) added every 
second day. Monocytes were concordantly either treated with 1µg/mL isotype control (left) or anti-CSF-1R, 
TG3003 (right). (c,d) CLL PBMC were cultured in high cell density (1.5x107 cells/mL) and treated with 1µg/mL 
isotype control antibody or TG3003 every second day (n=10) for 14 days (c) or for the indicated time periods 
(day 1-14, day 1-7 or day 8-14) (n=3) (d). Viability of CD5+CD19+ CLL cells was assessed by flow cytometry 
using Annexin V/7-AAD staining. (e,f) Quantification of NLC numbers in NLC cocultures cultured for 8 days in 
high cell density (1.5x107 cells/mL) and treated with 1µg/mL isotype control antibody or TG3003 twice (on 
day 1 and day 4) (n=3) (e) and representative light microscopy image after removal of suspension cell fraction 
(f). NLCs were incubated in MTT solution (0.5 mg/mL) for 2 hours. Quantification was performed using ImageJ 
software. (g,h) CLL PBMCs were cultured for 14 days in a high cell density of 1.5x107 cells/mL (0.75x107 CLL 
PBMCs in 500µL medium in a 48-well plate) and treated with 1µg/mL isotype control or TG3003 every second 
day. CCL2 (n=4), soluble CD14 (sCD14) (n=4), IL-6 (n=3), and CSF-1 (n=4) were measured in cell culture 
supernatants by cytometric bead array (g) or ELISA (h). (i) Annexin V/7-AAD flow cytometry assay of primary 
CD5+CD19+ CLL cells harvested from NLC cocultures (n=2). CLL cells were isolated and cultured for 10 days in 
a high cell density of 1.5x107 cells/mL and treated with 1µg/mL isotype control or TG3003 every second day. 
In addition, Fludarabine (25µM), Idelalisib (10µM) or DMSO were added once on day 8. P values were 
determined by paired Student t-test.  (Ann V/7-AAD=Annexin V/7-AAD) 
 
Finally, anti-CSF-1R treatment in NLC cocultures was combined with the CLL-targeting drugs 
Fludarabine and Idelalisib. Both combination approaches lead to a stronger reduction in CLL cell 
survival in the cultures compared to respective monotherapies, suggesting additive or synergistic 
effects and therefore appearing as promising strategy for in vivo testing (Figure 8i).  Altogether, the 
observed effects of targeting the CSF-1/CSF-1R axis on monocytes or NLCs in coculture with CLL 
cells, and especially the resulting outcome for CLL cell survival turned out to be a promising 
treatment option for monotherapy as well as combination therapy to be tested in a pre-clinical 
study. 
 
3.1.2 Targeting CSF-1R in the tumor microenvironment of CLL in vivo  
As CSF-1R antibody inhibited NLC formation in vitro and thereby reduced CLL cell survival, 
investigating the effect of targeting CSF-1R in vivo by using a CLL mouse model was the next goal. 
As TG3003 targets human CSF-1R, using the syngeneic TCL-1 AT model was not feasible. Hence, 
using a human CSF-1R knockin (KI) mouse line that expresses a chimeric CSF-1R protein comprising 
a human epitope within the murine CSF-1R, represented an excellent approach. This chimeric 
protein can be specifically targeted by TG3003 and can also bind the murine CSF-1R ligands CSF-1 
and IL-34313. An ‘almost syngeneic’ transplantation of Eµ-TCL-1 tumor cells in humanized CSF-1R KI 
mice served as perfect approach to test TG3003 in the context of CLL, while facilitating the 
possibility of subsequently testing this antibody for clinical applications.  
In order to prove the usability of this mouse line, a pilot study was conducted that verified tumor 
cell engraftment and skewing of myeloid cell populations, comparable to previous observations in 
adoptively transferred wildtype C57BL/6 mice (data not shown)203. 
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In an independent experiment the relevance of the CSF-1/CSF-1R axis for the TCL-1 adoptive 
transfer (AT) model for CLL was further suggested by results of a longitudinal study with animals 
sacrificed at different time points (week 2, week 4, week 6, and week 8 after transplantation). Here, 
a slight increase of CSF-1 levels in the serum of these mice during the course of leukemia 
progression was observed (Appendix Figure 2a). 
 
After that, three cohorts of CSF-1R KI mice were set up including 1) animals without tumor 
transplantation and without treatment (’Wildtype’ = ‘WT’), 2) animals injected with TCL-1 tumor 
and treated with the control antibody Synagis (‘Control’), and 3) animals injected with tumor and 
treated with TG3003 (‘TG3003’). Synagis, a human IgG1 monoclonal antibody against the 
respiratory syncytial virus, was chosen as control antibody with similarities to TG3003 but no 
antigen target in mice. CSF-1R KI mice were injected intravenously with a pool of TCL-1 splenocytes. 
The tumor cells were depleted for CD4-, CD8-, CD11c-, CD49b-, CD90.2-, Ly-6C/G (Gr-1)-, and 
TER119-positive cells using the EasySep™ Mouse Pan-B Cell Isolation Kit before injection, in order 
to achieve a high purity of CD5+CD19+ malignant B cells and avoid transfer of non-tumor cells. 
Treatment was started at day 1 after tumor cell injection. Synagis and TG3003 were injected 
intraperitoneally three times per week in a concentration of 3mg/kg, as suggested and described 
by Transgene SA314. As monocytes are rapidly repopulating cells, the last injection was conducted 
one day before animals were sacrificed. Mice were treated for a period of 6 weeks and tumor load 
was monitored in the peripheral blood every second week, in addition to signs of illness. At the 
endpoint of the study, all animals were sacrificed and lymphoid organs were harvested and 
evaluated with a special focus on the analysis of myeloid cell populations. As leukemia development 
was very heterogeneous in this study, animals which did not display splenomegaly at the endpoint 
were excluded from the analysis. 
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3.1.2.1 Anti-CSF-1R treatment with TG3003 impacts on myeloid cell numbers in the TCL-
1 AT model 
Myeloid cells were examined using a multicolor flow cytometry marker panel allowing a specific 
discrimination of monocytes, conventional dendritic cells (cDCs), their respective subsets and 
macrophages (Appendix Figure 1). Monocytes and cDC absolute cell numbers from control mice 
were highly elevated in the spleen compared to WT mice, whereas macrophages showed decreased 
numbers, all together confirming previous results on the myeloid TME in the TCL-1 AT model (Figure 
9a). Treatment with TG3003 lead to a significant reduction of monocyte numbers (3.07-fold 
reduction) (Figure 9a, left). However, despite the antibody’s strong effect on monocytes, their 
numbers remained significantly elevated compared to WT animals. Similarly, also cDCs were 
significantly reduced in numbers upon treatment (1.44-fold reduction), but also not fully 
normalized to WT levels (Figure 9a, middle). Interestingly, macrophages that are decreased in 
leukemic animals compared to WT mice seemed not further affected by the treatment in most 
animals (Figure 9, right). 
In the bone marrow compartment, there was only a tendency (p=0.0702) towards normalization of 
the overall amount of CSF-1R-expressing cells, whereby the control cohort appeared to be 
heterogeneous (Figure 9b). CSF-1R-expressing cells in the bone marrow typically comprise 
monocytic and dendritic cell precursors in addition to mature monocytes. Gating on mature 
monocyte subsets in the bone marrow revealed a similar pattern as in the spleen, which was a 
partial reversal of disease-associated accumulation of monocytes upon treatment (Appendix Figure 
2b). These results suggest that TG3003 systemically reduces monocyte numbers, and to some 
degree also cDCs. 
By gating on the two main splenic monocyte subsets, distinguished by differential expression of 
Ly6C, a significant increase of both populations, Ly6Chigh as well as Ly6Clow monocytes, was 
confirmed in the leukemic control group (Figure 9c,d). As expected, the Ly6Clow population was 
much stronger enriched compared to the Ly6Chigh monocyte population (25.66-fold and 3.9-fold 
compared to WT mice) (Figure 9c). While TG3003 did not notably affect the Ly6Chigh population, 
Ly6Clow monocytes displayed a significant reduction upon treatment (4.25-fold reduction). 
However, similar as the total monocyte population, the leukemia-induced cell numbers were only 
partially reduced to normal levels by TG3003. 
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Figure 9: TG3003 treatment of CSF-1R KI mice after TCL-1 AT impacts on myeloid cell numbers. 
CSF-1R KI mice were transplanted i.v. with 2x106 malignant splenocytes pooled from four leukemic TCL-1 
donor mice. Starting at day 1 post-transplantation, mice were injected i.p. with control antibody (Synagis) or 
TG3003 at 3mg/kg/week for 6 weeks. Untransplated CSF-1R KI wildtype (WT) mice (n=6) served as healthy 
control group. Analyses at the study endpoint were performed for animals showing >50% of CD5+CD19+ cells 
in the spleen and presence of clear splenomegaly (control cohort: n=9, anti-CSF-1R cohort: n=7). (a) Absolute 
numbers of monocytes (left), cDCs (middle), and macrophages (right) in the spleen as measured by flow 
cytometry. (b) Absolute numbers of CSF-1R-expressing cells in the bone marrow (BM) (one femur). (c) 
Absolute numbers and (d) representative flow cytometry density plots of Ly6Chigh and Ly6Clow monocyte 
subsets in the spleen, after gating on monocytes. A detailed gating scheme is illustrated in Appendix Figure 
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1. (e) Percentage of PD-L1-expressing splenic monocytes (left) and representative histogram illustrating 
bimodal distribution of PD-L1 signal on total monocytes (right). (f) PD-L1 expression level on Ly6Chigh 
monocytes (left) and Ly6Clow monocytes (right). (g) Absolute numbers of granulocytes (left), eosinophils 
(middle), and neutrophils (right) in the spleen. (splenic granulocytes: DAPI-CD45+CD5-CD19-NK.1.1-CD3-
CD11b+Ly6G+; splenic eosinophils: DAPI-CD45+CD5-CD19-NK.1.1-CD3-CD11b+Ly6G+Ly6Chi; splenic neutrophils: 
DAPI-CD45+CD5-CD19-NK.1.1-CD3-CD11b+Ly6G+Ly6Clow; bone marrow CSF-1R-expressing cells: DAPI- Lin-
(CD19-CD3-Ly6G-NK1.1-TER119-)CSF-1R+.) P values were determined by unpaired Student t-test.  
 
Expression of PD-L1, which controls T cell effector function as part of the PD-L1/PD-1 axis and which 
was shown to be capable of creating an immune suppressive TME, was measured on the different 
myeloid cell populations. An aberrantly high percentage of PD-L1-expressing monocytes was 
detected in leukemic mice in the control group, while the proportion was significantly reduced upon 
treatment with TG3003 (Figure 9e, left). Notably, Ly6Clow monocytes turned out to be the main PD-
L1-expressing subpopulation with higher median fluorescence intensities (MFIs) as compared to 
Ly6Chigh monocytes (Figure 9f). As TG3003 treatment neither influenced PD-L1 expression level of 
Ly6Chigh nor of Ly6Clow monocytes (Figure 9f), this highly suggests that the observed reduction in PD-
L1 percentages on total monocytes was due to a reduction in the Ly6Clow monocyte population as 
the main PD-L1-expressing subset. 
In order to track effects of TG3003 on other myeloid cells in the spleen, granulocytes, and 
particularly eosinophils and neutrophils, were quantified. As reported before, granulocyte numbers 
highly increase with disease progression in the TCL1 mouse model, which seemed to be mainly 
attributed to neutrophils315. Similarly as for monocytes, targeting CSF-1R reduced the elevated 
neutrophil numbers, nevertheless not to a full normalization (Figure 9g). 
TG3003´s mode of action was proposed to be immunomodulatory and not via blockade of CSF-1R 
downstream signaling. It was proposed to drive differentiation of monocytes towards a DC-
phenotype in vitro316. Therefore, potential changes of DC subsets and their phenotype were 
investigated316. Along with the unchanged frequency of cDCs in the spleen, there was no detectable 
effect of TG3003 on the two main cDC subsets (either CD11c+ CD8a+ CD11b- or CD11c+ CD8a- 
CD11b+). Expression of maturation and activation markers of cDCs, such as CD86, CD54, CD83 and 
MHC-II remained at similar levels compared to control antibody-treated mice (data not shown).  
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3.1.2.2 Anti-CSF-1R treatment with TG3003 does not affect T cell numbers or T cell 
effector functions and does not improve disease development in the TCL-1 AT 
model 
In addition to investigations of cell subsets in the myeloid compartment, also T cells, as crucial 
players of the TME were immunophenotyped with respect to typical CLL-induced changes and 
defects. As T cells are not the main focus of the current thesis, only a few of the results will be 
briefly summarized here. Firstly, quantification of T cell populations revealed that CLL-induced 
elevated numbers of CD4+ and CD8+ T cells remained high after treatment with TG3003, which is 
also reflected in an increased CD4/CD8 ratio, a feature that is observed in approximately 40% of 
CLL patients317 (Figure 10a).  Secondly, the percentages of naïve, central memory and effector T 
cells within CD4+ and CD8+ T cell populations were evaluated as previous studies have shown 
skewing of the T cell compartment toward effector T cells in CLL patients and in the Eμ-TCL-1 mouse 
model115, 237.  While this abnormal change in T cell subset proportions was confirmed in leukemic 
animals, TG3003 treatment did not contribute to a normalization of the percentages of T cell 
subsets (data not shown). Thirdly, T cell exhaustion, arising in response to chronic antigen-mediated 
T cell receptor stimulation, is a hallmark of CLL and was investigated by measuring the expression 
of the exhaustion markers KLRG1 and LAG-3110. CLL-associated increase of KLRG-1 and LAG-3 
expression on T cells remained at an elevated level in TG3003-treated compared to untreated 
animals (data not shown). And finally, the effector function of CD4+ and CD8+ effector T cells was 
investigated via intracellular FACS staining by analyzing their capacity to produce IL-2, IFN-, and 
TNF-, upon T cell stimulation. The development of disease led to a decrease of PMA/Ionomycin-
stimulated TNF-+ IFN-- CD8 cells and an increase in the percentages of TNF-- IFN-+ CD8 cells 
which was in the case of TNF-- IFN-+ CD8 cells partially normalized (Figure 10b). 
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Figure 10: TG3003 treatment of CSF-1R KI mice after TCL-1 AT does not impact on T cells or disease outcome. 
TCL-1 AT and treatment was performed as described in Figure 9. (a) CD4/CD8 ratio based on absolute 
numbers of splenic CD4+ T cells and CD8+ T cells. (b) Percentage of TNF-and IFN- producing CD44+CD8+ T 
cells assessed by intracellular flow cytometry following PMA/Ionomycin stimulation of isolated splenocytes 
for 6 hours. (c) Tumor load in peripheral blood (PB) over time in mice treated with control antibody (n=8) or 
TG3003 (n=7). (d) Spleen weight, and (e) percentage of CD5+CD19+ cells in spleen (SPL), and (f) bone marrow 
(BM) as acquired by flow cytometry are presented in the three treatment groups. (Splenic CD4+ T cells: DAPI-
CD3+CD4+; splenic CD8+ T cells: DAPI-CD3+CD8+; leukemic CD5+CD19+ cells in the PB, SPL, and BM: 
CD45+CD5+CD19+; PB=peripheral blood, BM=bone marrow, SPL=spleen). P values were determined by 
unpaired Student t-test. 
 
In summary, the assessment of T cell populations did not reveal notable differences between 
TG3003- or control antibody-treated mice that could be attributed to an indirect effect of the 
observed alterations in monocyte numbers, monocyte subset composition or their decreased 
proportion of PD-L1, the ligand of PD-1 which is typically expressed by activated or exhausted T 
cells. 
During the treatment period as well as at the endpoint of the study, no significant difference in 
tumor load in peripheral blood of TG3003-treated and control antibody-treated animals was 
observed (Figure 10c). Evaluation of tumor burden at the endpoint revealed no difference in spleen 
weight and similar percentages of malignant CD5+CD19+ cells in spleen and bone marrow (Figure 
10d,e,f). Overall, despite promising initial in vitro results with TG3003, and considerable, partial 
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normalization of the monocyte compartment (in particular declined percentage of PD-L1high-
expressing monocytes), treatment of leukemic mice with TG3003 did not improve disease outcome 
in the presented study. 
 
3.2 Monocytes and cDCs in steady state, in CLL and under the influence of 
Ibrutinib 
To improve therapeutic targeting of myeloid cells in CLL, it is necessary to improve the 
understanding of how these cells develop and contribute to the pathogenesis during this disease. 
It is yet unclear, if myeloid cells mainly exhibit support for CLL cell survival or are rather major 
players in T cell suppression. Moreover, clinically applied drugs in CLL not only target the malignant 
cells directly, but also impact on other immune cells, including myeloid cells, and may thereby 
contribute both in a negative or positive way to treatment outcome. Fully understanding a drug’s 
spectrum of activities is of special importance for the development of efficient treatment regimens. 
Further, even in steady state condition, the function of immune cells and their interplay with each 
other are not fully unraveled, adding more complexity to the understanding of the roles of these 
cells under disease conditions. Therefore, the goal of this study was to gain a better understanding 
of myeloid cells in steady state, their pathobiological role in CLL, and under the influence of 
Ibrutinib, a clinically potent drug that targets BTK primarily in malignant B cells, but might also have 
effects on immune cells in the TME. As monocytes and cDCs, two closely related myeloid cell 
members, accumulate during leukemia development in the TCL-1 AT model, these cells were the 
focus of the following studies.  
 
3.2.1 Monocytes in steady state, in CLL and under the influence of Ibrutinib 
3.2.1.1 Ly6Clow monocytes are altered in CLL and display an expression signature 
associated with activation of cellular growth and proliferation 
To better characterize the CLL-induced molecular properties of Ly6Chi and Ly6Clow monocytes, an 
array-based gene expression profiling (GEP) from leukemic TCL-1 AT animals, five to six weeks after 
adoptive transfer of 2x107 splenocytes (n=3) and matched healthy wildtype (=WT) control animals 
(n=3) was performed. Splenocytes from three WT mice were pooled per data set to retrieve 
sufficient RNA for the analysis. Ly6Chi and Ly6Clow monocytes were flow sorted according to their 
surface markers and assessed to purity control (Appendix Table 1). Total RNA was isolated and 
submitted to the Genomics and Proteomics Core Facility Unit at the DKFZ for GEP using GeneChip 
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Mouse Gene 2.0 ST Array. Setting an adjusted p value of ≤ 0.05 revealed 31 genes in Ly6Chi 
monocytes and 105 genes in Ly6Clow monocyte to be significantly deregulated, when comparing 
cells isolated from leukemic TCL-1 AT and WT mice (Figure 11a). An increased number of biological 
functions were found to be enriched especially in Ly6Clow monocytes from TCL-1 AT mice. These 
identified biological functions within the top five categories, were (1) Cellular Development, (2) 
Cellular Growth and Proliferation, (3) Hematological System Development and Function, (4) 
Lymphoid Tissue Structure and Development, and (5) Tissue Morphology (ranked by p value ranges) 
(Figure 11c). In contrast, Ly6Chi monocytes displayed only a few differentially represented biological 
functions in TCL-1 AT and WT mice (data not shown). These were Inflammatory Response and 
Cellular movement, both predicted to be activated in TCL-1 AT mice. This was in line with the lower 
number of differentially expressed genes (DEGs) in Ly6Chi compared to Ly6Clow monocytes, pointing 
to a greater influence of Ly6Clow monocytes in CLL. 
Further, the top biological function within the top category Cellular Growth and Proliferation was 
proliferation of mononuclear leukocytes and comprised upregulated genes such as Serpina3g, Il21r, 
Dpp4, Nfil3, Itgb3, Id3, Trem1, Jak3, C5ar1, Il1b, and Traf2 (Figure 11d). Serpina3g, Il21r, Dpp4 were 
among the top 20 DEGs when comparing Ly6Clow monocytes from TCL-1 AT and WT mice (Figure 
11b). This gene list serves as a basis to identify candidate genes with relevance for CLL for future 
investigations. In particular, genes that are significantly upregulated in Ly6Clow but not Ly6Chi 
monocytes, such as Dpp4, Nfil3, Id3, Jak3, C5ar1, and Traf2, may serve as candidates for specific 
targeting of Ly6Clow monocytes. 
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Figure 11: Differential gene expression of Ly6Clow monocytes in TCL-1 AT mice compared to wildtype mice 
is associated with activation of cellular growth and proliferation. 
(a) Volcano plots showing upregulated (orange) and downregulated (blue) genes in Ly6Chi (left) and Ly6Clow 
(right) monocytes from leukemic TCL-1 AT (n=3) versus WT (n=3) samples. The dotted line indicates cutoff at 
a p value of 0.05. (b) Heatmap of top 20 differentially expressed genes in Ly6Clow monocytes in TCL-1 AT (n=3) 
versus WT (n=3) animals (c) Enrichment analysis of biological functions in Ly6Clow monocytes (top 10 
categories showed) including number of genes and p value ranges using IPA downstream effect analysis 
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(orange=category predicted to be activated, grey=category prediction unclear). (d) IPA network analysis of 
genes in Ly6Clow monocytes involved in the top biological function termed proliferation of molecular 
leukocytes which was predicted to be activated. A legend based on IPA tool: orange=increased measurement, 
blue: decreased measurement, predicted relationships=orange dashed line=leads to activation, blue dashed 
line=leads to inhibition, yellow dashed line=finding inconsistent with the state of the downstream molecule, 
gray dashed line=effect not predicted. 
 
3.2.1.2 Ibrutinib partially reverses CLL-induced gene expression signature of Ly6Chi and 
Ly6Clow monocytes 
To investigate effects of Ibrutinib on Ly6Chi and Ly6Clow monocytes, cells were flow-sorted and 
processed for GEP (Ibrutinib-treated: n=3) in parallel to monocytes from WT and leukemic mice, as 
described in the previous section. Two weeks after adoptive transfer of 2x107 splenocytes, animals 
were randomized to be treated for 2 ½ weeks with Ibrutinib added into the drinking water. Profiled 
samples from WT (treated with vehicle drinking water), TCL-1 AT and Ibrutinib-treated TCL-1 AT 
animals were confirmed to cluster according to their myeloid subpopulations (Appendix Figure 3). 
 
Interestingly, Ly6Chi and to a lesser extent Ly6Clow monocytes, clustered closer with samples from 
WT animals (Figure 12a; Appendix Figure 3). Ibrutinib treatment of TCL-1 AT mice induced 
differential expression of 11 genes in Ly6Chi and 32 genes in Ly6Clow monocytes when compared to 
TCL-1 AT mice. These identified DEGs between TCL-1 AT and Ibrutinib-treated mice were further 
checked for their expression in WT samples. Notably, all of them were more similarly expressed in 
WT and Ibrutinib-treated samples compared to vehicle-treated mice, suggesting a normalization of 
their expression pattern by Ibrutinib. Further analysis of Ly6Chigh and Ly6Clow monocytes using a venn 
diagram revealed 18 differentially expressed genes which were unique for the Ly6Clow 
subpopulation (not present in the Ly6Chi DEG list) (Figure 12b,c). Out of these genes, CD22 (SIGLEC-
2), Dpp4, and Pecam-1 appeared to be involved in the proliferation of Ly6Clow monocytes suggesting 
that Ibrutinib might impact on the proliferative capacity of these cells (Figure 11d).  
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Figure 12: Ibrutinib treatment of mice normalizes leukemia-induced gene expression of Ly6Chi and Ly6Clow 
monocytes. 
(a) Principle component analysis (PCA) of transcriptome data of isolated splenic Ly6Chi (left) and Ly6Clow (right) 
monocytes from three WT (blue), leukemic (red), and Ibrutinib-treated (green) samples each. (b) Venn 
diagram of unique and common DEGs in ‘TCL-1 AT vs WT’ (yellow+green) and ‘Ibrutinib vs TCL-1 AT’ 
(blue+red) in Ly6Chi (yellow+blue) and Ly6Clow (green+red). (c) List of 18 DEGs in ‘TCL-1 AT vs WT’, expressed 
in the opposed direction in ‘Ibrutinib vs TCL-1 AT’, and only differentially deregulated in Ly6Clow but not Ly6Chi 
monocytes. 
 
In summary, these data show that Ibrutinib does affect both Ly6Chi and Ly6Clow monocytes with a 
higher number of significant genes normalized in Ly6Clow monocytes. Samples preparations were 
performed at time points when there was no significant difference in tumor burden between the 
TCL-1 AT and Ibrutinib-treated cohort (data not shown). Therefore, the observed changes in GEP 
are assumed to be largely independent of secondary effects due to different amounts of CD5+CD19+ 
cells. 
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3.2.1.3 Ibrutinib abrogates pro-survival effects of monocytes for human CLL cells in vitro 
As gene expression profiling revealed Ibrutinib-induced changes in monocytes, it seemed likely that 
the drug impacts on monocyte-mediate survival of CLL cells. To address this, human CLL cells 
isolated from patients’ blood were cocultured with Ibrutinib pre-treated human monocytes for 48 
hours. This resulted in reduced survival of CLL cells compared to untreated control cultures (Figure 
13a). 
 
 
Figure 13: Ibrutinib treatment of monocytes reduced TNF- secretion and survival support for CLL cells in 
vitro. 
Monocytes were pre-treated for 1 hour with 5µM Ibrutinib, followed by washing steps to remove the drug. 
(a) Annexin V/7-AAD flow cytometry assay of primary CD5+CD19+ CLL cells harvested from CLL-monocyte 
cocultures (n=5) set up in a 5:1 ratio (CLL:monocytes) after 48 hours. (b) TNF- level was measured by ELISA 
in cell culture supernatants from monocyte monocultures (n=3) and CLL-monocyte cocultures (n=3), (2.5x106 
monocytes with or without 1.25x106 CLL-PBMCs) with or without pre-treatment with Ibrutinib. P values were 
determined by paired Student t-test. 
 
Quantification of TNF- in the supernatant of these cocultures as well as in monocyte monocultures 
revealed decreased levels upon Ibrutinib treatment (Figure 13b), suggesting that BTK inhibition in 
monocytes impairs their secretion of cytokines. As monocyte-derived secreted factors, including 
TNF-, are known to maintain CLL cell viability, the reduction of survival support of Ibrutinib-treated 
monocytes is likely partially mediated via their reduced capacity to secrete cytokines like TNF-. 
 
3.2.1.4 Ibrutinib inhibits phosphorylation of BTK in murine monocytes and leads to 
decreased cytokine levels in the TCL-1 AT mouse model 
To test if the TCL-1 AT mouse model is useful to study the effect of BTK inhibition on cells of the 
myeloid microenvironment in CLL, phosphorylation levels of BTK were determined for different cell 
populations in healthy C57BL/6 WT mice treated with vehicle or Ibrutinib for 3.5 weeks. 
Phosphorylated BTK was detected in B cells, monocytes, granulocytes, and conventional dendritic 
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cells, while being significantly reduced in Ibrutinib-treated mice only in B cells and monocytes 
(Figure 14a). 
 
According to literature, T cells do not express BTK but high amounts of ITK, while the other tested 
cell populations express BTK, but no ITK318. Since the only available antibody for the detection of 
phosphorylated BTK binds also phosphorylated ITK, a slight but not significant reduction in 
phosphorylated ITK in T cells by Ibrutinib was also observed (p=0.699) (Figure 14a). 
Leukemia development in TCL-1 AT mice is associated with increased expression of several 
cytokines including TNF- in monocytes (Figure 14b). As Ibrutinib treatment of mice reduced BTK 
activity in monocytes, we next assessed the impact of the drug on their cytokine expression levels. 
In line with the above described in vitro results, Ibrutinib treatment of mice resulted in decreased 
intracellular TNF-levels compared to vehicle-treated animals (Figure 14c). Comparable results 
were further obtained for IL-1 (Figure 14d). Notably, gating on Ly6Chi and Ly6Clow monocytes 
revealed that cytokines were mainly produced by the Ly6Clow monocyte subpopulation and Ibrutinib 
mainly affected cytokine levels in this subpopulation (data not shown).  
Intracellular TNF-levels in cDCs were not different in WT or TCL-1 AT animals (Figure 14e) and not 
affected by Ibrutinib treatment (Figure 14f).  However, cDCs showed lower expression of IL-1 upon 
Ibrutinib treatment (Figure 14g). 
 
Of note, the percentages of TNF--producing monocytes from leukemic untreated and leukemic 
vehicle-treated animals was different in the two studies (mean of 16.53% in TCL-1 AT mice in Figure 
14b versus 37.69% in vehicle-treated mice in Figure 14c). This cannot merely be explained by 
differences in tumor load in the two studies that might cause different levels of immune reaction 
by myeloid cells. The first study comparing WT and TCL-1 AT leukemic mice had a tumor load of 
82.25% in the spleen. In the second study comparing Ibrutinib-treated and vehicle-treated animals, 
tumor load in spleen was ~85% for vehicle-treated mice and ~75% for Ibrutinib-treated mice. Also, 
percentages of TNF--producing DCs were similar in leukemic mice in both studies, although they 
were in general quite heterogeneous. 
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Figure 14: Ibrutinib treatment of mice reduces BTK phosphorylation and cytokine expression in monocytes.  
(a) Quantification of MFIs of phosphorylated BTK/phosphorylated ITK gated splenic B cells, monocytes, 
granulocytes, cDCs, and T cells from WT animals treated with vehicle (n=4) or Ibrutinib (n=4), (left); 
representative staggered histogram with grey histograms representing each cell population’s specific FMO 
control. (B cells: CD4-Ly6G-CD19+; monocytes: CD19-CD4-CD11b+Ly6G-MHC-IIlow-intCD11chighCX3CR1hi; CD4+ T 
cells: CD19-Ly6G-CD11b-CD11c-MHC-II-CD4+; granulocytes: CD19-CD4-CD11b+Ly6G+; cDCs: CD19-Ly6G-
CD11c+MHC-IIhigh) (b-g) Percentage of TNF- and IL-1 producing monocytes (b-d) and cDCs (e-g) assessed by 
intracellular flow cytometry after 6 hours of LPS stimulation of isolated splenocytes. Two independent 
experiments are shown here: (b,e) Comparison of healthy wildtype (WT) (n=4) and leukemic TCL-1 AT (n=4) 
mice; (c,d,f,g) Comparison of leukemic TCL-1 AT mice treated with vehicle (n=6) or Ibrutinib (n=4) for 3.5 
weeks. Treatment start was at ~5% tumor load in the blood. (Ly6Chigh monocytes: Viability dye (VD)-CD19-
Ly6G-CD11b+CD11clow-intMHC-IIlowCXCR1+Ly6Chigh; Ly6Clow monocytes: VD-CD19-Ly6G-CD11b+CD11clow-intMHC-
IIlowCXCR1+Ly6Clow; cDCs: VD-CD19- CD11chighMHC-II+) P values were determined by unpaired Student t-test. 
 
In summary, these results indicate that monocytes and cDCs from TCL-1 AT mice possess a 
differential potential to produce cytokines and that inhibition of BTK signaling by Ibrutinib is capable 
of reducing cytokine expression in particular in Ly6Clow monocytes. As these cells are the main 
myeloid cell population that accumulates in the TCL-1 AT model, Ibrutinib-induced changes in these 
cells might positively contribute to the drug’s efficacy. 
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3.2.1.5 BTK blockade inhibits the accumulation of Ly6Clow monocytes in the TCL-1 AT 
model 
To further investigate if Ibrutinib treatment in mice might impact on monocytes, cell numbers of 
LyC6hi and Ly6Clow subsets were quantified in the spleen and peripheral blood. Two weeks of 
treatment with Ibrutinib lead to lower numbers of both monocyte subsets in peripheral blood 
(Figure 15a). Similarly, also splenic monocyte numbers were reduced by Ibrutinib and were at levels 
of WT animals (Figure 15b). 
 
Figure 15: Ibrutinib treatment inhibits the accumulation of Ly6Clow monocytes in the TCL-1 AT model. 
(a,b) Absolute numbers of Ly6Chi monocytes (top) and Ly6Clow monocytes (bottom) in (a) peripheral blood 
(PB) and (b) spleen (SPL) from leukemic TCL-1 AT mice treated with vehicle (n=10) or Ibrutinib (n=4) for 2 
weeks. (c,d) Absolute numbers of Ly6Chi monocytes (top) and Ly6Clow monocytes (bottom) in (c) peripheral 
blood (PB) and (d)  spleen (SPL) from non-leukemic wildtype (WT) mice treated with vehicle (n=6) or Ibrutinib 
(n=5) for 2 weeks.  
 
Because the Ibrutinib-induced effect on cell numbers in leukemic TCL-1 AT mice was not restricted 
to blood monocytes but was also observed in the spleen, this excluded the possibility that subset 
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and cell number changes in the blood were solely due to a redistribution of cells from lymphoid 
organs (Figure 15a,b). 
 
To explicitly answer the question whether the drug's effect observed at week 2 was solely due to a 
controlled tumor development and therefore rather an indirect effect on the microenvironment, 
WT mice were treated for the same period of time with Ibrutinib or vehicle control respectively. As 
expected, non-leukemic control animals administered with vehicle drinking water showed 
moderate numbers of Ly6Chi and Ly6Clow monocytes in peripheral blood and spleen, without any of 
them being elevated (as indicated by the generally lower cell numbers compared to leukemic mice) 
(Figure 15c,d). In these wildtype animals, Ibrutinib did not lead to a reduction of the absolute 
number of monocyte subsets (Figure 15c,d). However, by comparing the ratios of absolute numbers 
of splenic Ly6Chi and Ly6Clow monocytes for each wildtype animal, an increase of this ratio was 
induced by Ibrutinib, suggesting that Ibrutinib is capable of impacting directly on monocytes and 
their subset distribution (Figure 15e,f). 
 
3.2.1.6 Ly6Chi monocytes increase in size in the TCL-1 AT model which is normalized by 
Ibrutinib treatment 
To further investigate monocyte subset-specific differences Ly6Chi and Ly6Clow monocytes were 
checked concerning their cell size and granularity. 
This revealed that Ly6Chi monocytes display a higher forward and side scatter compared to Ly6Clow 
monocytes in leukemic mice (Figure 16a). This is in line with previous reports for murine 
monocytes164. However, a comparison to of each subset to the respective population in WT mice 
revealed an increase in size as well as granularity of Ly6Chi monocytes in the TCL-1 AT model (Figure 
16b). This was reversed by treatment with Ibrutinib leading to a phenotype similar to WT mice 
(Figure 16c). Monocytes from non-leukemic animals treated with Ibrutinib, however, did not show 
a difference in the forward and side scatter properties. This indicates that the observed CLL-
associated size change was prevented by treatment. 
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Figure 16: Ly6Chi monocytes from TCL-1 AT mice exhibit an increased cell size and granularity, which is 
prevented by Ibrutinib.  
(a) Representative overlay of flow cytometry dot plots showing forward and side scatter of Ly6Chi and Ly6Clow 
monocytes from WT animals. (b) Overlay of flow cytometry dot plots showing forward and side scatter of 
Ly6Chi monocytes from WT animals and TCL-1 AT animals (n=6) (left) and quantification of forward scatter 
intensities (right). (c) Overlay of flow cytometry dot plots showing forward and side scatter of Ly6Chi 
monocytes from TCL-1 AT animals (n=4) treated for two weeks with vehicle or Ibrutinib (left) and 
quantification of forward scatter intensities (right). (Ly6Chigh monocytes: Viability dye (VD)-LIN-(CD19-CD3-
Ly6G-NK1.1-TER119-)CD11b+CD11clow-intMHC-IIlowCXCR1+Ly6Chigh; Ly6Clow monocytes: VD-LIN-CD11b+CD11clow-
intMHC-IIlowCXCR1+Ly6Clow) P values were determined by unpaired Student t-test. 
 
3.2.1.7 Ibrutinib prevents tolerogenic phenotype of Ly6Clow monocytes by preventing 
PD-L1 induction possibly mediated through IFN- 
PD-L1 was reported previously to be highly upregulated on monocytes from TCL-1 mice as well as 
CLL patient monocytes. As shown in a previous section of this work, PD-L1 displays differential 
expression on Ly6Chi and Ly6Clow monocytes and in particular, the Ly6Clow monocyte population 
represents the subpopulation expressing high PD-L1 surface levels (Figure 12e,f). 
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Figure 17: Ibrutinib reduces PD-L1 expression in Ly6Clow monocytes from TCL-1 AT and wildtype mice.  
(a) Representative histogram illustrating PD-L1 expression on total splenic monocytes from mice treated with 
vehicle or Ibrutinib for 2 weeks. (b) PD-L1 expression level on Ly6Chigh (left), Ly6Cint (middle) and Ly6Clow (right) 
monocytes from leukemic TCL-1 AT mice treated with vehicle (n=4) or Ibrutinib (n=4). (c) PD-L1 expression 
level on Ly6Clow monocytes from leukemic TCL-1 AT mice treated with anti-IFNR (n=6) or isotype control 
antibody (n=5). Mice were injected i.p. with 1 mg of anti-IFNR, or rat IgG1 isotype control antibody, followed 
by subsequent doses of 0.5 mg every 3 days for another 2 weeks. The present marker measurements were 
incorporated into a project designed by Bola Hanna. (d) PD-L1 expression level on Ly6Clow monocytes from 
non-leukemic wildtype mice treated with vehicle (n=4) or Ibrutinib (n=4) for two weeks. (Ly6Chigh monocytes: 
Viability dye (VD)-LIN-(CD19-CD3-Ly6G-NK1.1-TER119-)CD11b+CD11clow-intMHC-IIlowCXCR1+Ly6Chigh; Ly6Clow 
monocytes: VD-LIN-CD11b+CD11clow-intMHC-IIlowCXCR1+Ly6Clow) P values were determined by unpaired 
Student t-test. 
 
Splenic monocytes isolated from Ibrutinib-treated TCL-1 AT mice possessed a reduced surface level 
of PD-L1 on Ly6Clow monocytes, which was even stronger reduced on monocytes expressing 
intermediate levels of Ly6C (Ly6Cint) (Figure 17a,b). It was hypothesized that leukemia-induced T 
cell-derived IFN- could regulate PD-L1 expression, and indeed anti-IFN-R-treated leukemic 
animals displayed lower levels of PD-L1 on Ly6Clow monocytes (Figure 17c). To exclude that reduced 
PD-L1 levels were merely due to the reduced tumor load achieved by anti-IFN-R or Ibrutinib 
treatment, additionally, non-leukemic mice treated with Ibrutinib were analyzed. This confirmed a 
reduction of PD-L1 expression upon treatment also in wildtype mice (Figure 17d). These results 
suggest that inhibition of BTK by Ibrutinib leads to lower PD-L1 expression in monocytes which is 
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may still be mediated through IFN-, while this mechanism seems however independent of the 
presence specifically tumor-induced IFN-. 
 
3.2.1.8 BTK inhibition normalizes CLL-associated TREM-1 overexpression on monocytes 
and granulocytes 
As BTK is proposed to play a key role as positive regulator within the TREM-1 signaling pathway, 
TREM-1 expression under the influence of Ibrutinib was analyzed. In TCL-1 AT mice, TREM-1 
expression was previously reported to be increased on monocytes compared to WT mice. Subset 
specific measurements of TREM-1 revealed that Ly6Clow monocytes showed higher TREM-1 levels 
compared to Ly6Chi cells, while overall still showing a unimodal signal distribution (Figure 18a). 
 
Figure 18: Ibrutinib treatment normalizes leukemia-associated TREM-1 overexpression on monocytes and 
granulocytes in TCL-1 AT mice. 
(a) TREM-1 expression level on Ly6Chigh (left) and Ly6Clow (right) monocytes from leukemic TCL-1 AT mice 
treated with vehicle (n=4) or Ibrutinib (n=4) for 2 weeks in the spleen (SPL). (b) TREM-1 expression level on 
Ly6Chigh (left) and Ly6Clow (right) monocytes from leukemic TCL-1 AT mice treated with vehicle (n=10) or 
Ibrutinib (n=4) for 2 weeks in peripheral blood (PB). (c) TREM-1 expression level on Ly6Clow monocytes from 
non-leukemic wildtype mice treated with vehicle (n=6) or Ibrutinib (n=6) in the spleen (SPL). (d) TREM-1 
expression level on granulocytes from leukemic TCL-1 AT mice treated with vehicle (n=10) or Ibrutinib (n=4) 
in peripheral blood (PB) (left) and representative histogram (right). (e) TREM-1 expression level on 
granulocytes from non-leukemic wildtype mice treated with vehicle (n=6) or Ibrutinib (n=6) in peripheral 
blood (PB). (Ly6Chigh monocytes: Viability dye (VD)-LIN-(CD19-CD3-Ly6G-NK1.1-TER119-)CD11b+CD11clow-
intMHC-IIlowCXCR1+Ly6Chigh; Ly6Clow monocytes: VD-LIN-CD11b+CD11clow-intMHC-IIlowCXCR1+Ly6Clow; 
granulocytes: VD- LIN-(CD19-CD3- NK1.1-TER119-)CD11b+Ly6G+) P values were determined by unpaired 
Student t-test. 
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TREM-1 expression on monocytes in spleen and peripheral blood was reduced after treatment of 
TCL-1 AT mice with Ibrutinib, with a similar strength on both monocyte subsets (Figure 18a,b). 
Notably, different than for PD-L1, Ibrutinib treatment of non-leukemic WT animals was not capable 
to reduce steady state TREM-1 expression levels (Figure 18c). Similarly, also TREM-1 induction on 
granulocytes was only suppressed after Ibrutinib treatment in the leukemic context but not in WT 
animals (Figure 18d,e).  
 
3.2.1.9 BTK inhibition alters PECAM-1 and CD38 as part of the CLL-monocyte crosstalk 
PECAM-1 and CD38 are proposed to be a ligand/receptor system orchestrating lymphocyte 
adhesion. In particular, they were suggested to play a role in adhesion of CLL cells to NLCs in lymph 
nodes of CLL patients86. 
 
Figure 19: Ibrutinib treatment of mice alters expression of PECAM-1 and CD38 on monocytes and malignant 
B cells, respectively. 
(a) PECAM-1 expression level (left) and representative histogram (right) of monocytes from leukemic TCL-1 
AT mice treated with vehicle (n=10) or Ibrutinib (n=4) for two weeks. (b) PECAM-1 expression level on 
monocytes from non-leukemic wildtype animals (WT) treated with vehicle (n=4) or Ibrutinib (n=4) for two 
weeks. (c) CD38 expression level on CD5+CD19+ cells from leukemic TCL-1 AT mice treated with vehicle (n=4) 
or Ibrutinib (n=4) for two weeks. (Monocytes: Viability dye (VD)-LIN-(CD19-CD3-Ly6G-NK1.1-TER119-) 
CD11b+CD11clow-intMHC-IIlowCXCR1+; Leukemic CD5+CD19+ cells: VD-CD45+ CD5+CD19+) P values were 
determined by unpaired Student t-test. 
 
PECAM-1 expression on total splenic monocytes from TCL-1 AT mice was elevated compared to WT 
mice. Ibrutinib treatment lead to significantly reduced levels compared to monocytes isolated from 
vehicle arm animals (Figure 19a). In addition, this Ibrutinib-induced change in PECAM-1 expression 
was independent of the presence of leukemic cells as it was also reduced in non-leukemic animals 
(Figure 19b). Within the same study, CD38, the receptor for PECAM-1, was examined on leukemic 
cells from the spleen. In contrast to the ligand’s expression on monocytes, CD5+CD19+ leukemia 
cells showed an increased expression of CD38 (Figure 19c). The altered balance of the PECAM-
  RESULTS 
79 
 
1/CD38 ligand/receptor system, induced by the Ibrutinib treatment, may impact on the adhesion 
of CD5+CD19+ to myeloid cell, thereby preventing leukemic cells from residing in their nourishing 
TME. 
 
3.2.2 Conventional dendritic cells in steady state, in CLL and under the influence of 
Ibrutinib 
3.2.2.1 cDCs from TCL-1 AT mice express a gene signature associated with 
developmental and functional impairment 
Similar as for the monocyte subsets, also a thorough analysis of cDCs, which represent the least 
characterized myeloid cell population in CLL, was performed. cDCs were isolated from the same 
animals as used for monocyte analysis and were processed as described above (Chapter 3.2.1.1). 
Gene expression analysis revealed 2,279 genes in cDCs to be significantly deregulated when 
comparing cells isolated from leukemic TCL-1 AT and WT mice (Figure 20a). Hence, cDCs from TCL-
1 AT animals, downregulated a large number of genes, while DEGs identified in Ly6Chi and Ly6Clow 
monocytes were much lower in numbers and notably, most of them were upregulated. 
Using the IPA tool, many biological functions were identified to be affected and mainly predicted 
to be inhibited in cDCs from TCL-1 AT mice (Figure 20b). These were among others: (1) 
Hematological System development and function, (2) Lymphoid Structure and Development, (3) 
Cellular Growth and Maintenance, and (4) Cellular Development (ranked by p value ranges). 
Similarly, IPA revealed several dendritic cell-associated pathways to be among the top 10 canonical 
pathways. Among these were Role of Macrophages, Fibroblasts and Endothelial Cell in Rheumatoid 
Arthritis, Phagosome Formation, Role of Pattern Recognition Receptors of Bacteria and Viruses, 
Protein Kinase A Signaling, NF-kB Signaling, TREM1 Signaling, and Phospholipase C (Figure 20c). The 
majority of genes belonging to these pathways were downregulated thereby pointing to an 
impaired dendritic cell function in TCL-1 AT mice.  
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Figure 20: Gene expression profiling of cDCs from TCL-1 AT mice reveals an inhibition of pathways involved 
in their development and function. 
(a) Volcano plots showing upregulated (orange) and downregulated (blue) genes in cDCs from leukemic TCL-
1 AT (n=3) versus WT (n=3) animals. The dotted line indicates cutoff at a p value of 0.05. (b) Enrichment 
analysis of biological functions into categories (top 10 categories showed) using IPA downstream effect 
analysis, showing number of involved genes and p value ranges (blue=category predicted to be inhibited, 
grey=category prediction unclear). (c) Top 10 canonical pathways identified in cDCs from TCL-1 AT (n=3) 
versus WT (n=3) animals using IPA. See Appendix Table 1 for additional information on samples.  
 
3.2.2.2 cDCs from TCL-1 AT mice display a CLL-associated subset composition which is 
normalized by Ibrutinib treatment  
As previously reported, cDC numbers increase during CLL development in TCL-1 AT mice and were 
suggested to represent a rather immature and tolerogenic population. Therefore, it was of interest 
if Ibrutinib could potentially act also on this myeloid cell population in a direct or indirect manner.  
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Figure 21: Ibrutinib treatment reverses the leukemia-associated alterations in cDC subset composition. 
(a) Absolute numbers (left) and tumor cell-normalized numbers (right) of cDCs in the spleen from WT (n=3) 
and leukemic TCL-1 AT mice treated with vehicle (n=10) or Ibrutinib (n=10) for two weeks. (b) Absolute 
numbers of cDCs in the spleen from non-leukemic WT mice treated with vehicle (n=4) or Ibrutinib (n=4) for 
two weeks. (c) Percentages of CD8+ cDCs, CD8-CD4+ cDCs, and CD8-CD4- cDCs out of total cDCs from WT mice 
(n=6) and TCL-1 AT mice treated with vehicle (n=10) or Ibrutinib (n=10) for two weeks, and (d) representative 
gating strategy. (e) Percentage of CD8+ cDCs, CD8-CD4+ cDCs, and CD8-CD4- cDCs out of total cDCs from non-
leukemic WT mice treated with vehicle (n=4) or Ibrutinib (n=4) for two weeks. (CD8+ cDCs: Viability dye (VD)-
LIN-(CD19-CD3-Ly6G-NK1.1-TER119-)CD11chighMHC-II+CD8+; CD8-CD4+ cDCs: VD-LIN-CD11chighMHC-II+CD8-
CD4+; CD8-CD4- cDCs: VD-LIN-CD11chighMHC-II+CD8-CD4+) P values were determined by unpaired Student t-
test. 
 
Different than for monocytes, Ibrutinib did not inhibit the accumulation of dendritic cells in TCL-1 
AT mice compared to the vehicle-treated group (Figure 21a, left). Also in non-leukemic WT animals, 
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Ibrutinib treatment did not influence the number of cDCs confirming the latter results (Figure 21b). 
However, normalizing cDC numbers to the respective number of CD5+CD19+ CLL cells revealed that 
the ratio of cDCs to CD5+CD19+ cells was different in the two treatment arms (Figure 21a, right). In 
particular, there were more splenic cDCs in relation to CD5+CD19+ cells in the spleen when analyzing 
numbers two weeks after treatment, at which Ibrutinib was controlling the tumor burden in the 
spleen (% CD5+CD19+ cells for vehicle: 93%, for Ibrutinib: 66%). 
Since cDCs are constituted of different populations, a deeper insight into their subset composition 
was gained. The three murine cDC populations of interest are distinguished by the following 
expression patterns: (i) CD8+, (ii) CD8-CD4+, and (iii) CD8-CD4-. In addition to these markers, CD8- 
cDC subsets were confirmed to express higher levels of CD11b compared to CD8+, and CD11c was 
also confirmed to be higher on the CD4+ cDC subset as compared to the CD4- subset (Appendix 
Figure 4a,b). First, altered numbers (not shown) as well percentages of these three cDC subsets 
were assessed in TCL-1 AT vehicle-treated mice compared to WT animals. Leukemic animals 
displayed a significantly increased percentage of CD8+ cDCs and CD8- CD4- cDCs, and a decrease in 
the percentage of CD8-CD4+ cDCs on the other hand (Figure 21c,d). This suggested that CD8+cDCs 
and CD8-CD4- cDCs might represent the main increasing cDC populations that explain leukemia-
induced accumulation of total cDCs described just before. These alterations caused a changed 
subset composition of cDCs compared to steady state, where CD8-CD4+ cDCs represent the most 
frequent subset, followed by CD8-CD4- and finally CD8+ cDCs190. In line with this observation, the 
gene expression profile of cDCs isolated from leukemic TCL-1 AT mice highly resembled CD8+ DCs 
but not CD4- DCs among different splenic DC populations (Appendix Figure 5a,b) This confirmed, 
that leukemia-induced differences in DC subpopulations seem to be indeed true and not solely 
restricted to changes in a few marker proteins (namely CD4 and CD8 here). 
 
Next, the impact of Ibrutinib on the proportions of cDC subsets was addressed. After two weeks of 
treatment, the distribution of CD8+, CD8-CD4+, and CD8-CD4- cDCs was mostly, though not fully 
normalized and resembled rather the distribution in WT mice (Figure 21c). Ibrutinib was able to 
induce a similar subpopulation skewing in a leukemia-free set-up of treated WT animals suggesting 
that these data present CLL-independent, Ibrutinib-mediated effects on cDCs (Figure 21e). 
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3.2.2.3 Ibrutinib induces a tolerogenic cDC immunophenotype in the TCL-1 AT model 
Conventional dendritic cells from TCL-1 AT cells were proposed to express higher PD-L1 and lower 
MHC-II surface levels and display decreased percentages of double-positive CD83+ CD86+ cDCs319. 
Prior investigating the effect of Ibrutinib on cDCs these proposed changes between wildtype and 
leukemic animals were revised. Several experiments verified these changes for MHC-II and PD-L1, 
but could not confirm a downregulation of the costimulatory molecules CD83 and CD86 on splenic 
cDCs from TCL-1 AT mice compared to WT animals. Indeed, for both molecules and for ICAM-1, a 
dendritic cell activation marker, an increased expression was observed repeatedly in TCL-1 AT 
compared to wildtype mice (data not shown). Yet, it was of interest whether Ibrutinib treatment 
was able to result in a normalization of the activated but supposedly not fully functional cDC 
phenotype. Moreover, this study included a detailed analysis of the poorly characterized murine 
cDC subsets under treatment with Ibrutinib.  
 
While MHC-II expression was not altered by Ibrutinib treatment (data not shown), the activation 
and maturation markers ICAM-1, CD86 and CD83 turned out to be significantly downregulated by 
the drug (Figure 22a,c,e). Interestingly, the expression levels of these molecules were differently 
affected in CD8+, CD8-CD4+, and CD8-CD4- cDC subsets. For instance, ICAM-1 was expressed to a 
lesser extent on all subsets (Figure 22b). In contrast, CD86 and CD83 were similarly downregulated 
on CD8-CD4+, and CD8-CD4- cDC subsets, but not on CD8+ cDCs (Figure 22d,f). However, the effect 
on the overall expression on total cDCs was much stronger for CD83 which can be explained by the 
subset shift described above (Figure 22b).  
 
Notably, CD86 and CD83 expression on total cDCs were decreased to a similar extent upon Ibrutinib 
treatment of leukemia-free animals, and an unchanged low MHC-II expression was also confirmed 
in WT mice (data not shown). In contrast, ICAM-1 expression was not affected in that setting. 
Moreover, Ibrutinib treatment lead to an increased percentage of the PD-L1high-expressing cDC 
population (Figure 22g), supporting one more time that Ibrutinib may act partially counteractive on 
DCs by inducing an even stronger immune-suppressive surface phenotype of these cells. 
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Figure 22: Ibrutinib treatment enhances a tolerogenic cDC phenotype in the TCL-1 AT model. 
(a,c,e) ICAM-1 (a), CD86 (c), and CD83 (e) expression level on total splenic cDCs from mice treated with vehicle 
(n=4) or Ibrutinib (n=4) for two weeks. Representative flow cytometry histograms (left) and quantification of 
data (right). (b,d,f) Quantification of ICAM-1 (b), CD86 (d), and CD83 (f) expression on CD8+, CD8-CD4+, and 
CD8-CD4- cDC subpopulations from mice treated with vehicle (n=4) or Ibrutinib (n=4) for two weeks. (g) 
Percentage of PD-L1high-expressing cDCs (left) and representative density plots from mice treated with vehicle 
(n=10) or Ibrutinib (n=10) (right) for two weeks. (cDCs: Viability dye (VD)-LIN-(CD19-CD3-Ly6G-NK1.1-TER119-
)CD11chighMHC-II+; CD8+ cDCs: VD-LIN-CD11chighMHC-II+CD8+; CD8-CD4+ cDCs: VD-LIN-CD11chighMHC-II+CD8-
CD4+; CD8-CD4- cDCs: VD-LIN-CD11chighMHC-II+CD8-CD4+) P values were determined by unpaired Student t-
test. 
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In addition, IL-12, a pro-inflammatory cytokine, which is associated with CD8+ cDCs, showed a 
decreased level in intracellular flow cytometry staining of total cDCs from TCL-1 AT compared to 
WT mice that was not further changed upon Ibrutinib treatment (Appendix Figure 4c,d)188, 189. This 
again suggested, that despite an enrichment of the CD8+ cDCs subpopulation their capability for 
cytokine production with respect to their functionality might be impaired in leukemic versus 
healthy animals. 
 
3.2.2.4 Inhibition of IL-10RA receptor signaling partially reverses tolerogenic phenotype 
of cDCs in TCL-1 AT mice 
The effect of Ibrutinib on cDC activation, maturation, and tolerogenic markers seemed not 
favorable towards a restoration of the implied functional impairment of cDCs and even further 
supported the suggested dysfunctionality of these cells. This raised the question of how cDCs may 
possibly be targeted in order to regain their full capacity for antigen presentation and activation.  
In order to determine possible target molecules, a closer look on predicted upstream regulators, 
identified based on the gene expression results of their downstream targets, was performed using 
IPA. This type of analysis enables the identification of signaling axes and molecules of interest 
independent of their expression levels that may or may not be altered.  
IL-10 receptor A (IL-10RA) turned out to be among the top five predicted regulators and at the same 
time is known to be an important player in dendritic cell maturation and activation (Figure 23a)320. 
 
To evaluate the relevance of IL-10RA, TCL-1 AT mice were injected i.p. with an antibody directed 
against anti-IL-10RA or a respective isotype control antibody. After 2 weeks of treatment, isolated 
splenic cDCs from anti-IL-10RA-treated mice showed significantly increased levels of MHC-II. ICAM-
1, CD86 and CD83 expression were slightly but not significantly increased, while generally rather 
low for CD86 and CD83 (Figure 23b) and unchanged for PD-L1 (data not shown). These results 
suggest an involvement of the IL-10/IL-10 receptor axis in the activity of splenic dendritic cells in 
leukemic TCL-1 AT mice.  
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Figure 23: Inhibition of IL-10RA receptor signaling partially reverses tolerogenic phenotype of cDCs in TCL-
1 AT mice. 
(a) Top five predicted upstream regulators in cDCs from leukemic compared to WT mice identified in the GEP 
data using IPA. (b) CD83, CD54, CD86, and MHC-II expression levels on splenic cDCs cells from TCL-1 AT mice 
treated with anti-IL-10RA (n=6/5) or isotype antibody (n=4/5), measured by flow cytometry. Leukemic mice 
were injected i.p. with 1 mg of anti-IL-10RA, or rat IgG1 isotype control antibody, followed by subsequent 
doses of 0.5 mg every 3 days for another 2 weeks. The present marker measurements were incorporated into 
a project designed by Bola Hanna. (cDCs: Viability dye (VD)-LIN-(CD19-CD3-Ly6G-NK1.1-TER119-)CD11chighMHC-
II+) P values were determined by the unpaired Student t-test. 
 
In addition, TCL-1 AT mice were treated with an antibody blocking IFN receptor (anti-IFNR), 
another predicted upstream regulator identified in the cDC gene expression data (Figure 23a). The 
absence of IFN-mediated signaling lead to a very small and insignificant decrease in activation and 
maturation marker levels compared to isotype control (data not shown).  
However, both treatments resulted in unfavorable disease outcome as the tumor load was 
increased in animals receiving one or the other antibody (data not shown). Thus, the observed 
changes in expression levels of CD83, CD54 and CD86 which were of opposing directions in the two 
groups (anti-IL-10RA or anti-IFNR), were unlikely caused by changes in tumor burden but were 
presumably a direct consequence of the impaired access to Il-10. Thus, immunomodulation of the 
IL-10 receptor-mediated signaling might partially contribute to the reversal of the observed CLL-
induced cDC phenotype.  
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3.3 Treatment of TCL-1 AT mice with Ibrutinib results in tumor cell-intrinsic 
resistance to the drug 
While investigating effects of Ibrutinib on the myeloid TME in TCL-1 AT mice, a time-restricted 
response to treatment and tumor cell-intrinsic acquired resistance to Ibrutinib was observed. In the 
first 4-6 weeks of Ibrutinib treatment, the expected favorable outcome on disease development in 
TCL-1 AT mice was obtained. As control of leukemia development was not long-lasting, resistance 
development in Ibrutinib-treated mice was assumed. To validate and further investigate this 
observation, the initial goal was to confirm this observation by adoptive transfer of a different 
tumor sample into C57BL/6 mice. A comparative characterization of such generated Ibrutinib 
sensitive and resistant tumors was obtained by whole exome and transcriptome analyses. In 
addition, the growth kinetics of re-transplanted tumors that had undergone previous Ibrutinib or 
vehicle treatment was monitored. 
 
3.3.1 Loss of treatment response to Ibrutinib 
To confirm loss of treatment efficacy of Ibrutinib over time, animals were adoptively transferred 
with 1.3x107 splenocytes originating from a leukemic TCL-1 AT mouse (tumor: 1J4) by i.p. injection, 
and randomization into two groups was conducted, once the leukemia was established with a mean 
tumor load of at least 50% in peripheral blood (week 2 post-transplantation) (Appendix Figure 6a). 
Mice were then treated either with 25 mg/kg/day Ibrutinib (Ibr arm) or vehicle (Veh arm). Ibrutinib 
initially controlled disease progression leading to lower absolute numbers of malignant CD5+CD19+ 
cells compared to vehicle-treated mice (Figure 24a). Mice were sacrificed at three different time 
points: (1) An early time point where animals from the Ibrutinib arm were considered to be still 
sensitive to Ibrutinib (week 1 post treatment); (2) two later time points where animals had reached 
a high tumor load of at least 100,000 leukemic cells/µL blood which occurred first in the vehicle 
arm (week 3) and later in the Ibrutinib arm (week 6). At all three endpoints, leukemic cells from 
spleens were harvested, sorted by flow cytometry and frozen for later processing (Appendix Table 
2). 
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Figure 24: Loss of treatment response to Ibrutinib in the TCL-1 AT model. 
(a) Absolute numbers of CD5+CD19+ cells in the peripheral blood from mice adoptively transferred with 
malignant splenocytes isolated from spleens of leukemic TCL-1 mice. Mice were randomized 2 weeks post-
transplantation (=week 0) and treatment was started (black arrow) with vehicle (n=14, grey) or Ibrutinib 
(n=12, blue). Animals were sacrificed at different endpoints (red arrows). (b) Percentages of Ki-67-positive 
cells out of CD5+CD19+ cells in peripheral blood (PB), spleen (SPL), bone marrow (BM), and inguinal lymph 
nodes (LN) from mice adoptively transferred with tumor 1J4 and treated with vehicle (n=6) or Ibrutinib (n=6) 
for one week (left), or three weeks for vehicle (n=6) and six weeks for Ibrutinib (n=3) (right). TGI=Tumor 
growth inhibition. (Leukemic CD5+CD19+ cells: CD45+CD5+CD19+) P values were determined by unpaired 
Student t-test. 
 
Comparison of percentages of Ki-67-expressing CD5+CD19+ cells from different organs after one 
week of treatment revealed significantly lower percentages of proliferating cells in animals treated 
with Ibrutinib (Figure 24b,left). Comparison of percentages of Ki-67-expressing CD5+CD19+ cells 
from vehicle-treated animals at week three and Ibrutinib-treated animals at week six indicated that 
this difference was less prominent in the bone marrow and lymph nodes and disappeared in blood 
and spleen at these later time points (Figure 24b,right). In accordance with the latter observation 
also differences in spleen weight and tumor load in lymphoid organs, initially controlled by Ibrutinib 
treatment, became less distinct over time (Appendix Figure 6a-d). Hence, these data support the 
hypothesis of acquired resistance to Ibrutinib in this model. 
 
3.3.1.1 Re-transplantation of resistant tumors 
In order to monitor the responsiveness and growth kinetics of re-transplanted tumors that had 
undergone previous Ibrutinib or vehicle treatment, two tumors from a first round of treatment of 
each arm (vehicle=Veh and Ibrutinib=Ibr) with similar tumor load and cell viability were chosen. The 
second round of transplantation, randomization, and treatment with Ibrutinib (Veh_Ibr and Ibr_Ibr) 
or vehicle (Veh_Veh and Ibr_Veh) was conducted in the same manner as described in the section 
before (number of cells, route of administration etc) (Figure 25a).  
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Figure 25: Re-transplantation of Ibrutinib-treated tumor cells provides evidence for cell-intrinsic resistance. 
(a) Experimental setup of serial adoptive transfer of TCL-1 tumors and treatment of mice (Veh=vehicle, 
Ibr=Ibrutinib). Study endpoints are depicted as red lines. (b,c) Absolute numbers of CD5+CD19+ cells in 
peripheral blood of mice during vehicle (Veh) or Ibrutinib (Ibr) treatment. Mice were randomized for 
treatment at week 0 (black arrow) and sacrificed at different time points (red arrows). Group sizes were: 
Veh_Veh: n=10, Veh_Ibr: n=10, Ibr_Veh: n=7, Ibr_Ibr: n=6. (Leukemic CD5+CD19+ cells: CD45+CD5+CD19+) (d) 
Average growth kinetics of re-transplanted tumors within 2nd treatment round just before start of vehicle 
treatment and at week 2 post-treatment start. TGI=Tumor growth inhibition. (Leukemic CD5+CD19+ cells: 
CD45+CD5+CD19+) P values were determined by unpaired Student t-test. 
 
The re-transplanted tumor previously treated with vehicle engrafted similarly as the parental tumor 
and treatment was started at 2 weeks post tumor injection. In contrast, animals transplanted with 
a tumor that was previously treated with Ibrutinib displayed a delayed onset of disease 
establishment and randomization/treatment start was conducted one week later which was 3 
weeks post tumor transplantation (not shown here). 
Animals re-transplanted with vehicle tumors initially responded to Ibrutinib (Veh-Ibr arm), while 
also these animals displayed a loss of response from week 4 post treatment start on (Figure 25b). 
Within the Ibr-Veh arm, two animals rapidly developed leukemia with high absolute numbers of 
CD5+CD19+ cells. For the remaining mice of this group, leukemia development was not considerably 
different than for animals treated for the second round with Ibrutinib (Ibr-Ibr arm) (Figure 25c). 
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Hence, there was no treatment response to Ibrutinib with tumor cells that had previously been 
treated with Ibrutinib. Calculation of growth kinetics of re-transplanted tumors revealed shorter 
doubling times for Ibrutinib-pretreated tumors compared to vehicle-pretreated tumors at week 2 
post transplantation start (Figure 25d). Taken together, these data clearly show that Ibrutinib 
treatment of TCL-1 AT mice results in the development of resistance to the drug that is intrinsic to 
the tumor cells. 
 
3.3.2 Phenotypical changes in Ibrutinib-resistant CLL cells 
Interestingly, four weeks post-treatment start the majority of Ibrutinib-treated animals displayed 
two sub-populations of CD5+CD19+ cells in peripheral blood, that could be distinguished by high and 
intermediate expression of CD19 (CD19hi and CD19int cells) (Figure 26a). When analyzing these 
populations over time, the percentage of the CD19int sub-population increased and after six weeks 
of treatment became the dominant cell population. CD19int and CD19hi subpopulation were 
observed in 6 out of 11 animals in the Ibr arm and 8 out of 10 animals in the Veh_Ibr arm. For this 
study, we were not able to determine whether this is an event occurring solely within the Ibrutinib-
treated cohort, since at the time point of evident sub-population appearance all vehicle-treated 
animals were already sacrificed due to high tumor load. However, an accumulation of CD19int 
leukemic cells that was restricted to Ibrutinib-treated mice was confirmed in an independently 
performed treatment study in which animals from the vehicle arm survived longer (data not shown 
here). 
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Figure 26: Ibrutinib-resistant TCL-1 tumor cells develop a CD19int sub-population.  
(a) Representative flow cytometry dot plots showing the percentages of CD5+CD19int and CD5+CD19hi cells in 
peripheral blood of mice from 1st treatment round at week 2, 3, 4, and 6 after treatment start. (b-d) CD19 
MFI values of leukemic CD19+CD5+ cells were normalized to respective values of CD19+CD5- normal B cells 
(median CD19 MFI on CD19+CD5+ cells / median CD19 MFI on CD19+CD5- cells) in blood of mice (b) from 1st 
treatment round, (c) from 2nd treatment round with previous vehicle treatment, or (d) from 2nd treatment 
round with previous Ibrutinib treatment. (Leukemic CD5+CD19+ cells: CD45+CD5+CD19+) P values were 
determined by unpaired Student t-test. 
 
Interestingly, tumors from animals that were treated with Ibrutinib in the first round, did not display 
such development of sub-populations based on CD19 expression, neither in the vehicle nor in the 
Ibrutinib arm of the second treatment round (data not shown). To quantify these observations, 
CD19 expression levels on tumor cells were normalized to CD19 levels on normal B cells which was 
calculated as ratio of CD19 MFI from CD5+CD19+ cells vs CD19 MFI of CD5-CD19+ cells. This showed 
that Ibrutinib treatment at week 2 and 3 induced an increase in CD19 expression in leukemic cells 
which was lost after 5 to 6 weeks of treatment, presumably when cells acquired resistance to the 
drug (Figure 26 b,c). Of note, treatment with vehicle did not alter the expression of CD19 on 
leukemic cells. Tumor cells from mice that had been previously treated with Ibrutinib and did not 
respond to the drug during the second round of treatment showed no increase in CD19 levels, but 
rather displayed relatively low CD19 expression during the whole experiment (Figure 26d). These 
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results indicate that Ibrutinib induces an increase in CD19 expression only in sensitive tumor cells, 
whereas Ibrutinib resistant tumors show generally lower levels of CD19 expression. Further, tumor 
cells that were used for re-transplantation of the second treatment round possessed low CD19 
expression levels also in the spleen, reflecting the CD19 expression levels at week 0 in Figure 26c) 
and d) (Appendix Figure 6e). 
 
Figure 27: Ibrutinib-resistant TCL-1 leukemia cells show phenotypical changes. 
(a-c) CD38 expression level on CD5+CD19+ cells in blood from mice of the 1st and 2nd treatment round was 
analyzed by flow cytometry over time. (d-f) CD45 expression level on CD5+CD19+ cells in blood from mice of 
the 1st and 2nd treatment round was analyzed by flow cytometry over time. (g,h) Cell subset-specific 
quantification of CD45 expression levels on CD5+CD19int and CD5+CD19hi cells in blood from mice of the 1st 
treatment round. (i) Representative histogram of CD38 expression on CD5+CD19int and CD5+CD19hi cells in 
peripheral blood from mice of the 1st treatment round at week 4. (Leukemic CD5+CD19+ cells: 
CD45+CD5+CD19+) 
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As part of the weekly tumor load measurements in peripheral blood, cells were stained for CD38, a 
marker associated with enhanced aggressiveness in CLL patients. In addition, also the expression 
level of CD45 was quantified over time. Compared to the vehicle control, Ibrutinib induced a higher 
expression of CD45 and CD38 on malignant cells only in sensitive tumors (Ibr and Veh_Ibr) (Figure 
27a,b,d,e). For resistant tumors (Ibr_Ibr), this induction of expression was absent for CD38 and only 
modest for CD45 at week 1 (Figure 27 c,f). Interestingly, the higher expression levels of CD45 and 
CD38 started to decline again at the time point when the two malignant cell sub-populations 
defined by their differential CD19 expression appeared (week 4), suggesting again that this change 
phenotypical change is associated with Ibrutinib-resistant leukemia cells. Cell subset-specific 
quantification of CD45 and CD38 expression levels revealed a drop in expression upon resistance 
development only in CD19int cells, while CD19high cells retained rather stable expression levels 
(Figure 27g-i).  
Summarized, these findings show that Ibrutinib resistance in the TCL-1 AT model is associated with 
phenotypical changes in the malignant cells, which include decreased CD19, CD45 and CD38 
expression levels, all of which are known to be involved in the BCR pathway. 
 
3.3.3 Analysis of WES data of Ibrutinib resistant tumors 
In order to characterize mechanisms of Ibrutinib resistance, whole exome sequencing was 
performed from samples collected before and after treatment with vehicle or Ibrutinib at different 
time points (Figure 25 a). It is known that CLL patients, treated with Ibrutinib display a greater 
degree of clonal selection301, 321. Thus, the aim was to investigate whether such clonal selection 
would also arise in TCL-1 AT mice, treated with Ibrutinib. In order to determine the clonal 
architecture of the murine tumors, V(D)J rearrangement of the BCR were determined from WES 
data by IgBLAST.  
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Figure 28: Clonal architecture based on V(D)J rearrangements of the BCR. 
Identification of tumor subclones from WES of primary and secondary CLL mouse tumors based on V(D)J 
rearrangements of the BCR using IgBLAST. Each color represents a unique V(D)J BCR rearrangement. The 
three major V(D)J rearrangements are depicted in the legend. Primary = original tumor from primary Eµ-TCL-
1 donor mouse. Secondary = primary tumor was injected into C57BL/6 mice and expanded for the purpose 
of this study. Stars indicate samples with highly elevated numbers of mutations that will be explained in the 
following. Data analysis was performed by Yashna Paul.  
 
The first observation of this analysis was that the primary tumor from the parental donor TCL-1 
mouse was oligoclonal with regard to its V(D)J region and consisted of two to three major clones 
(Figure 28, left box). This was not expected as CLL patients usually harbor one major B cell clone. 
Additionally, the contribution of the predominant BCR clones only marginally changed upon serial 
transplantation and the major BCR clones remained the same. This was also the case for vehicle-
treated as well as Ibrutinib-treated animals early and late during treatment (Figure 28).   
 
In contrast to the unchanged architecture of the V(D)J rearranged BCR clones, four samples were 
identified displaying a high number of somatic mutations with very low allele frequency (Figure 28, 
marked with stars, Appendix Figure 7 a,b). These elevated numbers of mutations appeared in 
resistant (Ibr_late) and sensitive (Ibr_early and Veh_late) samples and therefore are unlikely to be 
directly linked to the resistance mechanism. Notably, these somatic variants were distributed 
across the whole genome without an apparent pattern (not shown). In addition, there was no 
increase of the proportion of somatic sequence variations annotated at dbSNP (The Single 
Nucleotide Polymorphism database), which would have implied a contamination with germline 
DNA of the recipient mice in these samples (Appendix Figure 7 b). 
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        Allele 
Frequencies 
Gene 
Name 
Chr. Pos. Ref. Alt. Effect Gene 
Region 
dbSNP 
status 
I9_late I2_late 
Grb14 2 65022658 G T n.a. 5’UTR n.a.  0.039 
Ets1 9 32728680 G T stopgain exonic n.a. 0.013  
Sos1 17 80434006 A G Nonsyn_SNV exonic n.a.  0.016 
Sos1 17 80455053 C A Nonsyn_SNV exonic n.a. 0.012  
Vav1 17 57311789 C T Nonsyn_SNV exonic n.a.  0.042 
Nfatc1 18 80663367 C A Nonsyn_SNV exonic n.a. 0.022  
Table 1: Single nucleotide variations in BCR pathway genes. 
Identification of potential mutations in BCR pathway-related genes, present in samples from two Ibrutinib-
resistant mice, but no other sample. (BCR = B cell receptor, Chr. = chromosome, Pos. = position, Ref. = 
reference, Alt. = alteration, Nonsyn = nonsynonymus, SNV = single nucleotide variation, n.a. = not available). 
Major data analysis was performed by Yashna Paul.  
 
Next, the aim was to determine if Ibrutinib resistance in the TCL-1 AT model had evolved due to 
point mutations in Btk, Plc2 or other genes of the BCR signaling pathway. Mutations present in the 
DNA of resistant animals but not Ibrutinib-sensitive and vehicle group animals were studied. For 
this analysis, samples with high numbers of low frequency mutations labeled with stars in Figure 28 
(including one Ibrutinib-resistant case), were removed from the analysis in order to exclude false 
positive passenger mutations. Mutations were filtered for nonsynonymus single nucleotide 
variations (SNVs) in exonic or 5’UTR regions and subsequently compared to a list of 86 genes 
involved in the BCR pathway including B cell commitment, cytoskeletal rearrangement, protein 
biosynthesis and transcription (exported from Ingenuity knowledge base). Grb14, Ets1, Sos1, Vav1, 
and Nfatc1 were identified to match these criteria while only Sos1 appeared in both animals (Table 
1).  
In summary, no single recurrent mutation that would likely contribute to drug resistance was 
identified, as all mutated genes displayed very low allele frequencies <15% (e.g. 1.3% and 1.6% for 
Sos1).  
 
3.3.4 Gene expression profiling of Ibrutinib-resistant Eµ-TCL1 tumors 
As no mutations in Btk and Plc2 and only one recurrent low allele frequency mutation in Sos1 (so 
far not found in patients) were identified in Ibrutinib-resistant tumors, it was hypothesized that 
changes in the gene expression signature could account for the rather rapid resistance 
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development in this mouse model. Transcriptome data of the same treated tumor samples 
described in the WES study, were first used for unsupervised hierarchical clustering analysis (Figure 
29 a).  
 
Figure 29: Unsupervised and supervised hierarchical clustering of RNA sequencing transcripts.  
(a) Unsupervised hierarchical clustering of the 1000 most variable transcripts across all samples. Stars indicate 
samples with highly elevated number of low allele frequency mutations. (b) Supervised clustering of DEGs 
between Ibrutinib resistant and sensitive samples, which is Ibr_late Vs Ibr_early + Ve_late + Veh_early. 
Samples with highly elevated number of low allele frequency mutations were excluded from the analysis. 
Data analysis was performed by Yashna Paul. 
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Besides one sample (V8_early), all samples clustered according to their treatment group. The 
analysis revealed, that the drug’s effect was not the only deciding factor for clustering the samples 
(vehicle samples vs Ibrutinib-treated samples), but the disease period seemed to play an important 
role as well. The order of sample clustering can be summarized from right to left with increasing 
distance as followed: week 3 vehicle – week 6 Ibrutinib (resistant) – week 1 Ibrutinib – week 1 vehicle 
(sample V8_early excluded). 
Ibrutinib late and Vehicle late clustered the closest, presumably because of the many shared 
characteristics of the full blown tumor disease at this point. The second closest group with respect 
to the Ibrutinib_late samples is the Ibrutinib_early group, hinting towards a shared expression 
signature caused by the treatment. And finally, Ibrutinib_early samples displayed the largest 
distance with the vehicle_early group, likely due to the difference in efficacy of Ibrutinib and its 
beneficial impact on the tumor cells, controlling the disease at this time point. 
 
Next, two differentially expressed gene (DEG) lists were created: (1) DEGs differential between 
Ibr_late VS Ve_late to identify transcripts highly expressed in non-responsive versus responsive 
tumors, and (2) Ibr_late VS Ibr_early + Ve_late + Veh_early in order to filter for more specific DEGs 
in the resistant samples only. 
Besides one gene, these two lists were identical regarding their transcript content (341/342 DEGs), 
while however, the second DEG list showed lower p values for some genes. Thus, the subsequent 
gene ontology (GO) and gene set enrichment (GSE) analysis were performed with the latter DEG 
list. 
Several biological complexes including fatty acid synthase complex, BcL-2 family complex, and NF-
kB complex were identified among others, involving Pim2 and Igf1-r all well-known genes in the 
context of cancer (Figure 30).  
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Figure 30: Gene ontology and gene set enrichment analysis of Ibrutinib resistance-specific transcripts. 
DEGs between Ibrutinib_late VS Ibr_early + Ve_late + Veh_early were applied to downstream analyses. (a) 
Gene ontology (GO) analysis of 203 upregulated DEGs was performed using Jensen COMPARTMENTS via the 
Ma'ayan lab web-tool EnrichR (see methods). (b) Gene set enrichment (GSE) analysis of pre-ranked DEGs, 
applied to mouse gene sets, showing the most significant enriched gene set with a NES (normalized 
enrichment score) of 2.64.  
 
Further, performing of gene set enrichment analysis p value pre-ranked list of resistance-specific 
DEGs revealed the gene set GSE1566_WT_VS_EZH2_KO_LN_TCELL_UP to be most strongly 
enriched in resistant tumor cells. EZH2 (Enhancer of zeste homolog 2) participates in histone 
methylation and therefore might point towards an altered epigenetic state acquired by Ibrutinib-
resistant tumor cells322. 
In summary, the transcriptional profiling analysis resulted in the identification of several 
upregulated genes and enriched gene sets, which require further testing and validation by other 
methods. Downstream analyses will then focus on characterizing the role of these genes and 
pathways in Ibrutinib resistance, and the identification of potential target molecules to improve 
treatment approaches for patients that relapse under Ibrutinib treatment. 
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4 DISCUSSION 
4.1 Modulating the myeloid tumor microenvironment in CLL by targeting 
the CSF-1 receptor 
Targeting the CSF-1R using a monoclonal antibody, named TG3003, changed 
monocyte/macrophage morphology in monocultures, reduced NLC numbers in NLC cocultures that 
mimic the lymph node microenvironment, slightly reduced the expression of factors with functional 
relevance in the CLL TME, and finally disrupted NLC-mediated survival support for CLL cells. These 
promising in vitro results served as the basis to move forward in testing TG3003 in a preclinical 
model of CLL using the TCL-1 AT in humanized CSF-1R KI mice.  
 
In recent years, targeting CSF-1R has been the focus of many preclinical cancer studies. Meanwhile, 
it has been shown by several groups that targeting CSF-1R signaling in mouse tumor models can 
have various effects on disease outcome. Most of these studies are focusing on solid tumors where 
TAMs were initially described and high TAM densities were linked to poor prognosis, as in breast 
and ovarian cancer323. But also in CLL, a higher number of CD163+/CD68+ myeloid cells in lymph 
nodes of CLL patients correlates with shorter overall survival324. 
In many solid tumors with involvement of CSF-1R-expressing TAMs, CSF-1 was reported to be 
elevated in the patients’ blood sera325, 326, 327. Quantification of CSF-1 in sera from CLL patients 
compared to healthy donors revealed slightly elevated CSF-1 levels (Dr. Angela Schulz, DKFZ 
Heidelberg, unpublished). Similarly, CSF-1 quantification in sera from TCL-1 AT mice compared to 
healthy wildtype mice revealed a modest but not significant increase of this factor with disease 
progression. The absence of a significantly upregulated CSF-1 in human and mouse sera could 
possibly point to a high consumption of this protein by the elevated monocyte number of in CLL 
patients and the TCL-1 AT model. Apart from blood, CSF-1 could be locally produced in lymphatic 
tissues. For example, CSF-1 secretion might be induced in the lymph nodes where it mediates the 
transition of monocytes towards tumor-promoting phenotypes, as suggested by results of this 
study showing secretion of CSF-1 in CLL-monocyte cocultures after 14 days. Similarly as proposed 
for solid tumors, also in CLL the malignant cells might be the source of CSF-1 in these cocultures328. 
Assessing CSF-1 levels in monocyte monocultures is not simple as the addition of CSF-1 itself is 
required for the maintenance of monocyte survival. Moreover, myeloid cells can produce CSF-1 
themselves and thereby create a feedback loop329. However, at least in the TCL-1 AT model, an 
altered CSF-1 production by monocytes themselves was not observed by GEP data presented in the 
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second section of this thesis. Neither CSF-1, nor CSF-1R were different in their gene expression 
levels in monocytes from TCL-1 AT mice compared to healthy wildtype mice (Appendix Table 3). 
 
The CSF-1/CSF-1R axis is essential for the generation of cells from the myeloid lineage as depicted 
in the introduction. Hence, the postulation was that targeting this axis would interfere with one or 
more of the proposed mechanisms CSF-1R is known to be involved in: (1) myeloid cell 
differentiation, (2) monocytic commitment, and (3) survival, proliferation and chemotaxis of 
macrophages141.  
The proposed mode of action of TG3003 was not via complete blockade of the CSF-1R pathway, but 
rather allowing binding of CSF-1 and partial signaling which would result in reprogramming of 
monocytes or TAMs, and their differential skewing towards DCs316. However, even though CSF-1 
levels did not increase upon treatment of NLC cocultures with TG3003 in vitro (supporting that CSF-
1 was used up by the cells), this antibody seemed to act in a different manner than proposed. Rather 
than having a reeducating effect on the myeloid microenvironment with consequences on adaptive 
immunity, TG3003 prevented the accumulation of NLCs in vitro, as well as monocytes and cDCs in 
vivo. In addition, the expression of surface molecules required for adhesion, co-stimulation of T 
cells, and antigen presentation remained at critically low levels in cDCs in leukemic mice after 
treatment with TG3003. In line with the observation that cDCs retain their leukemia-associated 
phenotype, adaptive immunity with respect to T cells was also not altered. Hence, this study 
suggests that TG3003 inhibits survival, proliferation, and/or differentiation of monocytes, rather 
than reprogramming of tumor-supporting myeloid cells.  
 
As TG3003 was able to reduce monocyte numbers in blood, spleen as well as CSF-1R-expressing 
cells in the bone marrow, its effect appears to be of systemic nature rather than limited to a specific 
microenvironment. This was of advantage for preclinical testing, as myeloid cells in the TCL-1 AT 
model accumulate in blood, spleen and bone marrow as well. However, in the TCL-1 AT model, 
TG3003 affected myeloid cell populations with different intensities. In the spleen, TG3003 mainly 
reduced Ly6Clow absolute numbers but showed only a modest trend towards fewer Ly6Chi 
monocytes. Similarly, Lenzo and colleagues have shown previously that mice treated with a 
neutralizing anti-CSF-1R antibody (AFS98) under steady state conditions had significantly lower 
levels of the Ly6Clow monocyte population, while the authors did not note a compensatory increase 
in the number of Ly6Chi monocytes330. Moreover, in steady state Ly6Clow monocytes express higher 
surface levels of CSF-1R than Ly6Chi monocytes, as confirmed by the GEP data analysis comparing 
the two wildtype subsets (Appendix Table 3). This differential expression of CSF-1R on monocyte 
subsets was confirmed for bone marrow and blood by published data318. Hence, it appears plausible 
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that TG3003 may act on the transition of Ly6Chi monocytes to the Ly6Clow subpopulation. Moreover, 
the impact of TG3003 on cDC numbers might reflect the dependency of their generation on 
monocytic precursor cells. 
Notably, TG3003 did not actively kill monocytes in vitro, and when added at later time points to 
NLC cocultures (when these had already differentiated), it also did not impact on their numbers, 
underscoring myeloid cell differentiation as one main mechanism targeted by this antibody. 
Interestingly, macrophage numbers which were decreased in the TCL-1 AT model, were not further 
changed by the antibody supporting that TG3003 impacts mainly on the differentiation of 
macrophages and DCs from monocytes, and not on their survival. Pyonteck and colleagues 
observed regression of tumors in a glioma model due to depletion of tissue-resident microglia using 
the brain-penetrant CSF-1R inhibitor BLZ945331. In contrast, newly recruited macrophages were 
specifically protected from CSF-1R-induced death in this study. The fact that different myeloid cell 
populations can be selectively targeted by different antibodies/inhibitors is of relevance as it is not 
yet clear whether NLCs in CLL patients are blood monocyte-derived (as mimicked in the NLC 
coculture model) or rather differentiate from tissue-resident macrophages. 
 
Recent attempts have addressed the importance of monocytes and macrophages in CLL mouse 
models. In a study by Hanna et al., myeloid cells were targeted using a genetic knockout mouse of 
CCR2 for the adoptive transfer of TCL-1 splenocytes in order to prevent chemotaxis and recruitment 
of monocytes in CLL203. This study revealed signiﬁcantly lower percentages and numbers of 
monocytes in the spleen of leukemic mice. However, even though there was a slight tendency 
towards decreased tumor cell numbers in CCR2−/− mice compared with WT controls, the impact 
on tumor development was not significant. Of note, even though, the CCL2/CCR2 axis is generally 
considered specific for recruitment of monocytes also other cell types have been reported to 
express CCR2. For example, it was reported that in BALB/c mice approximately 2-10% of CD8+ T cells 
and 5-15% of CD4+ T cells are positive for CCR2332. Also in humans, CCR2 has been described to be 
expressed on T cells and memory cell differentiation was associated with an increase in chemokine 
responsiveness333.  
 
Hanna et al. showed that depletion of myeloid cells using Clodronate liposomes as an early 
intervention resulted in remarkable reduction of disease progression in the TCL-1 AT model203. 
Liposomes are efficiently taken up by phagocytic cells and thereby Clodronate is delivered to the 
cells causing their death334. TCL-1 AT mice treated with Clodronate liposomes showed extremely 
low numbers of Ly6Chi and Ly6Clow monocytes and also a significant decrease in cDC numbers. In 
contrast to the obtained results with TG3003, the remaining cDCs showed a normalized phenotype, 
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as exemplified by higher MHC-II and lower PD-L1 expression following Clodronate treatment203. 
Moreover, this treatment resulted in a normalized T cell subset composition with an increased 
percentage of naïve CD4+ and CD8+ T cells and a lower percentage of memory/effector T cells in 
spleen, peripheral blood, and peritoneal cavity. Most importantly, Clodronate liposome treatment 
delayed leukemia development in TCL-1 AT mice. As an explanation, it was proposed that myeloid 
cell depletion by this treatment affected T-cell subset composition via altering their trafﬁcking and 
migration. This was supported by results showing reduced secretion of inflammatory cytokines and 
chemoattractants for T cells, such as TNF-α, CXCL9, and CXCL16, in Clodronate-treated mice.  
Even though this study served as a proof of principle for the importance of myeloid cells in CLL 
progression, there are considerations that need to be taken into account. In fact, phagocytic cells 
do not only comprise monocytes, macrophages, and dendritic cells, but also mast cells and 
neutrophils, and as already described in the introduction, neutrophils have been clearly shown to 
be involved in CLL development as well315, 335. Furthermore, even B cells were reported to be 
capable of phagocytosis336. Hence, treatment of mice with Clodronate liposomes might not 
exclusively target myeloid cells, but its success might be in part due to effects on other bystander 
cells. 
In contrast to this cell killing-approach, TG3003 treatment was intended as an elegant and specific 
approach to modulate myeloid cells and suppress their tumor-promoting activities. 
 
In a more recent publication, Galletti et al. comprehensively investigated different TAM depletion 
strategies including Clodronate liposomes and monoclonal antibodies against CSF-1R in various CLL 
transplantation mouse models217. Firstly, the authors conducted a similar approach as Hanna et al. 
using Clodronate liposomes in TCL-1 AT mice, but with late intervention onset (day 16 post-
transplantation). This resulted in reduced percentages of tumor cells in peripheral blood, spleen, 
and to a stronger extent in the peritoneal cavity, the site of Clodronate injection. While percentages 
of CD11b+F4/80+ monocytes and macrophages in the spleen and peritoneal cavity were significantly 
lower, Clodronate had no effect on effector and central memory CD8+ T cells and no effect on 
regulatory T cells when applied at this late time point of the disease. This is in contrast to the study 
of Hanna et al., however consistent with the results on T cells in the TG3003 study. 
Furthermore, Galletti et al. investigated the effect of a human monoclonal antibody (RG7155) in a 
xenograft transplantation model using the human MEC1 CLL cell line transplanted into RAG2-/- 
mice that are deficient for mature B and T cells. Two i.v. administrations of the anti-CSF-1R antibody 
RG1755 significantly lowered the cell number of CD11b+F4/80+ myeloid cells in the spleen but had 
no impact on the number of human leukemic cells in the same organ. On the other hand, RG7155 
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had only a modest, non-significant impact on CD11b+F4/80+ cells in the bone marrow while 
significantly lowering the tumor load in this but no other organ. 
 
Further, the group tested an anti-mouse CSF-1R antibody (2G2) in the TCL-1 AT model. In this study, 
the numbers of CD44+CD62Llow/neg effector memory, as well as CD44+CD62L+ central memory CD8+ 
T cells in the spleen were increased by 2G2 treatment. Moreover, the number of CD44+IFN--
producing cells in the spleen was also elevated. These observations differ from the here presented 
results obtained with TG3003, which did neither impact on CD4+ and CD8+ T cell numbers, nor their 
effector function with respect to TNF-and IFN- production. Effects of 2G2 treatment on tumor 
development in the TCL1 AT model were not presented in this study.  
 
Overall, it remains unclear whether targeting CSF-1R with RG7155 or 2G2 impacts on CLL 
development in mice, as no other lymphoid organ besides the bone marrow showed reduced tumor 
load with RG7155 antibody217. This raises the question which factors are responsible for limiting 
treatment success with anti-CSF-1R antibodies. Several reasons are conceivable, such as (1) 
compensatory recruitment of other immune cells or replenishment by higher de novo monocyte 
production, (2) resistance development, (3) variability in CSF-1R-dependency, or (4) insufficient 
depletion of myeloid cells by the antibodies. 
 
One possible compensatory mechanism could be via increased recruitment of neutrophils337. 
During inflammation, it is the neutrophils that facilitate the recruitment of monocytes to tissue 
sites338. It is possible, that killing of monocytes promotes inflammatory cytokine secretion which in 
turn leads to recruitment of neutrophils. Interestingly, Galletti and colleagues measured higher 
percentages of neutrophils in the blood upon RG7155 treatment, but lower percentages upon 
Clodronate-mediated depletion217. In the here presented study, TG3003 partially normalized CLL-
associated, elevated granulocyte/neutrophil numbers in the spleen, leading to the conclusion that 
neutrophils are not recruited due to the decrease in monocyte numbers. As all precursor cells of 
the myeloid lineage express CSF-1R, it appears plausible that granulocytes/neutrophils as members 
of the myeloid cell lineage might be directly affected by TG3003 as well.  
 
Acquired resistance in response to monotherapy targeting CSF-1R has indeed lately been observed 
and addressed. In a preclinical glioblastoma model, treatment with BLZ945, a small molecule kinase 
inhibitor for CSF-1R, resulted in a 50% relapse rate after initial responses339. TAMs were not 
depleted in this model but shifted in their phenotype towards M1 macrophages. These cells were 
shown to produce IGF-1 which triggers an IGF-1R-driven hyperactivation of PI3K in cancer cells, 
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which was at least partially accounting for the observed resistance. This was further proven as a 
combination of inhibitors targeting CSF-1R and IGF-1R or PI3K resulted in prolonged survival of 
mice339. Besides this acquired resistance, there are also earlier reports of inherent resistance in 
mice, where despite effective macrophage depletion using PLX3397, tumor growth in an orthotopic 
PyMT mammary tumor transplantation model was not changed in monotherapy340.  
 
Incomplete depletion of myeloid cell populations and therefore insufficient changes in the immune 
profile might represent the main reason for the lack of efficacy in the study with TG3003. Even so 
TG3003 significantly decreased monocyte numbers, these were still clearly more abundant in 
treated mice compared to wildtypes. Hence, one explanation could be that these remaining 
monocytes are sufficient to promote leukemia, as for example suggested by their secretion of T cell 
chemoattractants, further underscoring their impact on tumor progression. As the studies by Hanna 
et al. and Galletti et al. did not include control cohorts of untreated animals, the efficiencies of 
monocyte depletion in those studies remain unclear203, 217. However, there are several examples of 
solid tumor models, where upon targeting of CSF-1R, the macrophage number was somewhat 
reduced but not completely. For example, Patawardhan et al. reported a decrease of macrophages 
in tissue samples in peripheral nerve sheath tumors in response to the CSF-1R inhibitor PLX3397 
treatment, but no complete depletion341. A similar observation of remaining TAMs was also made 
by Quail and colleagues in glioblastoma multiforme tumors that were resistant to BLZ945339. Hence, 
it remains unclear whether in these studies a more efficient depletion of TAMs would promote a 
positive disease outcome, and whether also TG3003 would show a favorable outcome when used 
in higher doses.  
 
In order to proof that specific and efficient ablation of CSF-1R-expressing cells as a late intervention 
(after onset of the disease) would be favorable with regard to leukemia progression, the plan was 
to use MMDRT mice (provided by Dr. Markus Feuerer). This mouse strain is generated by crossing 
two mouse lines342. The first mouse strain carries a human diphtheria toxin receptor (DTR)-mCherry 
fusion protein under the Csf1r promotor with a floxed stop sequence arranged upstream of it 
(Csf1rLSL-DTR mice). The second strain carries the gene sequence for a Cre recombinase under the 
promotor for the gene coding for lysozyme protein (LysmCre mice). In crossed animals, mice can be 
depleted from myeloid phagocytic cells that express lysozyme and CSF-1R when treated with 
diphtheria toxin342. A pilot study with adoptively transferred TCL-1 splenocytes into these MMDTR 
mice and subsequent repeated diphtheria toxin injections lead to initial ablation of monocytes in 
peripheral blood. However rebound effects with increased myelopoiesis were observed, and no 
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effect on tumor load in the blood was evident (data not shown). Therefore, this approach was not 
further followed. 
 
Conclusions and Outlook 
The here presented in vivo approach of targeting CSF-1R signaling with TG3003 as an early 
intervention in the TCL-1 AT CLL mouse model revealed partial normalization of myeloid cell 
populations, no improvement in terms of disease development, and considerable room for 
improvement of this interesting treatment strategy. As depicted above, one aim could be a more 
efficient targeting of myeloid cells, for example through higher dosing of TG3003, or the use of 
other more efficient antibodies or inhibitors for CSF-1R. Moreover, even though CSF-1R targeting 
was apparently ineffective alone, it could potentially improve response to other therapies. Indeed, 
several studies have reported enhanced treatment efficacy when CSF-1R inhibitors were used in 
combination with other drugs, even in cases where CSF-1R inhibition alone was ineffective. 
 
4.2 Monocytes and cDCs in steady state, in CLL and under the influence of 
Ibrutinib 
The enrichment of Ly6Clow monocytes in CLL patients’ blood as well as in different lymphoid organs 
of the Eµ-TCL-1 mouse model of CLL was described previously202, 203. Before investigating how 
Ibrutinib might influence monocytes and their subset distribution, it was important to understand 
gene expression changes that are induced by the leukemia itself. There are very few investigations 
on the specific contribution of the two main monocyte subpopulations to CLL pathobiology, and 
these are mostly based on in vitro studies. The gene expression analysis presented in this thesis 
revealed that Ly6Clow monocytes are not only enriched in leukemic mice but also considerably 
altered in their gene expression signature. Transcriptional differences in Ly6Clow monocytes of 
wildtype and leukemic mice were associated with activation of cellular growth and proliferation.  
 
Potential target genes in Ly6Clow monocytes identified by GEP 
The acquired GEP data set provides a number of possible CLL-specific target genes in monocytes 
that might be useful to interfere with the ‘activation of cellular growth and proliferation’ program 
of this subset of cells. Implicated genes included CD14 and PECAM-1, which have been previously 
reported to support the crosstalk between CLL cells and their myeloid microenvironment as 
summarized in the introduction80, 343. Other promising candidate genes are currently investigated 
within the group, mainly in the context of understanding the oncogenic role of monocytes and 
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granulocytes. Several novel candidates, so far unrecognized in the context of myeloid cells in CLL, 
were identified, such as IL-21r (top upregulated gene), Dpp4, Irg1, and F11r. The potential of a few 
of these candidates as drug candidates for CLL will be discussed in the following paragraph.  
IL-21, the ligand for the upregulated IL-21r, was previously reported to enhance FcRγ-mediated 
phagocytosis of human monocytes and SYK was identified as a novel molecular target of IL-21-
mediated singaling344. Moreover, IL-21 was reported to maintain the expression of the Fc receptor 
CD16 on monocytes via the production of IL-10 by human naïve CD4+ T cells345. Interestingly, bone 
marrow CD14+ cells from patients with multiple myeloma significantly upregulated IL-21R that is 
involved in osteoclast formation346. However, in order to assess whether IL-21 or IL-21R are suitable 
for therapeutic purposes, their role for normal B or CLL cells have to be considered as well: A study 
by De Totero and colleagues suggested that IL-21 promotes apoptosis in CLL cells347. This finding 
was underscored by a publication from Browning et al., in which the authors proposed that IL-21 
mediates cytotoxicity of CLL cells as part of the mechanism of Lenalidomide’s clinical activity in 
CLL348. In contrast to these findings, Pascutti et al. suggested that IL-21, produced by activated 
follicular helper T cells, contributes to the induction of proliferation in CLL cells in the nourishing 
niche in lymph nodes349. Taken together, the IL-21/IL-21R axis as a potential target for monocytes 
will require further investigations on both, monocytes and CLL cells and careful evaluation of 
possible counteractive treatment effects on disease development.  
 
Dipeptidyl peptidase IV (DPP-4; or CD26) is an exopeptidase that among others cleaves 
chemoattractant MCP-2 upon binding and thereby is able to modulate chemotaxis350, 351. Indeed in 
a mouse model of atherosclerosis, a disease in which chronic inflammation is a key process in the 
pathogenesis, treatment with the high-affinity DPP-4 inhibitor Alogliptin reduced adipose tissue 
macrophages and plaque macrophages352, 353. In the same study, DPP-4 inhibition prevented 
monocyte migration and actin polymerization in in vitro assays via a Rac-dependent mechanism. 
Moreover, DPP-4 inhibition prevented in vivo migration of labeled monocytes to the aorta in 
response to exogenous TNF-α and DPP-4352. The DPP-4 inhibitor Sitagliptin was further shown to 
attenuate atherosclerosis by promoting M2 macrophage polarization354. Several DPP-4 inhibitors 
are currently in clinical trials (Alogliptin, Sitagliptin, and Linagliptin) and may be of interest to target 
monocytes in CLL.  
 
Another highly interesting candidate, upregulated in Ly6Clow monocytes is the junction adhesion 
molecule F11r (or JAM-A; CD321). F11r can serve as a ligand for the integrin LFA1, involved in 
leukocyte transendothelial migration355. However, the specific biological function of F11r in 
monocytes has not been assessed so far, even though there has been a report describing its 
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involvement in disease-related monocytes. In this study, Pong et al. identified F11r among the 
transcripts that were differentially expressed between brainstem microglia and bone marrow 
monocytes in non-neoplastic brain. High-grade murine gliomas contained F11r+ microglia and 
macrophages and F11r expression correlated with glioblastoma malignancy grade and survival of 
mice356. Interestingly, also monocytes isolated from HIV-infected individuals were identified to 
express increased surface F11r compared to cells from individuals without HIV357. The authors 
found, that F11r was critical for the extravasation of CD14+CD16+ monocytes, demonstrated by their 
decreased migration across the blood brain barrier when treated with blocking antibody against 
F11r357. Notably, recently Boissard et al. performed gene expression (meta-)analysis of NLCs, in vitro 
derived from PBMCs of CLL patients, and compared these with monocytes from healthy individuals. 
F11r was among a list of 27 genes that were associated with functional ontology criteria, such as 
‘cell binding function’ and ‘cell membrane expression’, on which they, however, did not comment 
further358. Future studies will be required to evaluate whether F11r-expressing monocytes in the 
context of CLL represent a unique subset of monocytes that produces specific chemokines and 
cytokines critical for CLL leukemogenesis and progression, and therefore might serve as a novel 
therapeutic target to limit seeding of Ly6Clow monocytes to leukemic niches. 
 
Previous reports have suggested, that myeloid cells in CLL may possess a suppressive phenotype. 
For example, Jitschin et al. reported the presence of suppressive CD14+HLA-DRlow MDSCs in CLL 
patients, expressing high IDO levels and T cell suppressive capability204. However, besides a more 
activated and motile (‘Cellular movement’, ’Immune cell trafficking’) phenotype, major pathways 
that would suggest a suppressive MDSC phenotype in CLL-associated monocytes could not be 
confirmed. Genes typically associated with suppressive myeloid cell phenotype and function, such 
as IDO and Arg1, were manually checked for their presence among the DEG and not found to be 
changed. Also, genes that would suggest a metabolic impairment of monocytes were not altered in 
their expression level. However, as most of these candidates are enzymes, they might rather affect 
their activity. Therefore, a potential role of metabolic alterations in CLL monocytes cannot be 
excluded by this study.  
 
Ibrutinib’s effect on monocytes 
One major goal of this study was to investigate, which CLL-associated changes in monocytes might 
be reversed by Ibrutinib treatment, or contrary might be further promoted which is of major 
interest to develop rational combination therapies. The higher transcriptional similarity of Ly6Chi 
and Ly6Clow monocytes from leukemic animals treated with Ibrutinib and their respective wildtype 
counterparts suggested that Ibrutinib reverses CLL-induced gene expression changes. A special 
DISCUSSION   
108 
 
focus was given to the question whether transcriptional changes observed in Ibrutinib-treated mice 
were positively or negatively associated with the number of leukemic CD5+CD19+ cells, which are 
the main target of Ibrutinib. For example, inhibition of BTK by Ibrutinib was found to significantly 
reduce surface TREM-1 levels on both monocyte subsets as well as granulocytes in different organs. 
In a recent publication, Ibrutinib was demonstrated to inhibit TREM-1-mediated activation of 
neutrophils by inhibiting oxidative burst and shedding of CD62L in vitro and in vivo359. These data 
fit to the proposal that BTK is a positive regulator of the TREM-1 signaling pathway287, 288. However, 
the lack of the effect on TREM-1 in treated healthy mice suggests at least a partial dependency of 
its expression levels on the tumor load, rather than on a BTK-dependent regulation of TREM-1 in 
this model.  Moreover, it is not clear whether there exists a native feedback loop that would result 
in a downregulation of TREM-1 by Ibrutinib in monocytes. 
 
PD-L1, in contrast, was an example for a direct effect of Ibrutinib on its expression level, irrespective 
of the involvement of tumor cells and/or tumor-induced IFN. This indicates that BTK in myeloid 
cells might be directly linked to the initiation of their immune suppressive properties via regulation 
of PD-L1 expression. However, it cannot be excluded that non-tumor microenvironmental 
components in healthy animals may mediate Ibrutinib’s inhibiting potential on PD-L1 in monocytes. 
The complexity of the immune system further requires simplifying (in vitro) experiments in order 
to answer how exactly Ibrutinib acts on these different pathways.  
In summary, this study shows that Ibrutinib positively impacts on a number of molecules and 
signaling axes that promote leukemia development by being involved in immune suppression, 
inflammation, and CLL-myeloid cell crosstalk (PD-L1, TREM-1, PECAM-1/CD38 axis). This may 
contribute to the clinical efficacy of Ibrutinib on tumor development via the monocytic 
microenvironment of CLL. 
 
Conventional dendritic cells and their role in CLL 
Little is known about dendritic cells in the myeloid CLL microenvironment, despite the fact that 
these immune cells are considered to be indispensable for antigen presentation to T cells and 
recruitment of effector T cells360. Orsini and colleagues provided first evidence for an abnormal 
phenotype of dendritic cells in the context of CLL361. The isolation of DC precursors from peripheral 
blood of CLL patients revealed a lack of expression of the maturation antigen CD83 and the 
costimulatory molecule CD80, while CD86 was even slightly increased. The authors showed that 
this phenotype could be also induced in normal DC precursors (CD3-, CD16-, CD11b-, CD4+) when 
cocultured with CLL cells. They furthermore suggested some functional impairment with respect to 
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T cell activation. However, the main pitfall of this in vitro study was the low purity of DC precursors 
ranging from 32–87% when isolated from healthy donors and 27–64% from CLL patients. 
 
To obtain highly pure cDC fractions for comprehensive gene expression profiling, cells were isolated 
by flow cytometry from TCL-1 AT and wildtype mice. cDCs from TCL-1 AT mice displayed a high 
number of downregulated genes, which was mirrored in a number of inhibited biological functions 
and various downregulated signaling pathways in the leukemic state. The data clearly revealed that 
cDCs from TCL-1 AT mice display a tremendous change in the expression pattern of genes that are 
important for detection and phagocytosis of foreign particles. In support of that, pathways including 
‘Role of Pattern Recognition Receptors of Bacteria and Viruses and Phagosome Formations’ were 
downregulated as suggested by the gene expression signature analysis. Hence, the GEP suggested 
that CLL induces impairment of antigen loading in MHC-II molecules and of cytokine-mediated 
stimulation of T cell responses in cDCs. Moreover, additional features, such as inhibited NF-B 
signaling and TREM-1 signaling, also illustrate the far-reaching ‘downstream’ signaling 
consequences. NF-B signaling in DCs is well-known to be essential for DC differentiation, antigen 
presentation, and MHC-II regulation 362, 363. Notably, TREM-1 signaling has been previously reported 
to enhance TLR and NOD-like receptor (as part of PRRs) signaling and be important for host 
defense364, 365, 366, 367. It is worth to mention that TREM-1 itself was not differentially expressed in 
cDCs from WT or leukemic mice, neither detected by GEP nor by flow cytometry. Instead, TREM-3, 
an activating receptor of the same family, was downregulated in cDCs. Murine TREM-3 was 
proposed to have a similar function as TREM-1 and to arise from Trem-1 gene duplication368.  
 
Changes of the subset composition of the DC compartment may also differentially regulate cell-
mediated immunity. Hence, the increased percentage of CD8+ cDCs indicates a Th1 immune 
response, comprising the production of IL-12 and IFN, characteristics assigned to this DC subset190. 
In a publication from Ruffel et al., the authors clearly demonstrated that for example CD8+ T cell-
dependent responses to chemotherapy are blocked by macrophage-derived IL-10 that suppressed 
IL-12 expression in dendritic cells369. However, IL-12 expression in cDCs was reduced in leukemic 
mice compared to WT mice, further suggesting that these cells might not be able to induce 
appropriate immune responses. Unpublished group-internal mouse and human data on T cells 
propose a Th1 response in CLL. At this point, it is not yet clear whether DCs contribute to such a 
Th1 response or not.  
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cDCs in the TCL-1 AT model under Ibrutinib treatment 
To address the question which effects Ibrutinib might have on the impaired phenotype of cDCs in 
CLL, functionally relevant markers were investigated in TCL-1 AT mice upon treatment with 
Ibrutinib. One observation made, was the changed cDC subset composition that was independent 
of the presence of leukemic cells. One might assume that the changed cell composition in the spleen 
might create an altered microenvironmental milieu that is more beneficial as less CLL-derived 
stimuli are present. In contrast to this assumption, ICAM-1, CD86, and CD83 were even further 
decreased by Ibrutinib treatment and also an increased percentage of the PD-L1-expressing 
proportion of cDCs was quantified. Hence, Ibrutinib seems to aggravate the impaired phenotype of 
cDCs.  
 
In a recent in vitro study, Natarajan et al. suggested that Ibrutinib promotes maturation and 
activation of dendritic cells370. The authors observed an enhanced development and maturation of 
bone marrow-derived DCs, among others exemplified by an increased percentage of the CD11c+ 
population, which in turn displayed higher MFI expression levels for MHC-II and CD80 (a maturation 
marker expressed on DCs but also B cells). Furthermore, LPS-induced cytokine secretion was higher 
in Ibrutinib-treated DCs for IL-10 and IFN- (measured by ELISA in culture supernatants). On the 
other hand, IL-12 was significantly reduced and TNF- showed a slight tendency towards a 
reduction, which is similar to the results presented here. These data initially seem, at least in part 
contradictory and even more with respect to their final conclusion that Ibrutinib promotes 
maturation and activation of dendritic cells. However, there are a few points to be considered with 
respect to technical aspects as well as the author’s general perspective. Like in many in vitro studies, 
the study technically suffered from impure cDC populations as the authors cultured PBMCs with 
CSF-2 which is known to induce DC differentiation, and considered all CD11c+ cells as DCs, which 
were > 60 %. These impure CD11c+ cells may include other cells such as for example B cells that also 
express CD11c. Hence, the exact source of the secreted cytokines in response to LPS stimulation in 
the presence of Ibrutinib is debatable. Further, this published study focused on in vitro effects of 
Ibrutinib on the development of healthy bone marrow-derived DCs, and not on CLL-associated DCs 
that show an impaired phenotype and are treated in vivo with Ibrutinib, which might be the reason 
for the observed differences. The results presented in this thesis much closer reflect the situation 
of DC development in a mouse model of CLL.  
 
Potential treatment approaches to restore CLL-associated impaired phenotype of cDCs 
The goal of this study was to identify targetable molecules that are suitable for therapy approaches 
to restore the CLL-associated cDC phenotype. Among others, the IL-10RA was predicted as an 
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upstream regulator that was inhibited in cDCs sorted from leukemic TCL-1 AT mice compared to 
cDCS from wildtype mice. This was surprising as the IL-10/IL-10RA axis is considered to mediate 
suppression of DCs leading to inhibited maturation and a tolerogenic phenotype320, 371. For example, 
IL-10 pretreatment inhibited the LPS-induced up-regulation of CD40 and CD86 on DC which was 
suggested to be mediated through suppression of the PI3K/Akt pathway and of IκB kinase 
activity/NFb inhibition372. A neutralizing anti-IL-10 antibody induced spontaneous maturation in 
DCs in vitro and enhanced immune responses in vivo373. Therefore, it was of interest whether 
inhibition of IL-10R signaling would have a similar effect in leukemic animals. Indeed, even though 
the gene expression profiling revealed an inhibited IL-10RA pathway, its blockade showed a partial 
reversal of the tolerogenic cDC phenotype. However, despite an ‘improved’ cDC phenotype, disease 
progression in these animals even worsened. It remains difficult to evaluate which might be the 
reasons for the negative impact on the tumor burden. This will likely be focus for future studies.  
 
Conclusions and Outlook 
In summary, this study shows that Ibrutinib treatment impacts transcriptionally and functionally on 
cDCs and monocytes. On the one hand, Ibrutinib induces a partial reversal of many CLL-associated 
alterations in Ly6Chi and Ly6Clow monocytes and therefore normalizes the transcriptome of 
monocytes. On the other hand, it further enhances and worsens the immature tolerogenic 
phenotype of cDCs. Notably, Ibrutinib treatment was reported to significantly downregulate 
multiple gene signatures in CD19+ cells from CLL patients, including genes that are involved in 
cytokine signaling and cell adhesion, and therefore most likely impacts on the interaction of 
malignant cells with their microenvironment374. Altogether, these results show that the general 
high efficacy of Ibrutinib in CLL patients arises from complex activities of the drug on the tumor and 
its microenvironment. Combination therapies with improved efficacies might include drugs that 
promote the function of DCs, or DC-mediated vaccination approaches. The latter is based on ex vivo 
generation of functionally potent dendritic cells that have been manipulated to be able to take up 
and present tumor antigen in vivo and thereby to elicit potent anti-tumor immunity375, 376. This 
approach has been proven to be feasible, and promising results in CLL were obtained within the 
last years375, 376. 
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4.3 CLL tumor-microenvironment-independent and cell-intrinsic resistance 
to Ibrutinib 
Major findings 
In line with the growing number of Ibrutinib-treated patients who relapse with resistance and 
fulminant disease progression, treatment of TLC-L1 AT mice with Ibrutinib did not result in long-
lasting response, but was rather characterized by a loss of efficacy which was accompanied by an 
induced proliferation of leukemic cells. Furthermore, re-transplantation of tumor cells from animals 
previously treated with Ibrutinib showed lack of treatment response to Ibrutinib, confirming that 
these cells indeed had acquired resistance to Ibrutinib. The appearance of a leukemic sub-
population with weaker expression of CD19, CD38 and CD45 along with treatment, exclusively in 
mice that received Ibrutinib further suggested a resistance-specific phenotype of CD5+CD19+ CLL 
cells under the selection pressure of Ibrutinib. 
 
Relevance of phenotypic differences between sensitive and resistant tumors 
One clear difference between retransplanted tumors that previously received vehicle or Ibrutinib 
was their different potential to engraft in recipient mice. The capacity to engraft and to then achieve 
a substantial and detectable tumor load in the blood, the defined criterion to start treatment, was 
decreased in tumors of Ibrutinib-pretreated animals and therefore delayed treatment start for one 
week. One explanation for this is that BTK activity might be required for leukemia cell engraftment. 
Freshly transplanted tumor cells most likely still show inhibition of BTK signaling, as Ibrutinib 
irreversibly binds to the kinase. Over time this inhibition is lost due to turnover of BTK, and cells 
that regained BTK activity might then engraft with a time delay. Another explanation could be that 
Ibrutinib treatment had induced robust molecular changes downstream of BTK leading to impaired 
engraftment. This might also affect only some of the leukemic cells, and as the remaining cells which 
still possess the capacity to engraft are less in numbers, it requires longer until they expand 
sufficiently to become detectable. It is difficult to clearly state if this trait is cell-intrinsic and belongs 
to the resistant phenotype of the cells, or if continuous Ibrutinib treatment and permanent BTK 
blockade is responsible for the delay in engraftment. One hint, that the resistant tumor cells had 
stably acquired changes, was the observed decreased expression of CD19 at the end of the first 
treatment round which stayed similarly low in the second treatment round.  
 
CD19 serves as a costimulatory molecule for amplifying BCR signaling377. B cells from mice deficient 
for CD19 display hyporesponsiveness to BCR-mediated signals and generate modest immune 
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responses378. Notably, a physical and functional association between CD19 and BTK has been 
investigated379. In particular, the interaction of CD19 and BTK was not required for initial BTK 
phosphorylation, but CD19 expression was necessary to maintain the phosphorylation of BTK379. 
Moreover, CD19-induced Ca2+ influx, in turn, depends on BTK379. In CLL patients, CD19 expression 
levels are lower compared to healthy donors380, 381. In a study by Herishanu et al., the authors 
investigated the intratumoral diversity of CLL cells in response to IgM stimulation and CD19 
engagement, and could classify CD19-responsive and CD19-nonresponsive cells382. The authors 
showed that the responsive subpopulation expressed higher levels of surface CD19, and of c-myc 
mRNA. In this study, responsiveness (and CD19 expression) positively correlated with disease 
progression382.  
In addition to CD19, also the surface molecules CD38 and CD45 are involved in the BCR signaling. 
CD45 is a receptor-like tyrosine phosphatase and pan-leukocyte marker383. It dephosphorylates 
inhibitory tyrosine kinases of the Src family, such as Lyn, and by this positively regulates antigen 
receptor signaling in B cells383. In CD45-/- B cells, BCR ligation failed to activate Pi3k, NF-b, Erk1, or 
Erk2 kinases384.  
CD38 was described to have diverse functional properties. As elucidated before, CD38 functions as 
an adhesion molecule binding CD31 for example on NLCs343. In addition, CD38 serves as a 
bifunctional extracellular enzyme, catalyzing the transformation of NAD+ into cyclic ADP-ribose 
(cADPR), and cADPR into ADPR385. cADPR induces mobilization of internal calcium and promotes 
proliferative responses in activated B cells385. Moreover, CD38 is dependent on the expression of 
the BCR complex and involved in augmenting BCR responses resulting in IL-2 production385. Overall, 
the decreased expression of these BCR-associated surface molecules on Ibrutinib-resistant 
leukemia cells points towards a potentially weakened BCR signaling which raises the question which 
compensatory mechanism might cause the enhanced proliferation and survival of Ibrutinib 
resistant cells 384. 
 
Ibrutinib resistance in CLL patients versus the TCL-1 AT model 
The progression rate of CLL patients on Ibrutinib treatment constitutes about 18 percent298. Ten 
out of 15 patients develop resistance due to somatically acquired mutations in genes encoding BTK 
and its downstream target PLC2. The remaining patients experience heterogeneous 
transformation to more aggressive lymphoma, mainly DLBCL and Hodgkin Lymphoma. Loss of 
treatment response to Ibrutinib in the TCL-1 AT mouse model has been repeatedly observed in 
different studies conducted over the course of this thesis and the penetrance of resistance was 100 
percent. This illustrates that the TCL-1 AT model reflects in this respect only a subgroup of CLL 
patients. Besides the many commonalities between CLL in humans and the TCL-1 AT model, there 
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are striking differences between the two which are of interest for the current subject. While in 
patients, CLL represents an accumulation of mainly non-cycling B cells, leukemia cells in Eµ-TCL-1 
mice have higher proportions of proliferating cells, but also more apoptotic cells compared to non-
leukemic lymphocytes234. In the here presented study, a high rate of proliferation was detected not 
only in resistant tumors but also in the vehicle-treated (sensitive) tumors. Moreover, tumor cells in 
all analyzed lymphoid organs, including peripheral blood, were positive for Ki-67, while in human 
patients, the proliferative cell pool is located in the pseudo follicles in the lymph nodes and makes 
up 0.1-1% of the entire CLL clone per day. The outcome of the high rate of leukemia cell 
proliferation in TCL-1 AT mice might be an enhanced acquisition of genetic mutations that 
contribute to disease evolution and resistance development.  
 
Richter’s transformation, as a potential event conferring Ibrutinib resistance 
Ahn et al. comprehensively studied 15 CLL patient cases with progression on Ibrutinib treatment298. 
Mutations in BTK and PLC2 were mostly found in patients with CLL progression after more than 18 
months of treatment, but not associated with the early, mostly aggressive transformations. Four 
out of 15 cases with early transformation were considered as Richter’s transformation. Hence, it 
was hypothesized that resistance development against Ibrutinib in the TCL-1 AT model might 
represent or be similar to patients developing Richter’s transformation. There are several points 
that argue for, but more observations against this hypothesis: Commonly used but not reliable 
clinical features for the prediction of Richter’s transformation in patients are a short lymphocyte 
doubling time, and a high percentage of bone marrow involvement, which are also given in the 
Ibrutinib-resistant TCL-1 AT mice19. An increased size of tumor cells is another feature of most 
Richter transformation cases, which was not observed based on the FSC/SSC characteristics of the 
murine leukemic cells acquired by flow cytometry (data not shown)386. Elevated ß-2 microglobulin 
and LDH levels are commonly valued as signs of Richter’s transformation but were not measured in 
the present study19. One clinical feature more clearly associated with Richter’s transformation is 
the involvement of lymph nodes in patients which was not observed in the presented animal 
study19. But as also mouse models for more aggressive B-cell lymphoma, like DLBCL, show mostly 
tumor growth in the spleen and not in the lymph nodes, the site of disease in patients, it remains 
unclear whether mice are in general good models to study lymphoma development in lymph nodes. 
Further, there exist several biological characteristics that are associated with a higher risk of 
Richter’s transformation for CLL patients, such as ZAP70, CD49d, and CD38 overexpression, while 
at least CD38 oppositely was downregulated in Ibrutinib-resistant CD5+CD19+ cells in mice19. Two 
molecular drivers suggested to be involved in Richter’s transformation are TP53 and CDKN2A. 
Acquired loss of function mutations in TP53 lead to c-Myc activation which drives aggressive tumor 
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cell growth. Other genetic characteristic, associated with high-risk Richter’s transformation are 
mutations leading to Richter’s transformation are trisomy 12 and Notch mutations 19. 
The WES data discussed in the following section will also help to identify such Richter 
transformation-associated genetic events. 
 
Whole exome sequencing of resistant and sensitive tumors 
DNA whole exome sequencing was the method of choice to retrieve a broad and deep view of the 
genetic mutational landscape in Ibrutinib-resistant TCL-1 AT tumor cells. Analyzing the typical 
candidate regions for mutations observed in Ibrutinib resistant patients (exon 15 of BTK, and exons 
19, 20, and 24 of PLC2) by targeted sequencing would have underestimated the clonal complexity 
of the tumor298. Landau et al. have reported that patients who received therapy exhibited a greater 
degree of clonal evolution and that this increased tumor heterogeneity was linked to a poor clinical 
outcome387. Hence, DNA exome sequencing does not only allow for a broad insight into genomic 
aberrations acquired by the tumor cells, but - based on sequences of immunoglobulin genes - it also 
permits an estimation of the subclonal structure of the tumor and of the abundance of specific 
mutations in a given tumor. The above-described finding of the outgrowth of a therapy-driven 
CD19int leukemic population suggests that a subpopulation of the tumor might have been positively 
selected by the therapy. Whether this population was present prior to treatment and had an 
inherited selection advantage or rather developed de novo due to acquired mutations is one of the 
central questions in order to explain the resistance mechanism. 
The finding of several expanded B cell clones in the primary and secondary TCL-1 model suggests 
additional clonal processes and implies the existence of ‘several tumors’ within one patient. Indeed, 
there are a few reports on the existence of several immunoglobulin clones in CLL patients. For 
example, Nakamine and colleagues suggested, that even a different immunoglobulin isotype might 
not necessarily represent a unique tumor clone by demonstrating a common cytogenetic 
abnormality (trisomy 12) in both the CLL and DLBCL cells in a patient with Richter’s transformation 
displaying different immunoglobulin isotypes. The authors proposed that these two tumors 
originated from a single progenitor cell that contained the same genomic abnormality388.  
Indeed, a similar scenario could be possible in the TCL-1 model. The development of leukemia in 
the primary Eµ-TCL-1 model, which serves as the donor for the adoptive transfer experiments, is 
based on the transgenic overexpression of the human TCL-1 gene, confined to mature and 
immature B-cells220. Therefore, additional transforming events driving tumorigenesis may happen 
before V(D)J rearrangement takes place in B cell follicles, resulting in polyclonal V(D)J rearranged 
BCRs in this model. Hence, this represents an additional difference between the TCL-1 model and 
the majority of CLL patients. 
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However, the absence of a selection process for a BCR clone after Ibrutinib treatment remains 
somewhat puzzling. One explanation could be, that such an Ibrutinib-selected clone would be 
“hidden” as a minor fraction within a BCR clone and therefor is not obvious. Another possibility 
could be, that the majority of tumor cells become non-responsive to the treatment and an inherent 
resistance capacity is attributed to all tumor cells from the TCL-1 model. Such an inherent resistance 
ability could or example lead to a changed epigenetic program or a metabolic switch resulting in 
non-responsive cells. 
 
Transcriptional changes as drivers of Ibrutinib resistance 
As only low frequency nucleotide variations in BCR pathway genes were detected, they were 
excluded as cause for the loss of response to Ibrutinib. Therefore, it was hypothesized that the rapid 
de novo resistance development in TCL-1 AT mice after a few weeks of treatment could be in part 
due to phenotypic adaptations, including compensatory signaling, changes in the kinome, and/or 
other adaptive responses. Hence, RNA sequencing was chosen in addition to DNA exome 
sequencing to elucidate a potential compensatory signaling in Ibrutinib resistant leukemia cells.  
 
The gene set enrichment analysis suggested a gene set that was identified in wildtype versus Ezh2 
KO T cells, to be enriched in Ibrutinib resistant tumor cells. Ezh2 is part of a methyltransferase 
complex that has been linked to actin polymerization in different cell types, including 
polymerization-dependent antigen receptor signaling in T cells389. In the context of B cells, EZH2 
was suggested to be involved in germinal center formation, immunoglobulin heavy chain 
rearrangement and DLBCL development390, 391, 392, 393. The here presented data show that Ezh2 itself 
was not deregulated in Ibrutinib resistant tumors. The respective gene set contained interesting 
molecules that are known to be required for B cell differentiation (Ebf1),  progression from G1 to S 
phase of the cell cycle (Cdc25a), and molecules previously identified to be deregulated in CLL 
(Ccdc61, Adam10, and Atpif1)394, 395, 396. At the time being, the relevance of this gene set and its 
individual genes further need to be tested and validated. 
 
Performing GO analysis with DEG from in the resistant samples compared to all other groups, 
revealed several interesting transcripts, including the receptor tyrosine kinase Pim2. A role for PIM2 
in the context of CLL was suggested, as it is overexpressed in poor prognosis CLL patients397. 
Interestingly, another PIM kinase family member, PIM1, has been recently linked to an Ibrutinib-
resistant ABC DLBCL subtype, where a point mutation was suggested to stabilize PIM1 and result in 
an enhanced NF-B signaling398. 
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Another upregulated gene in resistant tumor cells was Igf1-r. Notably, recently high IGF1-R 
expression was linked to worse prognosis in CLL patients that are resistant to a PI3K-δ inhibitor 399. 
In a serial adoptive transfer mouse model of CLL, transplanting the TCL1-192 cell line into 
immunocompromised CB17.SCID mice, overexpression of IGF1-R was identified as a result to the 
treatment-induced selection pressure resulting from continuous PI3K-δ inhibitor treatment400.  
 
Conclusions and Outlook 
In brief, the results of this study are currently at a stage where validation of the identified 
differentially expressed molecules and pathways has to follow. Subsequent studies will focus on 
the characterization of mechanisms that are potentially involved in resistance development to 
Ibrutinib in the TCL-1 AT model. Treatment regimens, co-targeting these phenotypic adaptations in 
the resistant cells may induce broader, deeper, and more durable responses in CLL patients. This is 
of high relevance as successful therapies for relapsed, refractory, and treatment resistant cases are 
still lacking and an urgent clinical need in CLL. The observed resistance to Ibrutinib in the TCL-1 AT 
model for CLL may help to investigate and to target therapy-induced cancer evolution, that is a 
branched evolutionary process and the reason why many treatments ultimately fail.  
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APPENDIX 
 
Sample 
name 
Treatment 
condition 
Cell population Sort panel Sort Purity RIN 
H1_A Wildtype/Vehicle Ly6Chi 
monocytes 
DAPI-Lin- (CD19-
CD3-NK.1.1-
TER119-) 
CD11b+CD11clow-
intMHCII-
F4/80intLy6Chi 
n.a. 5.7 
H2_A Wildtype/Vehicle n.a. 7.20 
H3_A Wildtype/Vehicle n.a. 7.9 
V1_A Leukemic/Vehicle 93.3 5.2 
V2_A Leukemic/Vehicle 92.1 7.1 
V4_A Leukemic/Vehicle 81.4 5.3 
I1_A Ibrutinib 98 7.9 
I3_A Ibrutinib 84.6 6.00 
I4_A Ibrutinib 93 6.80 
H1_B Wildtype/Vehicle Ly6Clow 
monocytes 
DAPI-Lin-
CD11b+CD11clow-
intMHCII-
F4/80intLy6Clow 
n.a. 7.6 
H2_B Wildtype/Vehicle n.a. 7.4 
H3_B Wildtype/Vehicle n.a. 8.1 
V1_B Leukemic/Vehicle 95.7 6 
V2_B Leukemic/Vehicle 96.8 6.6 
V4_B Leukemic/Vehicle 93.3 6,7 
I1_B Ibrutinib 97.7 7.6 
I3_B Ibrutinib 93.3 7.1 
I4_B Ibrutinib 90.1 8.3 
H1_C Wildtype/Vehicle conventional 
DCs 
DAPI-Lin- 
CD11chighMHCII+ 
n.a. 7.70 
H2_C Wildtype/Vehicle n.a. 7.70 
H3_C Wildtype/Vehicle n.a. 8.30 
V1_C Ibrutinib 97.4 6.90 
V2_C Ibrutinib 98 7.30 
V4_C Ibrutinib 93.4 6.7 
I1_C Leukemic/Vehicle 93.5 8.60 
I3_C Leukemic/Vehicle 92.1 7.00 
I4_C Leukemic/Vehicle 97.7 7.60 
Appendix Table 1: Information on samples of cDCs, Ly6Chi, and Ly6Clow monocytes used for gene expression 
profiling. 
Sample name, treatment condition, sorted cell population, sort panel, sort purity, and RIN (RNA integrity 
number) after RNA isolation are provided. Wildtype animals were treated with vehicle drinking water as well, 
for better comparison to vehicle control-treated and Ibrutinib-treated animals. 
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Sample name Treatment 
condition 
Sort Purity RIN DIN 
V2_er week 1 post 
treatment start 
with vehicle 
99.1 9.9 9.1 
V5_er 99.4 9.7 9.3 
V6_er 98.7 9.8 9.2 
V8_er 98.9 9.8 8.7 
I3_er week 1 post 
treatment start 
with Ibrutinib 
96.9 9.4 9.1 
I5_er 98.4 10.0 7.9 
I10_er 97.3 9.6 8.7 
I11_er 97.7 9.5 9.1 
V3_la week 3 post 
treatment start 
with vehicle 
 
98.6 9.8 9.1 
V7_la 98.3 10.0 9 
V9_la 98.8 9.9 8.9 
V11_la 98.9 9.4 9.2 
I2_la week 6 post 
treatment start 
with Ibrutinib 
99 9.4 8.7 
I6_la 98.3 9.6 9.5 
I9_la 99 9.7 9.2 
Appendix Table 2: RNA and DNA sequencing of Ibrutinib sensitive and resistant tumor cells.   
Leukemic CD5+CD19+ were sorted by flow cytometry (DAPI-CD45+CD5+CD19+) from freshly isolated 
splenocytes. Sort purities were assessed before flash freezing cell pellets in appropriate amounts of RLT 
buffer. RNA and DNA were isolated and submitted for mRNA (library preparation: ‘total RNA’, 125 base 
paired-end; 5 samples/lane on HiSeq2000) and DNA Exome (library preparation: ‘low input exome-seq 
mouse’, 100 base paired-end; 3 samples/lane in Hiseq4000) sequencing to the DKFZ Genomics and 
Proteomics Core Facility Unit.  
 
 Ly6Chi Ly6Clow cDCs 
 WT TCL-1 AT WT TCL-1 AT WT TCL-1 AT 
CSF-
1 
6.1 6 6.2 5.9 6 5.5 
CSF-
1R 
11.8 11.8 12.2 12.2 9.4 8.1 
Appendix Table 3: Detailed GEP data of selected molecules of cDCs, Ly6Chi, and Ly6Clow monocytes used for 
gene expression profiling. 
Normalized array signal intensity of CSF-1 and CSF-1R, averaged from each three samples per condition from 
GEP of myeloid cells. 
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Appendix Figure 1: Gating scheme, exemplified for splenic Ly6Chi and Ly6Clow monocytes, macrophages, 
and cDCs. 
After exclusion of duplets viable cells were gated as follows: monocytes: DAPI-CD45+CD19-Lin-(CD3-Ly6G-
NK1.1-TER119-)CD11b+CD11clow-intMHC-IIlowF4/80int; Ly6Chigh monocytes: DAPI-CD45+CD19-Lin-
CD11b+CD11clow-intMHC-IIlowF4/80intLy6Chigh; Ly6Clow monocytes: DAPI-CD45+CD19-Lin-CD11b+CD11clow-intMHC-
IIlowF4/80intLy6Clow. Either CD11b (as here) or CD43 (as in Figure 9d) was used for final gating on Ly6Chigh and 
Ly6Clow monocytes); macrophages: DAPI-CD45+CD19-Lin-CD11blowF4/80high; cDCs: DAPI-CD45+CD19-Lin-
CD11chigh. 
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Appendix Figure 2: CSF-1 level in TCL-1 AT mice over time and monocyte subsets in BM of CSF-1 KI AT mice 
(a) CSF-1 was measured in sera from mice adoptively transferred i.v. with 1.8x106 leukemic splenocytes and 
sacrificed at week 2 (n=2), week 4 (n=2), week 6 (n=4), and week 8 (n=4) post transplantation and 
untransplated WT mice (n=4) at week 8 by Luminex bead array. (b) Absolute numbers of Ly6Chigh monocytes 
(left) and Ly6Clow monocytes (right) gated from CSF-1R-expressing cells in the bone marrow (BM) as measured 
by flow cytometry. CSF-1R KI mice were adoptively transferred i.v. with 2x106 splenocytes, pooled from four 
leukemic donor mice. Mice were treated with control antibody (Synagis) or TG3003 at 3mg/kg/week via i.p. 
injections starting at day 1 post-transplantation. Untransplated CSF-1R KI wildtype (WT) mice (n=6) served as 
healthy control group. Analyses were performed for animals that showed >50% of CD5+CD19+ cells in the 
spleen and clear signs of splenomegaly (control cohort: n=9, anti-CSF-1R cohort: n=7). (BM Ly6Chigh 
monocytes: DAPI-Lin-CSF-1R+Ly6C+; BM Ly6Clow monocytes: DAPI-Lin-CSF-1R+Ly6C-) P values were determined 
by unpaired Student t-test. 
 
 
Appendix Figure 3: Cluster dendrogram of gene expression profiled Ly6Chi and Ly6Clow monocytes and cDCs. 
Cluster dendrogram of profiled WT, TCL-1 AT and Ibrutinib-treated samples showing that cDCs (left), Ly6Chi 
(middle) and Ly6Clow monocytes (right) cluster independently. Within all three cell populations, samples from 
TCL-1 AT mice (V=vehicle) cluster closely together. Samples from WT animals (H=healthy;WT) and Ibrutinib-
treated leukemic mice (I=Ibrutinib) cluster together.  
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Appendix Figure 4: cDC subset composition in TCL-1 AT and WT mice and IL-12 production by cDCs. 
(a,b) CD11b (top) and CD11c (bottom) expression on CD8+ cDCs, CD8-CD4+ cDCs, and CD8-CD4- cDCs out of 
total cDCs from non-leukemic WT mice (n=3) (a) and TCL-1 AT mice (n=6) (right). (CD8+ cDCs: Viability dye 
(VD)-LIN-(CD19-CD3-Ly6G-NK1.1-TER119-)CD11chighMHC-II+CD8+; CD8-CD4+ cDCs: VD-LIN-CD11chighMHC-II+CD8-
CD4+; CD8-CD4- cDCs: VD-LIN-CD11chighMHC-II+CD8-CD4+; cDCs: VD-CD19- CD11chighMHC-II+) (c,d) Percentage 
of IL-12 producing cDCs assessed by intracellular flow cytometry after 6 hours of LPS stimulation of isolated 
splenocytes. Two independent experiments are shown here: (c) Comparison of healthy wildtype (WT) (n=4) 
and leukemic TCL-1 AT (n=4) mice; (d) Comparison of leukemic TCL-1 AT mice treated with vehicle (n=6) or 
Ibrutinib (n=4) for 3.5 weeks. Treatment start was at ~5% tumor load in the blood. (cDCs: Viability dye (VD)-
CD19- CD11chighMHC-II+) P values were determined by unpaired Student t-test. 
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Appendix Figure 5: Heatmap of top DEGs from TCL-1 AT vs WT mice in comparison to publically available 
datasets.  
Heatmap of 25 upregulated and 25 downregulated genes (TCL-1 AT (n=3) versus WT (n=3)) in comparison to 
six available splenic dendritic cell gene expression signatures (Immgen data base, v1 datasets)318 which 
include: CD4+ DCs, CD8+ DCs, CD8-CD4-CD11b-, CD8-CD4-CD11b+, CD8- pDCs, and CD8+ pDCs. (a) Top 25 
upregulated DEGs show greatest overlap with expression of respective genes in splenic CD8+ DCs (‘DC 8+_ST’). 
(b) Top 25 downregulated DEGs show least overlap with expression of respective genes in splenic CD4+ DCs 
(‘DC 4+_ST’). (DEG=differentially expressed genes) 
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Appendix Figure 6: Spleen weight and tumor load in lymphoid organs in Ibrutinib- and vehicle-treated mice.  
(a-d) Spleen weight (a,b) and percentages of CD5+CD19+ cells in peripheral blood (PB), spleen (SPL), bone 
marrow (BM), and inguinal lymph nodes (LN) (c,d) of mice, adoptively transferred with clone 1J4 splenocytes 
and treated with vehicle (n=6) or Ibrutinib (n=6) for one week (left), and vehicle for three weeks (n=6) or 
Ibrutinib for six weeks (n=3) (left). (e) CD19 MFI values of leukemic CD19+CD5+ cells were normalized to 
respective values of CD19+CD5- normal B cells (median CD19 MFI on CD19+CD5+ cells / median CD19 MFI on 
CD19+CD5- cells) in spleen of mice transplanted with tumors and treated with vehicle or Ibrutinib. Animals 
were sacrificed at week 4 and week 6 post treatment start to achieve comparable tumor loads for re-injection. 
Black data points represent values from those tumor samples that were re-injected for the purpose of 2nd 
treatment round. P values were determined by unpaired Student t-test. 
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Appendix Figure 7: Characterization of mutational variants from WES.  
(a) Mutation allele frequencies (b) counts and (c) proportions of SNVs, germline DNA, and dbSNPs of Ibrutinib-
resistant and sensitive samples. Data analysis was performed by Yashna Paul. 
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